Roche Group Financial Data

WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5xI75I3R
Year-To-Date in CHFm at reported exchange rates Year-To-Date CHF growth rates

Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023
Pharmaceuticals Division 11,159 22,347 33,189 45,551 11,699 22,681 33,622 44,612 5% 3% -1% 1% 5% 1% 1% -2%
United States 5,489 11,363 17,199 23,322 5,853 11,743 17,680 23,606 4% 5% 3% 4% 7% 3% 3% 1%
Europe 2,072 4,104 6,100 8,143 2,071 4,105 6,259 8,306 -5% -8% -8% -8% 0% 0% 3% 2%
Japan 1,337 2,202 3,029 4,949 1,390 2,210 2,937 3,745 57% 22% -5% 10% 4% 0% -3% -24%
International 2,261 4,678 6,861 9,137 2,385 4,623 6,746 8,955 -1% 2% 0% 0% 5% -1% -2% -2%
thereof China 821 1,618 2,351 3,039 796 1,505 2,224 2,875 -5% -3% -6% -7% -3% -7% -5% -5%
Diagnostics Division 5,286 9,948 13,848 17,730 3,623 7,098 10,431 14,104 22% 10% 4% 0% -31% -29% -25% -20%
EMEA 1,902 3,350 4,595 5,888 1,253 2,456 3,569 4,768 -3% -19% -20% -22% -34% -27% -22% -19%
North America 1,705 2,868 3,923 5,141 1,029 1,940 2,853 3,826 62% 40% 25% 18% -40% -32% -27% -26%
thereof United States 1,465 2,511 3,470 4,518 936 1,745 2,543 3,424 55% 36% 22% 15% -36% -31% -27% -24%
Asia-Pacific 1,395 3,171 4,522 5,639 1,098 2,205 3,263 4,496 33% 38% 25% 19% -21% -30% -28% -20%
thereof China 635 1,298 1,992 2,580 620 1,289 1,920 2,475 15% 6% 7% 6% -2% -1% -4% -4%
Latin America 284 559 808 1,062 243 497 746 1,014 6% 2% -4% -3% -14% -11% -8% -5%
Group 16,445 32,295 47,037 63,281 15,322 29,779 44,053 58,716 10% 5% 1% 1% -7% -8% -6% -7%
Quarterly in CHFm at reported exchange rates Quarterly Year-To-Date CHF growth rates
Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Pharmaceuticals Division 11,159 11,188 10,842 12,362 11,699 10,982 10,941 10,990 5% 1% -7% 6% 5% -2% 1% -11%
Roche Online Financial Information System Group Sales CHF 04/03/2024 1/43
Year-To-Date in CHFm at constant full year 2022 exchange rates Year-To-Date constant exchange rate growth rates
Pharmaceuticals Division 11,154 22,173 33,054 45,525 12,131 23,907 35,996 48,230 6% 3% 0% 2% 9% 8% 9% 6%
United States 5,675 11,493 17,259 23,322 6,040 12,293 18,703 25,078 2% 1% -1% -1% 6% 7% 8% 8%
Europe 2,003 3,990 6,051 8,143 2,105 4,197 6,448 8,606 -1% -4% -1% -2% 5% 5% 7% 6%
Japan 1,222 2,082 2,961 4,949 1,445 2,373 3,264 4,253 69% 34% 7% 26% 18% 14% 10% -14%
International 2,254 4,608 6,782 9,110 2,541 5,044 7,581 10,293 0% 2% 0% 1% 13% 9% 12% 13%
thereof China 803 1,578 2,316 3,039 834 1,619 2,454 3,207 -9% -7% -8% -7% 4% 3% 6% 6%
EMEA 1,855 3,272 4,560 5,886 1,295 2,567 3,793 5,121 2% -14% -13% -16% -30% -22% -17% -13%
North America 1,757 2,893 3,932 5,141 1,066 2,035 3,023 4,071 59% 34% 20% 13% -39% -30% -23% -21%
thereof United States 1,515 2,539 3,482 4,514 966 1,827 2,690 3,638 51% 31% 17% 10% -36% -28% -23% -19%
Asia-Pacific 1,353 3,082 4,453 5,640 1,147 2,369 3,592 5,013 34% 39% 28% 23% -15% -23% -19% -11%
thereof China 621 1,266 1,963 2,580 650 1,388 2,120 2,763 11% 2% 5% 6% 5% 10% 8% 7%
Latin America 285 546 797 1,063 262 548 848 1,210 9% 2% -3% -1% -8% 0% 6% 14%
Group 16,404 31,966 46,797 63,255 15,901 31,426 47,252 63,645 11% 5% 2% 2% -3% -2% 1% 1%
Quarterly in CHFm at constant full year 2022 exchange rates Quarterly constant exchange rate growth rates
Pharmaceuticals Division 11,154 11,019 10,881 12,471 12,131 11,776 12,089 12,234 6% 0% -6% 9% 9% 7% 11% -2%
Roche Online Financial Information System Group Sales CER 04/03/2024 2/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52V
Global - Year-To-Date in CHFm at reported exchange rates Global - Year-To-Date CHF growth rates
Pharma Products Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023
Ocrevus 1,449 2,910 4,427 6,036 1,636 3,200 4,767 6,381 18% 19% 19% 19% 13% 10% 8% 6%
Hemlibra 853 1,826 2,778 3,823 1,034 2,087 3,112 4,147 29% 31% 28% 27% 21% 14% 12% 8%
Perjeta 993 2,061 3,090 4,087 1,049 2,082 2,995 3,768 1% 5% 4% 3% 6% 1% -3% -8%
Tecentriq 825 1,758 2,692 3,717 920 1,853 2,791 3,766 6% 10% 9% 12% 12% 5% 4% 1%
Actemra/RoActemra 792 1,455 2,039 2,701 676 1,296 1,943 2,630 2% -11% -24% -24% -15% -11% -5% -3%
Vabysmo 21 109 282 591 432 957 1,613 2,357 - - - - 1957% 778% 472% 299%
Xolair 456 1,025 1,625 2,208 479 1,031 1,601 2,176 11% 16% 15% 14% 5% 1% -1% -1%
Kadcyla 511 1,074 1,590 2,080 509 1,001 1,486 1,966 7% 12% 9% 5% 0% -7% -7% -5%
MabThera/Rituxan 564 1,117 1,596 2,075 459 882 1,260 1,630 -20% -19% -19% -19% -19% -21% -21% -21%
Herceptin 607 1,179 1,672 2,142 477 878 1,261 1,626 -20% -16% -19% -20% -21% -26% -25% -24%
Avastin 581 1,142 1,652 2,122 416 837 1,210 1,573 -33% -31% -31% -31% -28% -27% -27% -26%
Alecensa 361 745 1,127 1,513 372 758 1,126 1,502 21% 18% 14% 12% 3% 2% 0% -1%
Evrysdi 226 500 793 1,119 363 705 1,065 1,419 183% 106% 100% 86% 61% 41% 34% 27%
Activase/TNKase 247 559 881 1,177 302 621 903 1,173 -19% -7% -4% -10% 22% 11% 2% 0%
Phesgo 146 325 526 740 241 517 817 1,120 403% 239% 147% 118% 65% 59% 55% 51%
Polivy 81 177 290 437 150 353 605 837 88% 88% 74% 77% 85% 99% 109% 92%
Gazyva/Gazyvaro 165 349 539 730 197 402 615 811 6% 8% 8% 8% 19% 15% 14% 11%
Ronapreve 587 609 631 1,679 567 550 532 525 254% 2% -42% 3% -3% -10% -16% -69%
Lucentis 256 572 800 1,012 167 299 396 460 -24% -14% -21% -25% -35% -48% -51% -55%
Pulmozyme 136 279 414 543 127 238 342 452 -2% 1% 0% -4% -7% -15% -17% -17%
Mircera 89 191 296 408 105 198 318 426 -15% -11% -11% -6% 18% 4% 7% 4%
CellCept 134 270 386 503 103 201 295 393 -13% -9% -15% -15% -23% -26% -24% -22%
Madopar 99 189 289 379 87 185 274 355 -8% -3% 0% -4% -12% -2% -5% -6%
Enspryng 41 84 133 192 54 120 186 256 193% 115% 93% 79% 32% 43% 40% 33%
Erivedge 63 131 200 271 58 122 185 245 5% 3% 2% 1% -8% -7% -8% -10%
Other Products 876 1,711 2,441 3,266 719 1,308 1,924 2,618 -10% -13% -19% -19% -18% -24% -21% -20%
Global - Year-To-Date in CHFm at reported exchange rates Global - Year-To-Date CHF growth rates
Launched since 2015 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023
Cotellic 12 24 35 48 12 29 39 50 20% 0% 0% -4% 0% 21% 11% 4%
Alecensa 361 745 1,127 1,513 372 758 1,126 1,502 21% 18% 14% 12% 3% 2% 0% -1%
Tecentriq 825 1,758 2,692 3,717 920 1,853 2,791 3,766 6% 10% 9% 12% 12% 5% 4% 1%
Ocrevus 1,449 2,910 4,427 6,036 1,636 3,200 4,767 6,381 18% 19% 19% 19% 13% 10% 8% 6%
Hemlibra 853 1,826 2,778 3,823 1,034 2,087 3,112 4,147 29% 31% 28% 27% 21% 14% 12% 8%
Luxturna 5 12 21 45 4 8 43 44 -44% -37% -53% -32% -20% -33% 105% -2%
Xofluza 2 4 6 67 18 26 32 90 - - - 1575% 800% 550% 433% 34%
Polivy 81 177 290 437 150 353 605 837 88% 88% 74% 77% 85% 99% 109% 92%
Rozlytrek 16 34 53 75 19 40 63 86 78% 55% 51% 53% 19% 18% 19% 15%
Phesgo 146 325 526 740 241 517 817 1,120 403% 239% 147% 118% 65% 59% 55% 51%
Enspryng 41 84 133 192 54 120 186 256 193% 115% 93% 79% 32% 43% 40% 33%
Evrysdi 226 500 793 1,119 363 705 1,065 1,419 183% 106% 100% 86% 61% 41% 34% 27%
Gavreto 5 12 20 26 10 24 32 55 - - 300% 189% 100% 100% 60% 112%
Ronapreve 587 609 631 1,679 567 550 532 525 254% 2% -42% 3% -3% -10% -16% -69%
Susvimo 1 2 3 2 1 1 3 3 - - - 100% 0% -50% 0% 50%
Vabysmo 21 109 282 591 432 957 1,613 2,357 - - - - 1957% 778% 472% 299%
Lunsumio 0 0 1 3 14 28 43 58 - - - - - - 4200% 1833%
Columvi 0 0 0 0 0 5 10 28 - - - - - - - -
Global - Quarterly in CHFm at reported exchange rates Global - Quarterly CHF growth rates
Pharma Products Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Ocrevus 1,449 1,461 1,517 1,609 1,636 1,564 1,567 1,614 18% 21% 18% 21% 13% 7% 3% 0%
Hemlibra 853 973 952 1,045 1,034 1,053 1,025 1,035 29% 33% 22% 23% 21% 8% 8% -1%
Perjeta 993 1,068 1,029 997 1,049 1,033 913 773 1% 9% 2% 2% 6% -3% -11% -22%
Tecentriq 825 933 934 1,025 920 933 938 975 6% 13% 6% 22% 12% 0% 0% -5%
Actemra/RoActemra 792 663 584 662 676 620 647 687 2% -23% -44% -24% -15% -6% 11% 4%
Vabysmo 21 88 173 309 432 525 656 744 - - - - 1957% 497% 279% 141%
Xolair 456 569 600 583 479 552 570 575 11% 19% 13% 11% 5% -3% -5% -1%
Kadcyla 511 563 516 490 509 492 485 480 7% 17% 3% -6% 0% -13% -6% -2%
MabThera/Rituxan 564 553 479 479 459 423 378 370 -20% -18% -19% -20% -19% -24% -21% -23%
Herceptin 607 572 493 470 477 401 383 365 -20% -11% -26% -26% -21% -30% -22% -22%
Avastin 581 561 510 470 416 421 373 363 -33% -28% -32% -29% -28% -25% -27% -23%
Alecensa 361 384 382 386 372 386 368 376 21% 15% 7% 5% 3% 1% -4% -3%
Evrysdi 226 274 293 326 363 342 360 354 183% 68% 92% 58% 61% 25% 23% 9%
Activase/TNKase 247 312 322 296 302 319 282 270 -19% 6% 0% -24% 22% 2% -12% -9%
Phesgo 146 179 201 214 241 276 300 303 403% 167% 72% 69% 65% 54% 49% 42%
Polivy 81 96 113 147 150 203 252 232 88% 88% 55% 84% 85% 111% 123% 58%
Gazyva/Gazyvaro 165 184 190 191 197 205 213 196 6% 9% 7% 8% 19% 11% 12% 3%
Ronapreve 587 22 22 1,048 567 -17 -18 -7 254% -95% -96% 92% -3% - - -
Lucentis 256 316 228 212 167 132 97 64 -24% -4% -35% -37% -35% -58% -57% -70%
Pulmozyme 136 143 135 129 127 111 104 110 -2% 4% -2% -15% -7% -22% -23% -15%
Mircera 89 102 105 112 105 93 120 108 -15% -6% -10% 8% 18% -9% 14% -4%
CellCept 134 136 116 117 103 98 94 98 -13% -6% -25% -16% -23% -28% -19% -16%
Madopar 99 90 100 90 87 98 89 81 -8% 3% 8% -15% -12% 9% -11% -10%
Enspryng 41 43 49 59 54 66 66 70 193% 72% 63% 55% 32% 53% 35% 19%
Erivedge 63 68 69 71 58 64 63 60 5% 1% 0% -3% -8% -6% -9% -15%
Other Products 876 835 730 825 719 589 616 694 -10% -17% -30% -18% -18% -29% -16% -16%
Global - Quarterly in CHFm at reported exchange rates Global - Quarterly CHF growth rates
Launched since 2015 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Cotellic 12 12 11 13 12 17 10 11 20% -14% 0% -13% 0% 42% -9% -15%
Alecensa 361 384 382 386 372 386 368 376 21% 15% 7% 5% 3% 1% -4% -3%
Tecentriq 825 933 934 1,025 920 933 938 975 6% 13% 6% 22% 12% 0% 0% -5%
Ocrevus 1,449 1,461 1,517 1,609 1,636 1,564 1,567 1,614 18% 21% 18% 21% 13% 7% 3% 0%
Hemlibra 853 973 952 1,045 1,034 1,053 1,025 1,035 29% 33% 22% 23% 21% 8% 8% -1%
Luxturna 5 7 9 24 4 4 35 1 -44% -30% -65% 14% -20% -43% 289% -96%
Xofluza 2 2 2 61 18 8 6 58 - - -33% 578% 800% 300% 200% -5%
Polivy 81 96 113 147 150 203 252 232 88% 88% 55% 84% 85% 111% 123% 58%
Rozlytrek 16 18 19 22 19 21 23 23 78% 38% 46% 57% 19% 17% 21% 5%
Phesgo 146 179 201 214 241 276 300 303 403% 167% 72% 69% 65% 54% 49% 42%
Enspryng 41 43 49 59 54 66 66 70 193% 72% 63% 55% 32% 53% 35% 19%
Evrysdi 226 274 293 326 363 342 360 354 183% 68% 92% 58% 61% 25% 23% 9%
Roche Online Financial Information System P Sales Global CHF 04/03/2024 3/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm
Ocrevus 1,449 2,910 4,427 6,036 1,636 3,200 4,767 6,381 18% 19% 19% 19% 13% 10% 8% 6%
thereof United States 1,050 2,140 3,283 4,487 1,188 2,346 3,492 4,684 15% 16% 18% 19% 13% 10% 6% 4%
thereof Europe 280 539 808 1,075 298 584 877 1,166 29% 28% 17% 17% 6% 8% 9% 8%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 119 231 336 474 150 270 398 531 25% 38% 33% 31% 26% 17% 18% 12%
Hemlibra 853 1,826 2,778 3,823 1,034 2,087 3,112 4,147 29% 31% 28% 27% 21% 14% 12% 8%
thereof United States 520 1,098 1,684 2,316 631 1,247 1,862 2,493 31% 31% 28% 28% 21% 14% 11% 8%
thereof Europe 170 360 542 741 206 419 637 845 25% 23% 23% 22% 21% 16% 18% 14%
thereof Japan 84 180 277 377 92 192 281 373 6% 8% 7% 3% 10% 7% 1% -1%
Perjeta 993 2,061 3,090 4,087 1,049 2,082 2,995 3,768 1% 5% 4% 3% 6% 1% -3% -8%
thereof United States 362 740 1,135 1,533 392 763 1,101 1,336 1% 5% 5% 8% 8% 3% -3% -13%
thereof Europe 228 457 661 871 220 413 615 776 -24% -21% -22% -22% -4% -10% -7% -11%
thereof Japan 59 120 175 234 53 109 161 215 -8% -9% -13% -13% -10% -9% -8% -8%
thereof International 344 744 1,119 1,449 384 797 1,118 1,441 31% 34% 32% 25% 12% 7% 0% -1%
Tecentriq 825 1,758 2,692 3,717 920 1,853 2,791 3,766 6% 10% 9% 12% 12% 5% 4% 1%
thereof United States 446 951 1,451 1,975 507 1,000 1,476 1,941 13% 17% 14% 17% 14% 5% 2% -2%
thereof Europe 183 383 573 794 195 398 628 845 9% 13% 10% 11% 7% 4% 10% 6%
thereof Japan 107 218 326 443 105 214 313 419 -11% -15% -16% -14% -2% -2% -4% -5%
thereof International 89 206 342 505 113 241 374 561 -3% 7% 15% 28% 27% 17% 9% 11%
Actemra/RoActemra 792 1,455 2,039 2,701 676 1,296 1,943 2,630 2% -11% -24% -24% -15% -11% -5% -3%
thereof United States 380 664 914 1,196 296 574 877 1,223 25% -4% -30% -32% -22% -14% -4% 2%
thereof Europe 220 420 602 802 193 383 583 775 -8% -8% -9% -12% -12% -9% -3% -3%
thereof Japan 87 174 256 342 77 157 232 311 4% -4% -10% -10% -11% -10% -9% -9%
thereof International 105 197 267 361 110 182 251 321 -30% -37% -40% -28% 5% -8% -6% -11%
Vabysmo 21 109 282 591 432 957 1,613 2,357 - - - - 1957% 778% 472% 299%
thereof United States 21 101 253 517 360 788 1,320 1,914 - - - - 1614% 680% 422% 270%
thereof Europe 0 0 4 22 44 103 185 276 - - - - - - 4525% 1155%
thereof Japan 0 7 24 47 21 46 70 98 - - - - - 557% 192% 109%
thereof International 0 1 1 5 7 20 38 69 - - - - - 1900% 3700% 1280%
Xolair 456 1,025 1,625 2,208 479 1,031 1,601 2,176 11% 16% 15% 14% 5% 1% -1% -1%
thereof United States 456 1,025 1,625 2,208 479 1,031 1,601 2,176 11% 16% 15% 14% 5% 1% -1% -1%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 0 0 0 0 0 0 0 0 - - - - - - - -
Kadcyla 511 1,074 1,590 2,080 509 1,001 1,486 1,966 7% 12% 9% 5% 0% -7% -7% -5%
thereof United States 204 415 619 820 198 386 568 757 2% 3% 1% 1% -3% -7% -8% -8%
thereof Europe 172 350 508 671 154 298 446 577 3% 4% 0% -2% -10% -15% -12% -14%
thereof Japan 32 68 101 131 26 52 77 102 19% 13% 7% 1% -19% -24% -24% -22%
thereof United States 347 691 1,002 1,316 274 534 761 987 -19% -19% -16% -15% -21% -23% -24% -25%
thereof Europe 54 105 156 204 51 96 140 180 -22% -22% -23% -24% -6% -9% -10% -12%
thereof Japan 8 17 24 32 6 13 19 24 -20% -15% -23% -24% -25% -24% -21% -25%
thereof International 155 304 414 523 128 239 340 439 -23% -18% -23% -26% -17% -21% -18% -16%
Herceptin 607 1,179 1,672 2,142 477 878 1,261 1,626 -20% -16% -19% -20% -21% -26% -25% -24%
thereof United States 144 263 376 476 91 176 258 331 -25% -24% -25% -25% -37% -33% -31% -30%
thereof Europe 122 233 329 422 97 183 271 353 -16% -16% -19% -22% -20% -21% -18% -16%
thereof Japan 15 28 40 51 9 17 24 30 -32% -35% -37% -38% -40% -39% -40% -41%
thereof International 326 655 927 1,193 280 502 708 912 -18% -10% -15% -17% -14% -23% -24% -24%
Avastin 581 1,142 1,652 2,122 416 837 1,210 1,573 -33% -31% -31% -31% -28% -27% -27% -26%
thereof Europe 58 116 158 193 30 57 78 98 -58% -55% -54% -55% -48% -51% -51% -49%
thereof Japan 131 263 378 490 91 177 250 318 -19% -20% -25% -27% -31% -33% -34% -35%
Alecensa 361 745 1,127 1,513 372 758 1,126 1,502 21% 18% 14% 12% 3% 2% 0% -1%
thereof United States 99 207 331 453 106 221 340 467 29% 24% 26% 24% 7% 7% 3% 3%
thereof Europe 75 149 218 292 73 148 220 292 1% 1% -1% -2% -3% -1% 1% 0%
thereof Japan 54 114 169 228 50 107 157 212 -2% -3% -7% -8% -7% -6% -7% -7%
thereof International 133 275 409 540 143 282 409 531 45% 39% 27% 21% 8% 3% 0% -2%
Evrysdi 226 500 793 1,119 363 705 1,065 1,419 183% 106% 100% 86% 61% 41% 34% 27%
thereof Europe 68 152 253 353 113 241 374 509 - 463% 308% 212% 66% 59% 48% 44%
thereof Japan 17 38 60 84 21 45 67 93 - - 1900% 342% 24% 18% 12% 11%
Activase/TNKase 247 559 881 1,177 302 621 903 1,173 -19% -7% -4% -10% 22% 11% 2% 0%
thereof United States 234 531 836 1,114 288 592 859 1,112 -20% -7% -5% -11% 23% 11% 3% 0%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 13 28 45 63 14 29 44 61 0% 0% 7% 11% 8% 4% -2% -3%
Phesgo 146 325 526 740 241 517 817 1,120 403% 239% 147% 118% 65% 59% 55% 51%
thereof Europe 76 163 263 367 114 240 384 534 986% 318% 186% 125% 50% 47% 46% 46%
thereof Japan 0 0 0 0 0 0 0 4 - - - - - - - -
Polivy 81 177 290 437 150 353 605 837 88% 88% 74% 77% 85% 99% 109% 92%
thereof Europe 22 46 84 132 40 80 136 173 0% 12% 33% 55% 82% 74% 62% 31%
thereof Japan 21 43 68 113 51 108 167 227 - 438% 134% 98% 143% 151% 146% 101%
Gazyva/Gazyvaro 165 349 539 730 197 402 615 811 6% 8% 8% 8% 19% 15% 14% 11%
thereof Europe 46 95 144 192 55 111 174 229 -10% -10% -14% -14% 20% 17% 21% 19%
thereof Japan 15 28 39 50 8 20 28 38 7% -10% -17% -19% -47% -29% -28% -24%
Ronapreve 587 609 631 1,679 567 550 532 525 254% 2% -42% 3% -3% -10% -16% -69%
thereof United States 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Europe 62 65 102 101 0 0 0 5 -63% -87% -82% -86% - - - -95%
thereof Japan 483 467 452 1,480 567 549 531 519 - - 26% 129% 17% 18% 17% -65%
thereof International 42 77 77 98 0 1 1 1 - -31% -51% -62% - -99% -99% -99%
Lucentis 256 572 800 1,012 167 299 396 460 -24% -14% -21% -25% -35% -48% -51% -55%
thereof United States 256 572 800 1,012 167 299 396 460 -24% -14% -21% -25% -35% -48% -51% -55%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Pulmozyme 136 279 414 543 127 238 342 452 -2% 1% 0% -4% -7% -15% -17% -17%
thereof United States 87 184 280 369 83 158 229 303 2% 6% 7% 2% -5% -14% -18% -18%
thereof Europe 26 51 73 96 20 39 57 76 -13% -15% -18% -18% -23% -24% -22% -21%
thereof Japan 0 0 0 1 0 0 0 1 - - - 0% - - - 0%
thereof International 23 44 61 77 24 41 56 72 -4% 2% -3% -9% 4% -7% -8% -6%
Mircera 89 191 296 408 105 198 318 426 -15% -11% -11% -6% 18% 4% 7% 4%
thereof Europe 14 26 38 48 12 23 34 44 8% -4% -7% -13% -14% -12% -11% -8%
thereof Japan 21 41 60 79 14 28 41 54 -28% -32% -33% -34% -33% -32% -32% -32%
thereof International 54 124 198 281 79 147 243 328 -14% -2% -1% 8% 46% 19% 23% 17%
CellCept 134 270 386 503 103 201 295 393 -13% -9% -15% -15% -23% -26% -24% -22%
thereof Europe 34 68 101 135 33 64 95 123 -11% -12% -12% -12% -3% -6% -6% -9%
thereof Japan 14 29 43 58 12 23 34 45 -18% -17% -17% -17% -14% -21% -21% -22%
Madopar 99 189 289 379 87 185 274 355 -8% -3% 0% -4% -12% -2% -5% -6%
thereof Europe 25 52 78 104 25 50 75 99 -4% -4% -5% -8% 0% -4% -4% -5%
Roche Online Financial Information System P Sales Regions CHF 04/03/2024 4/43
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 74 137 211 275 62 135 199 256 -10% -3% 2% -2% -16% -1% -6% -7%
Enspryng 41 84 133 192 54 120 186 256 193% 115% 93% 79% 32% 43% 40% 33%
thereof Europe 2 4 6 9 4 7 12 18 - - 500% 200% 100% 75% 100% 100%
thereof Japan 25 55 86 122 33 74 110 153 108% 83% 65% 53% 32% 35% 28% 25%
thereof International 1 1 4 7 2 6 12 16 - 0% 300% 600% 100% 500% 200% 129%
Erivedge 63 131 200 271 58 122 185 245 5% 3% 2% 1% -8% -7% -8% -10%
thereof United States 40 82 126 173 33 72 111 148 5% 1% -2% 0% -18% -12% -12% -14%
thereof Europe 15 30 44 58 15 28 42 55 0% 0% 0% -5% 0% -7% -5% -5%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Other Products 876 1,711 2,441 3,266 719 1,308 1,924 2,618 -10% -13% -19% -19% -18% -24% -21% -20%
thereof United States 364 710 983 1,346 237 469 757 1,028 -3% -11% -20% -20% -35% -34% -23% -24%
thereof Europe 120 240 355 461 79 140 196 258 -21% -21% -20% -19% -34% -42% -45% -44%
thereof Japan 164 312 451 587 154 279 375 509 4% -7% -18% -21% -6% -11% -17% -13%
thereof International 228 449 652 872 249 420 596 823 -20% -17% -18% -14% 9% -6% -9% -6%
Global - Quarterly in CHFm at reported exchange rates Quarterly in CHF growth rates
Ocrevus 1,449 1,461 1,517 1,609 1,636 1,564 1,567 1,614 18% 21% 18% 21% 13% 7% 3% 0%
thereof United States 1,050 1,090 1,143 1,204 1,188 1,158 1,146 1,192 15% 17% 23% 21% 13% 6% 0% -1%
thereof Europe 280 259 269 267 298 286 293 289 29% 26% 1% 18% 6% 10% 9% 8%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Hemlibra 853 973 952 1,045 1,034 1,053 1,025 1,035 29% 33% 22% 23% 21% 8% 8% -1%
thereof Europe 170 190 182 199 206 213 218 208 25% 22% 23% 18% 21% 12% 20% 5%
thereof Japan 84 96 97 100 92 100 89 92 6% 10% 3% -5% 10% 4% -8% -8%
Perjeta 993 1,068 1,029 997 1,049 1,033 913 773 1% 9% 2% 2% 6% -3% -11% -22%
thereof United States 362 378 395 398 392 371 338 235 1% 10% 5% 18% 8% -2% -14% -41%
thereof Europe 228 229 204 210 220 193 202 161 -24% -17% -24% -21% -4% -16% -1% -23%
thereof Japan 59 61 55 59 53 56 52 54 -8% -10% -19% -13% -10% -8% -5% -8%
Tecentriq 825 933 934 1,025 920 933 938 975 6% 13% 6% 22% 12% 0% 0% -5%
thereof Europe 183 200 190 221 195 203 230 217 9% 17% 5% 15% 7% 1% 21% -2%
thereof Japan 107 111 108 117 105 109 99 106 -11% -19% -17% -11% -2% -2% -8% -9%
thereof International 89 117 136 163 113 128 133 187 -3% 17% 28% 66% 27% 9% -2% 15%
Actemra/RoActemra 792 663 584 662 676 620 647 687 2% -23% -44% -24% -15% -6% 11% 4%
thereof United States 380 284 250 282 296 278 303 346 25% -26% -59% -39% -22% -2% 21% 23%
thereof Europe 220 200 182 200 193 190 200 192 -8% -8% -12% -21% -12% -5% 10% -4%
thereof Japan 87 87 82 86 77 80 75 79 4% -11% -20% -11% -11% -8% -9% -8%
thereof International 105 92 70 94 110 72 69 70 -30% -44% -45% 52% 5% -22% -1% -26%
Vabysmo 21 88 173 309 432 525 656 744 - - - - 1957% 497% 279% 141%
thereof United States 21 80 152 264 360 428 532 594 - - - - 1614% 435% 250% 125%
thereof Europe 0 0 4 18 44 59 82 91 - - - - - - 1950% 406%
thereof Japan 0 7 17 23 21 25 24 28 - - - - - 257% 41% 22%
thereof International 0 1 0 4 7 13 18 31 - - - - - 1200% - 675%
Xolair 456 569 600 583 479 552 570 575 11% 19% 13% 11% 5% -3% -5% -1%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Kadcyla 511 563 516 490 509 492 485 480 7% 17% 3% -6% 0% -13% -6% -2%
thereof United States 204 211 204 201 198 188 182 189 2% 5% -4% 0% -3% -11% -11% -6%
thereof Europe 172 178 158 163 154 144 148 131 3% 5% -8% -9% -10% -19% -6% -20%
thereof Japan 32 36 33 30 26 26 25 25 19% 9% -3% -17% -19% -28% -24% -17%
thereof International 103 138 121 96 131 134 130 135 23% 77% 46% -10% 27% -3% 7% 41%
thereof Europe 54 51 51 48 51 45 44 40 -22% -22% -26% -26% -6% -12% -14% -17%
thereof Japan 8 9 7 8 6 7 6 5 -20% -10% -36% -27% -25% -22% -14% -38%
Herceptin 607 572 493 470 477 401 383 365 -20% -11% -26% -26% -21% -30% -22% -22%
thereof Europe 122 111 96 93 97 86 88 82 -16% -15% -26% -32% -20% -23% -8% -12%
thereof Japan 15 13 12 11 9 8 7 6 -32% -38% -40% -42% -40% -38% -42% -45%
Avastin 581 561 510 470 416 421 373 363 -33% -28% -32% -29% -28% -25% -27% -23%
thereof Europe 58 58 42 35 30 27 21 20 -58% -51% -53% -58% -48% -53% -50% -43%
thereof Japan 131 132 115 112 91 86 73 68 -19% -22% -33% -35% -31% -35% -37% -39%
Alecensa 361 384 382 386 372 386 368 376 21% 15% 7% 5% 3% 1% -4% -3%
thereof United States 99 108 124 122 106 115 119 127 29% 20% 29% 18% 7% 6% -4% 4%
thereof Europe 75 74 69 74 73 75 72 72 1% 0% -5% -3% -3% 1% 4% -3%
thereof Japan 54 60 55 59 50 57 50 55 -2% -5% -13% -11% -7% -5% -9% -7%
thereof International 133 142 134 131 143 139 127 122 45% 34% 7% 7% 8% -2% -5% -7%
Evrysdi 226 274 293 326 363 342 360 354 183% 68% 92% 58% 61% 25% 23% 9%
thereof Europe 68 84 101 100 113 128 133 135 - 211% 189% 96% 66% 52% 32% 35%
thereof Japan 17 21 22 24 21 24 22 26 - - 633% 50% 24% 14% 0% 8%
Activase/TNKase 247 312 322 296 302 319 282 270 -19% 6% 0% -24% 22% 2% -12% -9%
thereof United States 234 297 305 278 288 304 267 253 -20% 6% -1% -26% 23% 2% -12% -9%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Phesgo 146 179 201 214 241 276 300 303 403% 167% 72% 69% 65% 54% 49% 42%
thereof Europe 76 87 100 104 114 126 144 150 986% 172% 89% 46% 50% 45% 44% 44%
thereof Japan 0 0 0 0 0 0 0 4 - - - - - - - -
Polivy 81 96 113 147 150 203 252 232 88% 88% 55% 84% 85% 111% 123% 58%
thereof Europe 22 24 38 48 40 40 56 37 0% 26% 73% 118% 82% 67% 47% -23%
thereof Japan 21 22 25 45 51 57 59 60 - 175% 19% 61% 143% 159% 136% 33%
Gazyva/Gazyvaro 165 184 190 191 197 205 213 196 6% 9% 7% 8% 19% 11% 12% 3%
thereof Europe 46 49 49 48 55 56 63 55 -10% -11% -20% -14% 20% 14% 29% 15%
thereof Japan 15 13 11 11 8 12 8 10 7% -24% -31% -27% -47% -8% -27% -9%
Ronapreve 587 22 22 1,048 567 -17 -18 -7 254% -95% -96% 92% -3% - - -
thereof Europe 62 3 37 -1 0 0 0 5 -63% -99% -56% - - - - -
thereof Japan 483 -16 -15 1,028 567 -18 -18 -12 - - - 261% 17% 13% 20% -
thereof International 42 35 0 21 0 1 0 0 - -69% - -79% - -97% - -
Lucentis 256 316 228 212 167 132 97 64 -24% -4% -35% -37% -35% -58% -57% -70%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Pulmozyme 136 143 135 129 127 111 104 110 -2% 4% -2% -15% -7% -22% -23% -15%
thereof United States 87 97 96 89 83 75 71 74 2% 10% 8% -12% -5% -23% -26% -17%
thereof Europe 26 25 22 23 20 19 18 19 -13% -17% -24% -18% -23% -24% -18% -17%
thereof Japan 0 0 0 1 0 0 0 1 - - - 0% - - - 0%
thereof International 23 21 17 16 24 17 15 16 -4% 11% -15% -27% 4% -19% -12% 0%
Mircera 89 102 105 112 105 93 120 108 -15% -6% -10% 8% 18% -9% 14% -4%
thereof Europe 14 12 12 10 12 11 11 10 8% -14% -14% -29% -14% -8% -8% 0%
thereof Japan 21 20 19 19 14 14 13 13 -28% -35% -37% -37% -33% -30% -32% -32%
thereof International 54 70 74 83 79 68 96 85 -14% 9% 1% 38% 46% -3% 30% 2%
Cellcept 134 136 116 117 103 98 94 98 -13% -6% -25% -16% -23% -28% -19% -16%
thereof Europe 34 34 33 34 33 31 31 28 -11% -13% -13% -13% -3% -9% -6% -18%
thereof Japan 14 15 14 15 12 11 11 11 -18% -17% -18% -17% -14% -27% -21% -27%
thereof International 76 77 59 59 50 48 46 51 -14% 3% -33% -18% -34% -38% -22% -14%
Madopar 99 90 100 90 87 98 89 81 -8% 3% 8% -15% -12% 9% -11% -10%
thereof Europe 25 27 26 26 25 25 25 24 -4% -4% -7% -16% 0% -7% -4% -8%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 74 63 74 64 62 73 64 57 -10% 7% 14% -15% -16% 16% -14% -11%
Enspryng 41 43 49 59 54 66 66 70 193% 72% 63% 55% 32% 53% 35% 19%
thereof Europe 2 2 2 3 4 3 5 6 - - 100% 50% 100% 50% 150% 100%
thereof Japan 25 30 31 36 33 41 36 43 108% 67% 41% 29% 32% 37% 16% 19%
thereof International 1 0 3 3 2 4 6 4 - - - - 100% - 100% 33%
Erivedge 63 68 69 71 58 64 63 60 5% 1% 0% -3% -8% -6% -9% -15%
thereof United States 40 42 44 47 33 39 39 37 5% -2% -6% 4% -18% -7% -11% -21%
thereof Europe 15 15 14 14 15 13 14 13 0% 0% 0% -18% 0% -13% 0% -7%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 8 11 11 10 10 12 10 10 14% 22% 38% -9% 25% 9% -9% 0%
Other Products 876 835 730 825 719 589 616 694 -10% -17% -30% -18% -18% -29% -16% -16%
thereof United States 364 346 273 363 237 232 288 271 -3% -18% -37% -21% -35% -33% 5% -25%
thereof Europe 120 120 115 106 79 61 56 62 -21% -20% -18% -18% -34% -49% -51% -42%
thereof Japan 164 148 139 136 154 125 96 134 4% -17% -35% -30% -6% -16% -31% -1%
thereof International 228 221 203 220 249 171 176 227 -20% -13% -21% 1% 9% -23% -13% 3%
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52V
Year-To-Date in CHFm at constant full year 2022 exchange rates Global - Year-To-Date constant exchange rate growth rates
Ocrevus 1,479 2,921 4,433 6,035 1,690 3,348 5,049 6,801 18% 17% 17% 17% 14% 15% 14% 13%
Hemlibra 859 1,817 2,771 3,819 1,066 2,189 3,307 4,446 30% 30% 28% 27% 24% 20% 19% 16%
Perjeta 989 2,036 3,066 4,076 1,097 2,212 3,237 4,137 1% 5% 5% 5% 11% 9% 6% 1%
Tecentriq 825 1,745 2,683 3,717 951 1,946 2,975 4,064 8% 11% 10% 14% 15% 12% 11% 9%
Actemra/RoActemra 792 1,441 2,030 2,700 699 1,361 2,071 2,830 3% -10% -23% -22% -12% -6% 2% 5%
Vabysmo 21 110 283 591 446 1,002 1,708 2,508 - - - - 1999% 809% 504% 324%
Xolair 472 1,036 1,631 2,208 494 1,079 1,693 2,312 9% 11% 10% 9% 5% 4% 4% 5%
Kadcyla 509 1,064 1,581 2,076 533 1,063 1,607 2,166 9% 14% 11% 7% 5% 0% 2% 4%
Herceptin 599 1,156 1,656 2,141 499 936 1,371 1,790 -19% -16% -18% -19% -17% -19% -17% -16%
Avastin 572 1,119 1,636 2,122 433 889 1,312 1,725 -32% -29% -29% -28% -24% -21% -20% -19%
Alecensa 356 731 1,117 1,513 386 803 1,214 1,636 23% 19% 16% 15% 9% 10% 9% 8%
Evrysdi 233 502 793 1,119 377 743 1,152 1,549 189% 106% 101% 87% 62% 48% 45% 39%
Activase/TNKase 255 565 883 1,177 312 652 956 1,248 -20% -10% -8% -14% 23% 15% 8% 6%
Phesgo 145 322 524 740 250 544 870 1,211 410% 241% 150% 121% 72% 69% 66% 64%
Polivy 79 174 288 437 155 373 651 910 89% 91% 79% 85% 96% 114% 126% 108%
Gazyva/Gazyvaro 165 346 536 729 203 421 653 868 7% 8% 8% 9% 24% 22% 22% 19%
Ronapreve 542 581 620 1,679 590 591 591 596 272% 11% -36% 17% 9% 2% -5% -65%
Lucentis 264 578 803 1,012 173 313 419 489 -26% -17% -25% -28% -35% -46% -48% -52%
Pulmozyme 138 279 413 542 131 250 364 486 -3% 0% -1% -5% -5% -10% -12% -10%
Mircera 88 188 293 405 108 208 340 457 -14% -10% -9% -5% 24% 11% 16% 13%
CellCept 131 263 381 502 107 215 322 434 -12% -8% -12% -11% -18% -18% -15% -14%
Madopar 97 185 286 379 90 194 291 380 -10% -4% 1% -2% -7% 5% 2% 0%
Enspryng 39 82 131 192 56 128 204 286 216% 132% 108% 93% 42% 56% 55% 49%
Erivedge 64 130 199 271 61 131 203 272 6% 2% 2% 1% -4% 0% 2% 0%
Other Products 871 1,686 2,425 3,266 746 1,390 2,091 2,874 -9% -13% -17% -17% -14% -18% -14% -12%
Year-To-Date in CHFm at constant full year 2022 exchange rates Global - Year-To-Date constant exchange rate growth rates
Launched since 2015 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023
Cotellic 12 25 35 49 12 31 43 55 20% 4% 1% -3% -2% 26% 23% 14%
Alecensa 356 731 1,117 1,513 386 803 1,214 1,636 23% 19% 16% 15% 9% 10% 9% 8%
Tecentriq 825 1,745 2,683 3,717 951 1,946 2,975 4,064 8% 11% 10% 14% 15% 12% 11% 9%
Ocrevus 1,479 2,921 4,433 6,035 1,690 3,348 5,049 6,801 18% 17% 17% 17% 14% 15% 14% 13%
Hemlibra 859 1,817 2,771 3,819 1,066 2,189 3,307 4,446 30% 30% 28% 27% 24% 20% 19% 16%
Luxturna 5 12 21 45 4 8 46 47 -48% -41% -55% -35% -23% -31% 121% 4%
Xofluza 2 4 6 67 19 27 35 100 - - - 1599% 788% 623% 540% 49%
Polivy 79 174 288 437 155 373 651 910 89% 91% 79% 85% 96% 114% 126% 108%
Rozlytrek 16 34 53 75 20 42 67 93 78% 54% 50% 51% 21% 25% 27% 25%
Phesgo 145 322 524 740 250 544 870 1,211 410% 241% 150% 121% 72% 69% 66% 64%
Enspryng 39 82 131 192 56 128 204 286 216% 132% 108% 93% 42% 56% 55% 49%
Evrysdi 233 502 793 1,119 377 743 1,152 1,549 189% 106% 101% 87% 62% 48% 45% 39%
Gavreto 5 12 20 26 10 25 34 58 - - 299% 175% 95% 102% 66% 120%
Ronapreve 542 581 620 1,679 590 591 591 596 272% 11% -36% 17% 9% 2% -5% -65%
Susvimo 1 2 4 2 1 2 3 3 - - - 75% -33% -2% -23% 54%
Vabysmo 21 110 283 591 446 1,002 1,708 2,508 - - - - 1999% 809% 504% 324%
Lunsumio 0 0 1 3 15 29 46 62 - - - - - - 4582% 2110%
Columvi 0 0 0 0 0 5 10 30 - - - - - - - -
Quarterly in CHFm at constant full year 2022 exchange rates Global - Quarterly constant exchange rate growth rates
Pharma Products Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Ocrevus 1,479 1,442 1,512 1,602 1,690 1,658 1,701 1,753 18% 17% 16% 18% 14% 15% 12% 9%
Hemlibra 859 958 954 1,048 1,066 1,122 1,119 1,139 30% 31% 23% 24% 24% 17% 17% 9%
Perjeta 989 1,048 1,030 1,010 1,097 1,115 1,025 900 1% 9% 5% 4% 11% 6% 0% -11%
Tecentriq 825 919 938 1,035 951 995 1,030 1,088 8% 13% 9% 24% 15% 8% 10% 5%
Actemra/RoActemra 792 649 589 670 699 662 710 759 3% -23% -42% -22% -12% 2% 21% 13%
Vabysmo 21 89 172 308 446 555 706 800 - - - - 1999% 524% 309% 160%
Xolair 472 565 595 577 494 585 614 619 9% 13% 8% 6% 5% 4% 3% 7%
Kadcyla 509 556 517 495 533 530 545 559 9% 18% 6% -3% 5% -5% 5% 13%
Herceptin 599 557 499 485 499 437 434 419 -19% -11% -23% -22% -17% -22% -13% -14%
Avastin 572 547 517 486 433 456 423 413 -32% -27% -28% -25% -24% -17% -18% -15%
Alecensa 356 376 386 396 386 416 411 422 23% 16% 11% 10% 9% 11% 7% 7%
Evrysdi 233 269 290 326 377 366 409 398 189% 65% 93% 59% 62% 36% 41% 22%
Activase/TNKase 255 310 318 294 312 339 305 292 -20% 1% -5% -27% 23% 9% -4% -1%
Phesgo 145 176 203 216 250 294 326 341 410% 168% 76% 73% 72% 67% 61% 58%
Polivy 79 95 114 149 155 217 278 259 89% 93% 63% 97% 96% 129% 144% 74%
Gazyva/Gazyvaro 165 181 191 193 203 218 232 215 7% 9% 9% 9% 24% 20% 22% 12%
Ronapreve 542 39 38 1,059 590 1 0 5 272% -91% -92% 118% 9% -98% -100% -100%
Lucentis 264 314 225 209 173 140 106 71 -26% -9% -39% -40% -35% -55% -53% -66%
Pulmozyme 138 141 134 130 131 119 114 122 -3% 2% -3% -15% -5% -15% -15% -6%
Mircera 88 100 105 112 108 100 132 116 -14% -5% -9% 8% 24% -1% 27% 4%
CellCept 131 132 118 121 107 107 107 112 -12% -3% -20% -9% -18% -19% -9% -8%
Madopar 97 88 101 93 90 104 97 89 -10% 3% 11% -11% -7% 18% -4% -4%
Enspryng 39 42 49 60 56 71 76 82 216% 86% 78% 67% 42% 69% 54% 36%
Erivedge 64 66 69 72 61 69 72 69 6% -1% 1% -1% -4% 4% 5% -4%
Other Products 871 816 738 842 746 645 701 783 -9% -17% -26% -15% -14% -21% -5% -7%
Quarterly in CHFm at constant full year 2022 exchange rates Global - Year-To-Date constant exchange rate growth rates
Launched since 2015 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Cotellic 12 12 10 13 12 19 12 12 20% -8% -5% -11% -2% 53% 15% -8%
Alecensa 356 376 386 396 386 416 411 422 23% 16% 11% 10% 9% 11% 7% 7%
Tecentriq 825 919 938 1,035 951 995 1,030 1,088 8% 13% 9% 24% 15% 8% 10% 5%
Ocrevus 1,479 1,442 1,512 1,602 1,690 1,658 1,701 1,753 18% 17% 16% 18% 14% 15% 12% 9%
Hemlibra 859 958 954 1,048 1,066 1,122 1,119 1,139 30% 31% 23% 24% 24% 17% 17% 9%
Luxturna 5 7 9 25 4 4 38 1 -48% -35% -66% 8% -23% -37% 320% -96%
Xofluza 2 2 2 61 19 8 8 64 - - -45% 556% 788% 410% 356% 5%
Polivy 79 95 114 149 155 217 278 259 89% 93% 63% 97% 96% 129% 144% 74%
Rozlytrek 16 17 19 22 20 22 25 26 78% 38% 44% 54% 21% 30% 31% 19%
Phesgo 145 176 203 216 250 294 326 341 410% 168% 76% 73% 72% 67% 61% 58%
Enspryng 39 42 49 60 56 71 76 82 216% 86% 78% 67% 42% 69% 54% 36%
Evrysdi 233 269 290 326 377 366 409 398 189% 65% 93% 59% 62% 36% 41% 22%
Roche Online Financial Information System P Sales Global CER 04/03/2024 8/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm
Ocrevus 1,479 2,921 4,433 6,035 1,690 3,348 5,049 6,801 18% 17% 17% 17% 14% 15% 14% 13%
thereof Europe 271 525 802 1,075 302 596 901 1,205 34% 34% 25% 25% 11% 13% 12% 12%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Hemlibra 859 1,817 2,771 3,819 1,066 2,189 3,307 4,446 30% 30% 28% 27% 24% 20% 19% 16%
thereof Europe 165 350 538 741 209 428 657 876 31% 30% 32% 30% 27% 22% 22% 18%
thereof Japan 77 170 271 377 95 206 312 424 15% 19% 20% 18% 24% 21% 15% 12%
Perjeta 989 2,036 3,066 4,076 1,097 2,212 3,237 4,137 1% 5% 5% 5% 11% 9% 6% 1%
thereof United States 375 749 1,139 1,533 404 799 1,165 1,419 -1% 1% 1% 4% 8% 7% 2% -7%
thereof Europe 221 445 656 871 223 421 632 801 -21% -17% -16% -16% 1% -5% -4% -8%
thereof Japan 54 113 171 234 55 117 179 244 -1% -1% -1% 0% 2% 3% 4% 4%
thereof International 340 729 1,100 1,439 414 875 1,262 1,672 32% 34% 33% 27% 22% 20% 15% 16%
Tecentriq 825 1,745 2,683 3,717 951 1,946 2,975 4,064 8% 11% 10% 14% 15% 12% 11% 9%
thereof United States 461 962 1,456 1,975 523 1,047 1,561 2,062 10% 13% 9% 12% 14% 9% 7% 4%
thereof Europe 177 372 569 794 198 406 646 875 14% 19% 19% 20% 11% 9% 14% 10%
thereof Japan 98 206 319 443 110 230 348 476 -5% -7% -5% -2% 12% 11% 9% 8%
Actemra/RoActemra 792 1,441 2,030 2,700 699 1,361 2,071 2,830 3% -10% -23% -22% -12% -6% 2% 5%
thereof United States 393 671 917 1,196 305 601 928 1,299 22% -7% -33% -35% -22% -11% 1% 9%
thereof Europe 213 409 597 802 197 392 602 804 -4% -3% -3% -6% -8% -4% 1% 0%
thereof Japan 80 164 250 342 80 169 258 353 12% 4% 1% 2% 0% 3% 3% 3%
thereof International 107 197 266 360 117 199 283 374 -30% -37% -39% -28% 10% 1% 6% 4%
Vabysmo 21 110 283 591 446 1,002 1,708 2,508 - - - - 1999% 809% 504% 324%
thereof United States 21 103 254 517 371 825 1,396 2,033 - - - - 1648% 705% 449% 293%
thereof Europe 0 0 4 22 45 106 192 287 - - - - - 756621% 5080% 1177%
thereof Japan 0 7 23 47 22 49 78 111 - - - - - 617% 236% 138%
Xolair 472 1,036 1,631 2,208 494 1,079 1,693 2,312 9% 11% 10% 9% 5% 4% 4% 5%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Kadcyla 509 1,064 1,581 2,076 533 1,063 1,607 2,166 9% 14% 11% 7% 5% 0% 2% 4%
thereof United States 211 420 621 820 205 404 601 805 0% -1% -3% -3% -3% -4% -3% -2%
thereof Europe 166 340 504 671 156 304 459 598 8% 10% 8% 5% -6% -10% -9% -11%
thereof Japan 30 64 99 131 27 56 85 116 28% 23% 21% 16% -8% -13% -14% -12%
thereof United States 358 699 1,005 1,316 282 559 805 1,049 -20% -22% -20% -19% -21% -20% -20% -20%
thereof Europe 52 103 155 204 52 98 145 186 -19% -17% -18% -19% 0% -4% -7% -9%
thereof Japan 7 16 24 32 6 14 21 28 -15% -8% -10% -14% -13% -14% -13% -13%
Herceptin 599 1,156 1,656 2,141 499 936 1,371 1,790 -19% -16% -18% -19% -17% -19% -17% -16%
thereof Europe 118 227 327 422 98 187 278 364 -13% -11% -13% -17% -17% -17% -15% -14%
thereof Japan 13 27 39 51 9 18 26 35 -30% -28% -28% -28% -30% -32% -33% -33%
thereof International 319 637 912 1,191 298 547 794 1,039 -18% -11% -15% -15% -7% -14% -13% -13%
Avastin 572 1,119 1,636 2,122 433 889 1,312 1,725 -32% -29% -29% -28% -24% -21% -20% -19%
thereof Europe 56 113 157 193 31 59 81 101 -56% -53% -51% -52% -45% -48% -48% -47%
thereof Japan 120 249 370 490 95 190 278 362 -12% -13% -15% -17% -21% -23% -25% -26%
Alecensa 356 731 1,117 1,513 386 803 1,214 1,636 23% 19% 16% 15% 9% 10% 9% 8%
thereof Europe 72 145 217 292 75 151 226 303 5% 7% 6% 5% 3% 4% 5% 4%
thereof Japan 50 108 165 228 52 115 174 240 7% 6% 5% 6% 5% 6% 6% 5%
Evrysdi 233 502 793 1,119 377 743 1,152 1,549 189% 106% 101% 87% 62% 48% 45% 39%
thereof Europe 66 148 251 353 115 246 386 528 - 489% 335% 236% 74% 66% 54% 49%
thereof Japan 15 36 58 84 22 48 75 106 - - 2163% 406% 47% 34% 29% 26%
Activase/TNKase 255 565 883 1,177 312 652 956 1,248 -20% -10% -8% -14% 23% 15% 8% 6%
thereof United States 242 537 839 1,114 297 620 908 1,182 -21% -10% -9% -15% 23% 15% 8% 6%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 13 28 45 63 15 31 48 66 -3% 1% 5% 9% 17% 12% 7% 5%
Phesgo 145 322 524 740 250 544 870 1,211 410% 241% 150% 121% 72% 69% 66% 64%
thereof Europe 73 157 260 367 117 247 398 557 977% 338% 204% 142% 59% 57% 53% 52%
thereof Japan 0 0 0 0 0 0 0 5 - - - - - - - -
Polivy 79 174 288 437 155 373 651 910 89% 91% 79% 85% 96% 114% 126% 108%
thereof Europe 21 45 83 132 40 82 141 180 4% 16% 41% 68% 93% 84% 70% 36%
thereof Japan 20 41 66 113 53 116 186 258 - 524% 161% 127% 169% 182% 181% 129%
Gazyva/Gazyvaro 165 346 536 729 203 421 653 868 7% 8% 8% 9% 24% 22% 22% 19%
thereof Europe 45 92 143 192 56 114 179 238 -5% -6% -7% -8% 25% 24% 25% 24%
thereof Japan 13 26 38 50 9 22 31 43 8% -2% -7% -8% -35% -17% -17% -14%
Ronapreve 542 581 620 1,679 590 591 591 596 272% 11% -36% 17% 9% 2% -5% -65%
thereof Europe 60 63 101 101 0 0 0 5 -61% -86% -81% -85% -100% -100% -100% -95%
thereof Japan 442 442 442 1,480 590 590 590 590 - - 42% 163% 33% 33% 33% -60%
thereof International 40 76 77 97 0 1 1 1 - -30% -49% -62% -100% -99% -99% -99%
Lucentis 264 578 803 1,012 173 313 419 489 -26% -17% -25% -28% -35% -46% -48% -52%
thereof United States 264 578 803 1,012 173 313 419 489 -26% -17% -25% -28% -35% -46% -48% -52%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Pulmozyme 138 279 413 542 131 250 364 486 -3% 0% -1% -5% -5% -10% -12% -10%
thereof Europe 25 49 72 96 21 40 59 79 -11% -11% -12% -12% -16% -18% -18% -18%
thereof Japan 0 0 0 1 0 0 1 1 11% 28% 18% 23% 18% 5% 13% 8%
thereof International 23 43 59 77 25 44 62 84 -4% 4% -2% -4% 10% 3% 6% 9%
Mircera 88 188 293 405 108 208 340 457 -14% -10% -9% -5% 24% 11% 16% 13%
thereof Europe 13 26 38 48 12 23 35 45 10% 3% -1% -7% -10% -10% -7% -6%
thereof Japan 19 39 59 79 15 30 46 61 -24% -24% -25% -25% -22% -22% -22% -22%
thereof International 55 123 197 278 81 154 260 350 -14% -6% -4% 4% 47% 25% 32% 26%
CellCept 131 263 381 502 107 215 322 434 -12% -8% -12% -11% -18% -18% -15% -14%
thereof Europe 33 66 100 135 33 65 97 127 -7% -7% -6% -6% 1% -2% -3% -6%
thereof Japan 13 27 42 58 12 25 38 51 -8% -8% -6% -5% -8% -8% -11% -11%
Madopar 97 185 286 379 90 194 291 380 -10% -4% 1% -2% -7% 5% 2% 0%
thereof Europe 24 51 78 104 25 51 77 102 3% 2% 2% -1% 3% 1% -1% -2%
Roche Online Financial Information System P Sales Regions CER 04/03/2024 9/43
thereof Japan 0 0 0 0 0 0 0 0 0% 0% 0% 0% 0% 0% 0% 0%
thereof International 73 134 209 275 65 143 215 278 -13% -6% 1% -3% -11% 7% 3% 1%
Enspryng 39 82 131 192 56 128 204 286 216% 132% 108% 93% 42% 56% 55% 49%
thereof Europe 2 4 6 9 4 8 13 19 1663% 1388% 513% 253% 96% 98% 108% 111%
thereof Japan 24 52 84 122 34 79 123 174 141% 102% 87% 73% 44% 53% 46% 43%
Erivedge 64 130 199 271 61 131 203 272 6% 2% 2% 1% -4% 0% 2% 0%
thereof United States 41 83 126 173 34 75 117 157 2% -3% -6% -5% -18% -9% -7% -9%
thereof Europe 14 29 44 58 15 29 43 57 2% 6% 7% 3% 4% -2% -2% -2%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Other Products 871 1,686 2,425 3,266 746 1,390 2,091 2,874 -9% -13% -17% -17% -14% -18% -14% -12%
thereof United States 377 717 986 1,346 247 492 804 1,092 -4% -14% -23% -23% -35% -31% -18% -19%
thereof Europe 116 232 351 460 81 143 202 269 -18% -16% -14% -14% -30% -39% -42% -42%
thereof Japan 148 294 442 588 160 299 416 577 10% 2% -7% -9% 8% 2% -6% -2%
thereof International 231 443 646 872 259 456 669 937 -19% -18% -18% -13% 12% 3% 4% 8%
Ocrevus 1,479 1,442 1,512 1,602 1,690 1,658 1,701 1,753 18% 17% 16% 18% 14% 15% 12% 9%
thereof Europe 271 254 277 273 302 294 305 304 34% 34% 11% 26% 11% 16% 10% 11%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Hemlibra 859 958 954 1,048 1,066 1,122 1,119 1,139 30% 31% 23% 24% 24% 17% 17% 9%
thereof Europe 165 186 188 203 209 219 228 220 31% 29% 36% 27% 27% 18% 22% 8%
thereof Japan 77 93 101 106 95 111 106 112 15% 24% 22% 14% 24% 19% 5% 5%
Perjeta 989 1,048 1,030 1,010 1,097 1,115 1,025 900 1% 9% 5% 4% 11% 6% 0% -11%
thereof United States 375 374 390 394 404 395 366 254 -1% 4% 0% 13% 8% 6% -6% -35%
thereof Europe 221 224 211 214 223 198 211 169 -21% -12% -15% -15% 1% -12% 0% -21%
thereof Japan 54 59 58 63 55 62 61 66 -1% -1% -1% 3% 2% 5% 6% 3%
Tecentriq 825 919 938 1,035 951 995 1,030 1,088 8% 13% 9% 24% 15% 8% 10% 5%
thereof United States 461 501 494 519 523 524 514 501 10% 15% 3% 20% 14% 5% 4% -4%
thereof Europe 177 194 197 225 198 209 239 229 14% 24% 17% 23% 11% 7% 22% 2%
thereof Japan 98 109 112 124 110 120 118 128 -5% -9% 0% 6% 12% 11% 5% 3%
Actemra/RoActemra 792 649 589 670 699 662 710 759 3% -23% -42% -22% -12% 2% 21% 13%
thereof United States 393 279 246 279 305 295 328 371 22% -31% -61% -42% -22% 6% 33% 33%
thereof Europe 213 196 188 205 197 196 209 202 -4% -2% -3% -14% -8% 0% 11% -1%
thereof Japan 80 85 86 92 80 89 90 95 12% -2% -4% 6% 0% 5% 4% 3%
thereof International 107 90 69 94 117 82 84 91 -30% -44% -44% 51% 10% -9% 20% -3%
Vabysmo 21 89 172 308 446 555 706 800 - - - - 1999% 524% 309% 160%
thereof United States 21 81 152 263 371 453 571 637 - - - - 1648% 458% 276% 142%
thereof Europe 0 0 4 19 45 61 86 95 - - - - - 436483% 2227% 406%
thereof Japan 0 7 16 23 22 27 29 33 - - - - - 299% 77% 42%
Xolair 472 565 595 577 494 585 614 619 9% 13% 8% 6% 5% 4% 3% 7%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Kadcyla 509 556 517 495 533 530 545 559 9% 18% 6% -3% 5% -5% 5% 13%
thereof United States 211 209 201 199 205 199 197 204 0% -1% -8% -4% -3% -5% -2% 3%
thereof Europe 166 174 165 167 156 148 155 139 8% 12% 3% -2% -6% -15% -6% -17%
thereof Japan 30 35 34 33 27 29 29 31 28% 20% 16% 2% -8% -17% -15% -6%
thereof International 102 139 117 96 145 154 164 184 26% 81% 46% -3% 42% 11% 41% 91%
thereof Europe 52 51 52 49 52 46 47 41 -19% -16% -18% -21% 0% -9% -11% -15%
thereof Japan 7 9 8 8 6 7 7 7 -15% -2% -13% -23% -13% -15% -11% -15%
thereof International 154 143 111 116 136 123 116 118 -23% -13% -32% -28% -12% -14% 4% 2%
Herceptin 599 557 499 485 499 437 434 419 -19% -11% -23% -22% -17% -22% -13% -14%
thereof Europe 118 109 100 96 98 89 91 86 -13% -9% -18% -27% -17% -18% -9% -10%
thereof Japan 13 14 12 12 9 9 8 8 -30% -27% -28% -28% -30% -34% -35% -31%
Avastin 572 547 517 486 433 456 423 413 -32% -27% -28% -25% -24% -17% -18% -15%
thereof Europe 56 56 44 36 31 28 22 21 -56% -49% -47% -56% -45% -51% -50% -43%
thereof Japan 120 128 121 121 95 96 88 84 -12% -13% -19% -21% -21% -25% -28% -31%
thereof International 211 201 200 194 170 202 190 186 -23% -17% -23% -16% -19% 1% -5% -4%
Alecensa 356 376 386 396 386 416 411 422 23% 16% 11% 10% 9% 11% 7% 7%
thereof Europe 72 73 72 75 75 76 76 76 5% 8% 5% 3% 3% 5% 5% 1%
thereof Japan 50 58 57 63 52 63 59 66 7% 5% 4% 7% 5% 7% 5% 5%
Evrysdi 233 269 290 326 377 366 409 398 189% 65% 93% 59% 62% 36% 41% 22%
thereof Europe 66 82 103 103 115 132 139 142 - 227% 216% 116% 74% 61% 35% 39%
thereof Japan 15 21 23 26 22 26 27 31 - - 776% 83% 47% 25% 21% 19%
thereof International 39 50 45 77 112 70 106 91 4658% -5% 231% 73% 189% 39% 134% 18%
Activase/TNKase 255 310 318 294 312 339 305 292 -20% 1% -5% -27% 23% 9% -4% -1%
thereof United States 242 295 302 275 297 323 288 274 -21% 1% -6% -29% 23% 9% -5% -1%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
thereof International 13 15 17 18 15 17 17 18 -3% 4% 12% 20% 17% 8% -1% -1%
Phesgo 145 176 203 216 250 294 326 341 410% 168% 76% 73% 72% 67% 61% 58%
thereof Europe 73 84 102 107 117 131 151 159 977% 188% 107% 61% 59% 55% 47% 49%
thereof Japan 0 0 0 0 0 0 0 5 - - - - - - - -
Polivy 79 95 114 149 155 217 278 259 89% 93% 63% 97% 96% 129% 144% 74%
thereof Europe 21 24 38 49 40 42 59 39 4% 30% 88% 144% 93% 76% 53% -21%
thereof Japan 20 21 25 47 53 63 70 72 - 226% 34% 92% 169% 194% 178% 55%
Gazyva/Gazyvaro 165 181 191 193 203 218 232 215 7% 9% 9% 9% 24% 20% 22% 12%
thereof Europe 45 47 51 49 56 58 65 58 -5% -8% -9% -8% 25% 22% 29% 18%
thereof Japan 13 13 12 12 9 13 10 11 8% -10% -17% -12% -35% 1% -18% -4%
Ronapreve 542 39 38 1,059 590 1 0 5 272% -91% -92% 118% 9% -98% -100% -100%
thereof United States 0 0 0 0 0 0 0 0 0% - - - - - - -
thereof Europe 60 3 38 0 0 0 0 5 -61% -99% -54% -100% -100% -100% -100% 167600%
thereof Japan 442 0 0 1,038 590 0 0 0 - - - 313% 33% - - -
thereof International 40 36 0 21 0 1 0 0 - -68% -99% -81% -100% -97% - -
Lucentis 264 314 225 209 173 140 106 71 -26% -9% -39% -40% -35% -55% -53% -66%
thereof Europe 0 0 0 0 0 0 0 0 - - - - - - - -
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Pulmozyme 138 141 134 130 131 119 114 122 -3% 2% -3% -15% -5% -15% -15% -6%
thereof Europe 25 24 23 23 21 19 19 20 -11% -12% -12% -13% -16% -20% -18% -15%
thereof Japan 0 0 0 0 0 0 0 0 11% 44% -1% 38% 18% -4% 33% -4%
thereof International 23 20 15 19 25 19 18 22 -4% 14% -16% -9% 10% -5% 14% 18%
Mircera 88 100 105 112 108 100 132 116 -14% -5% -9% 8% 24% -1% 27% 4%
thereof Europe 13 12 12 11 12 11 12 10 10% -3% -8% -24% -10% -9% -2% -2%
thereof Japan 19 20 20 20 15 15 15 16 -24% -24% -27% -24% -22% -23% -22% -22%
thereof International 55 68 73 81 81 73 106 90 -14% 3% -2% 33% 47% 7% 44% 11%
Cellcept 131 132 118 121 107 107 107 112 -12% -3% -20% -9% -18% -19% -9% -8%
thereof Europe 33 33 34 35 33 32 32 30 -7% -7% -5% -4% 1% -5% -4% -14%
thereof Japan 13 14 15 16 12 13 12 14 -8% -9% -1% -4% -8% -8% -15% -12%
thereof International 74 75 60 62 54 54 56 59 -14% 3% -29% -11% -28% -28% -6% -4%
Madopar 97 88 101 93 90 104 97 89 -10% 3% 11% -11% -7% 18% -4% -4%
thereof Europe 24 26 27 27 25 26 26 26 3% 2% 1% -8% 3% -1% -5% -4%
thereof Japan 0 0 0 0 0 0 0 0 0% - - - 0% - - -
thereof International 73 62 74 66 65 78 72 63 -13% 4% 15% -12% -11% 27% -4% -4%
Enspryng 39 42 49 60 56 71 76 82 216% 86% 78% 67% 42% 69% 54% 36%
thereof Europe 2 2 2 3 4 4 5 6 1663% 1205% 209% 78% 96% 99% 125% 117%
thereof Japan 24 28 32 38 34 45 43 51 141% 78% 66% 49% 44% 60% 36% 35%
Erivedge 64 66 69 72 61 69 72 69 6% -1% 1% -1% -4% 4% 5% -4%
thereof United States 41 42 43 47 34 42 42 39 2% -8% -12% 1% -18% 0% -3% -16%
thereof Europe 14 15 14 15 15 14 14 14 2% 10% 10% -7% 4% -9% -1% -3%
thereof Japan 0 0 0 0 0 0 0 0 - - - - - - - -
Other Products 871 816 738 842 746 645 701 783 -9% -17% -26% -15% -14% -21% -5% -7%
thereof United States 377 341 268 361 247 246 311 288 -4% -23% -40% -24% -35% -28% 16% -20%
thereof Europe 116 116 119 109 81 62 60 66 -18% -15% -9% -13% -30% -47% -50% -39%
thereof Japan 148 147 148 146 160 139 117 160 10% -5% -21% -16% 8% -5% -21% 10%
thereof International 231 212 203 226 259 198 212 269 -19% -17% -17% 5% 12% -7% 5% 19%
Therapeutic areas Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023
Oncology 4,910 10,086 15,027 19,995 4,883 9,775 14,539 19,087 -4% -1% -2% -2% -1% -3% -3% -5%
Neuroscience 1,845 3,750 5,724 7,817 2,150 4,229 6,317 8,445 26% 26% 25% 25% 17% 13% 10% 8%
Immunology 1,892 3,752 5,440 7,181 1,566 3,095 4,647 6,242 -2% -6% -13% -14% -17% -18% -15% -13%
Haemophilia A 853 1,826 2,778 3,823 1,034 2,087 3,112 4,147 29% 31% 28% 27% 21% 14% 12% 8%
Ophthalmology 282 695 1,107 1,651 604 1,265 2,055 2,865 -18% 2% 4% 16% 114% 82% 86% 74%
Infectious diseases 689 810 938 2,161 760 819 877 1,056 109% -9% -38% -3% 10% 1% -7% -51%
Other therapeutic areas 688 1,428 2,175 2,923 702 1,411 2,075 2,770 -9% -7% -9% -10% 2% -1% -5% -5%
Total 11,159 22,347 33,189 45,551 11,699 22,681 33,622 44,612 5% 3% -1% 1% 5% 1% 1% -2%
Quarterly in CHFm at reported exchange rates Quarterly CHF growth rates

Therapeutic areas Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Oncology 4,910 5,176 4,941 4,968 4,883 4,892 4,764 4,548 -4% 2% -5% -2% -1% -5% -4% -8%
Neuroscience 1,845 1,905 1,974 2,093 2,150 2,079 2,088 2,128 26% 26% 24% 22% 17% 9% 6% 2%
Immunology 1,892 1,860 1,688 1,741 1,566 1,529 1,552 1,595 -2% -11% -26% -17% -17% -18% -8% -8%
Haemophilia A 853 973 952 1,045 1,034 1,053 1,025 1,035 29% 33% 22% 23% 21% 8% 8% -1%
Ophthalmology 282 413 412 544 604 661 790 810 -18% 22% 9% 52% 114% 60% 92% 49%
Infectious diseases 689 121 128 1,223 760 59 58 179 109% -78% -80% 72% 10% -51% -55% -85%
Other therapeutic areas 688 740 747 748 702 709 664 695 -9% -5% -14% -13% 2% -4% -11% -7%
Total 11,159 11,188 10,842 12,362 11,699 10,982 10,941 10,990 5% 1% -7% 6% 5% -2% 1% -11%
Roche Online Financial Information System P Therapeutic areas CHF 04/03/2024 13/43
Therapeutic areas Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023 Q1 2022 H1 2022 YTD Sep 22 2022 Q1 2023 H1 2023 YTD Sep 23 2023
Oncology 4,881 9,961 14,929 19,979 5,081 10,345 15,650 20,811 -3% -1% -1% -1% 4% 4% 5% 4%
Neuroscience 1,879 3,756 5,725 7,816 2,222 4,432 6,720 9,051 26% 24% 24% 23% 18% 18% 17% 16%
Immunology 1,912 3,741 5,430 7,179 1,620 3,250 4,944 6,693 -2% -7% -14% -14% -15% -13% -9% -7%
Haemophilia A 859 1,817 2,771 3,819 1,066 2,189 3,307 4,446 30% 30% 28% 27% 24% 20% 19% 16%
Ophthalmology 291 702 1,110 1,651 623 1,324 2,175 3,047 -20% -2% 0% 12% 114% 89% 96% 85%
Infectious diseases 643 779 924 2,161 790 877 969 1,185 118% -3% -33% 7% 23% 13% 5% -45%
Other therapeutic areas 688 1,417 2,166 2,920 728 1,491 2,230 2,998 -9% -8% -9% -10% 6% 5% 3% 3%
Total 11,154 22,173 33,054 45,525 12,131 23,907 35,996 48,230 6% 3% 0% 2% 9% 8% 9% 6%
Therapeutic areas Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Oncology 4,881 5,080 4,968 5,050 5,081 5,264 5,305 5,161 -3% 2% -2% 1% 4% 4% 7% 2%
Neuroscience 1,879 1,877 1,968 2,091 2,222 2,209 2,288 2,331 26% 23% 23% 21% 18% 18% 16% 11%
Immunology 1,912 1,828 1,689 1,749 1,620 1,629 1,695 1,748 -2% -12% -25% -17% -15% -11% 0% 0%
Haemophilia A 859 958 954 1,048 1,066 1,122 1,119 1,139 30% 31% 23% 24% 24% 17% 17% 9%
Ophthalmology 291 411 408 541 623 701 851 872 -20% 16% 5% 47% 114% 71% 108% 61%
Infectious diseases 643 135 145 1,237 790 87 92 216 118% -75% -76% 94% 23% -36% -37% -83%
Other therapeutic areas 688 729 748 754 728 763 739 767 -9% -6% -13% -12% 6% 5% -1% 2%
Total 11,154 11,019 10,881 12,471 12,131 11,776 12,089 12,234 6% 0% -6% 9% 9% 7% 11% -2%
Roche Online Financial Information System P Therapeutic areas CER 04/03/2024 14/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5xI75I3Rz
Diagnostics Division by Customer Area - Year-To-Date in CHFm at reported exchange rates Diagnostics Division by Customer Area - Year-To-Date CHF growth rates
Core Lab 1,896 3,875 5,833 7,775 1,928 3,935 5,836 7,750 6% 3% 3% 3% 2% 2% 0% 0%
thereof EMEA 679 1,352 1,971 2,648 669 1,362 1,999 2,681 2% -2% -3% -3% -1% 1% 1% 1%
thereof North America 348 716 1,074 1,440 337 691 1,017 1,374 5% 5% 7% 5% -3% -3% -5% -5%
thereof Asia-Pacific 736 1,521 2,355 3,100 774 1,575 2,356 3,068 10% 4% 5% 5% 5% 4% 0% -1%
thereof Latin America 133 286 433 587 148 307 464 627 13% 13% 11% 13% 11% 7% 7% 7%
Molecular Lab 1,189 1,980 2,735 3,450 593 1,118 1,647 2,220 19% -1% -10% -17% -50% -44% -40% -36%
thereof EMEA 460 732 982 1,212 198 363 530 712 21% -4% -11% -21% -57% -50% -46% -41%
thereof North America 404 714 1,010 1,343 256 489 729 993 10% 3% -6% -13% -37% -32% -28% -26%
thereof Asia-Pacific 286 466 656 785 120 227 326 424 38% 3% -10% -16% -58% -51% -50% -46%
thereof Latin America 39 68 87 110 19 39 62 91 -7% -22% -30% -32% -51% -43% -29% -17%
Pathology Lab 318 652 975 1,318 329 687 1,046 1,388 13% 11% 10% 10% 3% 5% 7% 5%
thereof EMEA 78 160 237 321 82 169 251 342 4% 3% 1% 1% 5% 6% 6% 7%
thereof North America 169 348 523 715 178 369 570 751 13% 13% 13% 14% 5% 6% 9% 5%
thereof Asia-Pacific 66 132 196 256 62 134 202 263 22% 12% 10% 8% -6% 2% 3% 3%
Point of Care 1,466 2,609 3,086 3,589 397 635 865 1,379 82% 45% 28% 15% -73% -76% -72% -62%
thereof EMEA 452 652 753 861 102 182 254 339 -24% -52% -54% -58% -77% -72% -66% -61%
thereof North America 726 974 1,135 1,399 203 288 385 506 554% 349% 204% 155% -72% -70% -66% -64%
thereof Asia-Pacific 236 908 1,106 1,223 79 140 189 487 382% 704% 341% 245% -67% -85% -83% -60%
Diabetes Care 417 832 1,219 1,598 376 723 1,037 1,367 -9% -7% -6% -5% -10% -13% -15% -14%
thereof EMEA 233 454 652 846 202 380 535 694 -8% -8% -9% -9% -13% -16% -18% -18%
thereof North America 58 116 181 244 55 103 152 202 -38% -28% -18% -14% -5% -11% -16% -17%
thereof Latin America 55 118 177 233 56 111 160 217 12% 22% 20% 20% 2% -6% -10% -7%
thereof EMEA 1,902 3,350 4,595 5,888 1,253 2,456 3,569 4,768 -3% -19% -20% -22% -34% -27% -22% -19%
thereof North America 1,705 2,868 3,923 5,141 1,029 1,940 2,853 3,826 62% 40% 25% 18% -40% -32% -27% -26%
thereof Asia-Pacific 1,395 3,171 4,522 5,639 1,098 2,205 3,263 4,496 33% 38% 25% 19% -21% -30% -28% -20%
thereof Latin America 284 559 808 1,062 243 497 746 1,014 6% 2% -4% -3% -14% -11% -8% -5%
Diagnostics Division by Customer Area - Quarterly in CHFm at reported exchange rates Diagnostics Division by Customer Area - Quarterly CHF growth rates
Core Lab 1,896 1,979 1,958 1,942 1,928 2,007 1,901 1,914 6% 0% 3% 3% 2% 1% -3% -1%
thereof EMEA 679 673 619 677 669 693 637 682 2% -5% -7% -1% -1% 3% 3% 1%
thereof North America 348 368 358 366 337 354 326 357 5% 6% 9% 1% -3% -4% -9% -2%
thereof Asia-Pacific 736 785 834 745 774 801 781 712 10% -1% 8% 6% 5% 2% -6% -4%
Molecular Lab 1,189 791 755 715 593 525 529 573 19% -20% -27% -38% -50% -34% -30% -20%
thereof EMEA 460 272 250 230 198 165 167 182 21% -28% -26% -48% -57% -39% -33% -21%
thereof North America 404 310 296 333 256 233 240 264 10% -5% -23% -28% -37% -25% -19% -21%
thereof Asia-Pacific 286 180 190 129 120 107 99 98 38% -27% -32% -37% -58% -41% -48% -24%
thereof Latin America 39 29 19 23 19 20 23 29 -7% -36% -49% -38% -51% -31% 21% 26%
Pathology Lab 318 334 323 343 329 358 359 342 13% 8% 8% 10% 3% 7% 11% 0%
thereof EMEA 78 82 77 84 82 87 82 91 4% 2% -3% 1% 5% 6% 6% 8%
thereof North America 169 179 175 192 178 191 201 181 13% 13% 14% 16% 5% 7% 15% -6%
thereof Asia-Pacific 66 66 64 60 62 72 68 61 22% 3% 7% 2% -6% 9% 6% 2%
Point of Care 1,466 1,143 477 503 397 238 230 514 82% 15% -23% -30% -73% -79% -52% 2%
thereof EMEA 452 200 101 108 102 80 72 85 -24% -74% -62% -73% -77% -60% -29% -21%
thereof North America 726 248 161 264 203 85 97 121 554% 134% 3% 51% -72% -66% -40% -54%
thereof Asia-Pacific 236 672 198 117 79 61 49 298 382% 950% 43% 13% -67% -91% -75% 155%
Diabetes Care 417 415 387 379 376 347 314 330 -9% -4% -3% -4% -10% -16% -19% -13%
thereof EMEA 233 221 198 194 202 178 155 159 -8% -8% -10% -10% -13% -19% -22% -18%
thereof North America 58 58 65 63 55 48 49 50 -38% -12% 7% 0% -5% -17% -25% -21%
thereof Latin America 55 63 59 56 56 55 49 57 12% 31% 16% 22% 2% -13% -17% 2%
Roche Online Financial Information System Dia Sales CHF 04/03/2024 15/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5xI75I3Rz
Diagnostics Division by CA - Year-To-Date in CHFm at constant full year 2022 exchange rates Diagnostics Division by Customer Area - Year-To-Date constant exchange rate growth rates
Core Lab 1,870 3,803 5,780 7,775 2,005 4,169 6,306 8,472 8% 4% 5% 6% 7% 10% 9% 9%
thereof EMEA 663 1,320 1,956 2,648 692 1,425 2,128 2,885 8% 5% 5% 6% 4% 8% 9% 9%
thereof North America 359 723 1,077 1,440 349 725 1,078 1,463 3% 1% 2% 1% -3% 0% 0% 2%
thereof Asia-Pacific 713 1,478 2,317 3,099 809 1,692 2,593 3,417 9% 3% 6% 8% 13% 15% 12% 10%
Molecular Lab 1,179 1,952 2,719 3,450 616 1,180 1,766 2,402 21% 1% -8% -15% -48% -40% -35% -30%
thereof EMEA 447 713 974 1,212 205 382 566 770 26% 2% -4% -15% -54% -46% -42% -36%
thereof North America 417 721 1,012 1,343 266 513 772 1,056 8% -1% -10% -16% -36% -29% -24% -21%
Pathology Lab 319 647 972 1,318 341 724 1,120 1,500 14% 10% 10% 11% 7% 12% 15% 14%
thereof EMEA 76 156 235 321 85 177 268 370 12% 11% 11% 11% 12% 13% 14% 15%
thereof Asia-Pacific 64 128 193 256 64 144 222 293 23% 13% 13% 12% 0% 12% 15% 15%
Point of Care 1,465 2,571 3,063 3,589 411 668 924 1,503 84% 46% 30% 17% -72% -74% -70% -58%
thereof EMEA 436 633 746 861 106 188 266 356 -21% -50% -51% -55% -76% -70% -64% -59%
thereof North America 747 981 1,136 1,399 209 302 408 538 541% 333% 192% 146% -72% -69% -64% -62%
thereof Asia-Pacific 229 882 1,089 1,223 82 150 209 550 396% 713% 357% 264% -64% -83% -81% -55%
Diabetes Care 416 819 1,210 1,598 397 777 1,140 1,538 -7% -5% -3% -2% -5% -5% -6% -4%
thereof EMEA 233 449 650 844 208 396 565 740 -3% -3% -3% -4% -11% -12% -13% -12%
thereof North America 60 117 181 244 57 109 162 215 -39% -30% -21% -17% -4% -7% -11% -12%
thereof Asia-Pacific 69 141 207 277 67 140 210 284 9% 1% 1% 0% -4% -1% 1% 2%
thereof EMEA 1,855 3,272 4,560 5,886 1,295 2,567 3,793 5,121 2% -14% -13% -16% -30% -22% -17% -13%
thereof North America 1,757 2,893 3,932 5,141 1,066 2,035 3,023 4,071 59% 34% 20% 13% -39% -30% -23% -21%
thereof Asia-Pacific 1,353 3,082 4,453 5,640 1,147 2,369 3,592 5,013 34% 39% 28% 23% -15% -23% -19% -11%
thereof Latin America 285 546 797 1,063 262 548 848 1,210 9% 2% -3% -1% -8% 0% 6% 14%
Diagnostics Division by CA - Quarterly in CHFm at constant full year 2022 exchange rates Diagnostics Division by Customer Area - Quarterly constant exchange rate growth rates
Core Lab 1,870 1,933 1,977 1,995 2,005 2,164 2,137 2,166 8% 1% 7% 9% 7% 12% 8% 9%
thereof EMEA 663 658 636 692 692 733 703 757 8% 2% 4% 7% 4% 12% 11% 9%
thereof North America 359 364 354 363 349 376 353 385 3% 0% 4% -3% -3% 3% 0% 6%
thereof Asia-Pacific 713 764 839 781 809 883 901 824 9% -2% 11% 14% 13% 15% 7% 5%
Molecular Lab 1,179 773 766 731 616 565 585 637 21% -20% -24% -35% -48% -27% -24% -13%
thereof EMEA 447 266 260 238 205 176 185 203 26% -23% -17% -42% -54% -34% -29% -15%
thereof North America 417 304 291 330 266 247 259 284 8% -11% -27% -31% -36% -19% -11% -14%
thereof Latin America 39 27 20 24 20 23 27 37 -4% -37% -44% -35% -48% -14% 37% 53%
Pathology Lab 319 328 325 346 341 384 395 380 14% 7% 10% 12% 7% 17% 22% 10%
thereof EMEA 76 81 79 87 85 93 91 102 12% 11% 9% 14% 12% 15% 16% 18%
thereof Asia-Pacific 64 64 65 63 64 80 78 71 23% 4% 12% 9% 0% 24% 21% 13%
Point of Care 1,465 1,107 491 527 411 257 256 578 84% 15% -16% -26% -72% -77% -48% 10%
thereof EMEA 436 197 112 115 106 82 78 90 -21% -72% -55% -70% -76% -58% -30% -21%
thereof North America 747 234 155 263 209 93 105 131 541% 112% -5% 46% -72% -60% -32% -50%
thereof Asia-Pacific 229 653 207 134 82 68 58 342 396% 955% 67% 42% -64% -90% -72% 155%
thereof Latin America 52 22 18 15 14 14 15 16 -4% -55% -70% -62% -74% -37% -17% 8%
Diabetes Care 416 403 391 388 397 380 363 398 -7% -3% 2% 1% -5% -6% -7% 3%
thereof EMEA 233 215 201 194 208 188 169 175 -3% -4% -3% -6% -11% -13% -16% -10%
thereof North America 60 57 64 63 57 51 53 53 -39% -18% 3% -3% -4% -10% -17% -15%
thereof Asia-Pacific 69 72 66 70 67 73 70 73 9% -6% 0% -2% -4% 2% 6% 5%
Roche Online Financial Information System Dia Sales CER 04/03/2024 16/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TP
Roche Group consolidated balance sheet (CHFm)
31 December 31 December 31 December

2023 2022 2021
Non-current assets
Property, plant and equipment 21,724 23,075 23,163
Right-of-use assets 1,215 1,133 1,249
Goodwill 9,390 10,820 10,809
Intangible assets 14,828 9,685 12,117
Deferred tax assets 6,882 6,427 5,583
Defined benefit plan assets 1,019 957 1,498
Other non-current assets 1,964 2,238 2,271
Total non-current assets 57,022 54,335 56,690
Current assets
Inventories 7,749 8,605 7,715
Accounts receivable 11,021 11,606 10,806
Current income tax assets 344 313 320
Other current assets 3,822 3,525 3,755
Marketable securities 5,134 4,776 6,181
Cash and cash equivalents 5,376 4,991 6,850
Total current assets 33,446 33,816 35,627
Total assets 90,468 88,151 92,317
Non-current liabilities
Long-term debt -24,809 -21,391 -16,076
Deferred tax liabilities -593 -645 -628
Defined benefit plan liabilities -4,379 -4,561 -6,103
Provisions -1,059 -1,111 -1,442
Other non-current liabilities -1,541 -1,189 -1,307
Total non-current liabilities -32,381 -28,897 -25,556
Current liabilities
Short-term debt -4,400 -3,960 -15,122
Current income tax liabilities -2,257 -3,187 -3,002
Provisions -1,684 -2,248 -2,526
Accounts payable -4,325 -4,556 -4,637
Accrued and other current liabilities -12,158 -13,288 -13,129
Total current liabilities -24,824 -27,239 -38,416
Total liabilities -57,205 -56,136 -63,972
Total net assets 33,263 32,015 28,345
Equity
Capital and reserves attributable to Roche shareholders 29,315 27,992 24,489
Equity attributable to non-controlling interests 3,948 4,023 3,856
Total equity 33,263 32,015 28,345
Net Cash (debt)

Cash and cash equivalents 5,376 4,991 6,850
Marketable securities 5,134 4,776 6,181
Long-term debt -24,809 -21,391 -16,076
Short-term debt -4,400 -3,960 -15,122
Net Cash (debt) -18,699 -15,584 -18,167
Capitalisation
Debt 29,209 25,351 31,198
Equity 33,263 32,015 28,345
Capitalisation 62,472 57,366 59,543
Roche Online Financial Information System Group Balance Sheet 04/03/2024 17/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5xI75I3RzX50LJmg57Fl5jX1WFr26y9oYDwwNDbXLIiCaYdk2NGO6YH+uF3e
Group results (CHFm) H1 2023 H1 2022 CHF % CER % H2 2023 H2 2022 CHF % CER % Year 2023 Year 2022 CHF % CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 29,779 32,295 -8% -2% 28,937 30,986 -7% 3% 58,716 63,281 -7% 1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other revenue 837 1,605 -48% -44% 888 928 -4% 2% 1,725 2,533 -32% -27% 5.0% 3.0% 2.8% 3.1% 4.0% 2.9%
Royalty income 416 492 -15% -14% 462 493 -6% -1% 878 985 -11% -7% 1.5% 1.6% 1.4% 1.6% 1.6% 1.5%
Other income from collaboration and out-licensing agreements 71 762 -91% -89% 55 80 -31% -26% 126 842 -85% -83% 2.4% 0.3% 0.2% 0.2% 1.3% 0.2%
Profit-sharing income and other 350 351 0% 3% 371 355 5% 14% 721 706 2% 8% 1.1% 1.1% 1.2% 1.3% 1.1% 1.2%
Cost of sales -7,931 -9,668 -18% -14% -8,426 -10,069 -16% -12% -16,357 -19,737 -17% -13% -29.9% -32.6% -26.7% -29.0% -31.2% -27.8%
Manufacturing cost of goods sold and period costs -5,950 -7,266 -18% -14% -6,324 -6,500 -3% 1% -12,274 -13,766 -11% -7% -22.5% -21.0% -20.0% -21.9% -21.8% -20.9%
Royalty expenses -886 -804 10% 15% -968 -940 3% 13% -1,854 -1,744 6% 14% -2.5% -3.0% -3.0% -3.3% -2.8% -3.2%
Collaboration and profit-sharing agreements -873 -946 -8% -3% -674 -1,130 -40% -35% -1,547 -2,076 -25% -20% -2.9% -3.6% -2.9% -2.3% -3.3% -2.6%
Amortisation of intangible assets -191 -289 -34% -32% -189 -271 -30% -26% -380 -560 -32% -29% -0.9% -0.9% -0.6% -0.7% -0.9% -0.6%
Impairment of property, plant and equipment -31 -27 15% 23% -85 -92 -8% -2% -116 -119 -3% 4% -0.1% -0.3% -0.1% -0.3% -0.2% -0.2%
Impairment of right-of-use assets 0 0 - - -3 0 - - -3 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -31 -27 15% 23% -88 -92 -4% 2% -119 -119 0% 7% -0.1% -0.3% -0.1% -0.3% -0.2% -0.2%
Impairment of intangible assets 0 -336 -100% -100% -183 -1,136 -84% -83% -183 -1,472 -88% -87% -1.0% -3.7% 0.0% -0.6% -2.3% -0.3%
Research and development -6,918 -6,516 6% 11% -7,282 -8,709 -16% -11% -14,200 -15,225 -7% -2% -20.2% -28.1% -23.2% -25.2% -24.1% -24.2%
Amortisation of intangible assets 155 165 -6% -4% 153 179 -15% -9% 308 344 -10% -7% 0.5% 0.6% 0.5% 0.5% 0.5% 0.5%
Impairment of intangible assets 260 87 199% 209% 165 1,278 -87% -86% 425 1,365 -69% -67% 0.3% 4.1% 0.9% 0.6% 2.2% 0.7%
Research & development expenses excluding non-cash items -6,503 -6,264 4% 8% -6,964 -7,252 -4% 2% -13,467 -13,516 0% 5% -19.4% -23.4% -21.8% -24.1% -21.4% -22.9%
Selling, general and administration -6,850 -6,600 4% 9% -8,031 -7,601 6% 13% -14,881 -14,201 5% 11% -20.4% -24.5% -22.9% -27.8% -22.4% -25.4%
Marketing and distribution -4,053 -4,008 1% 7% -4,470 -4,669 -4% 4% -8,523 -8,677 -2% 6% -12.4% -15.1% -13.6% -15.4% -13.7% -14.5%
Administration -2,654 -2,523 5% 8% -3,385 -2,793 21% 27% -6,039 -5,316 14% 18% -7.8% -9.0% -8.9% -11.7% -8.4% -10.3%
Business taxes and capital taxes -95 -81 17% 27% -115 -111 4% 14% -210 -192 9% 20% -0.3% -0.4% -0.3% -0.4% -0.3% -0.4%
Other general items - Selling, general and administration -48 12 - - -61 -28 118% 127% -109 -16 581% 540% 0.1% -0.1% -0.2% -0.3% 0.0% -0.2%
Other operating income and expense 847 431 97% 101% -455 394 - - 392 825 -52% -51% 1.3% 1.3% 2.8% -1.6% 1.3% 0.7%
Pensions - past service costs 0 0 - - 0 4 -100% -100% 0 4 -100% -100% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 2 9 -78% -71% 83 -5 - - 85 4 2025% 2356% 0.0% 0.0% 0.0% 0.3% 0.0% 0.1%
Gains (losses) on disposal of property, plant and equipment 2 7 -71% -63% 83 -5 - - 85 2 4150% 4797% 0.0% 0.0% 0.0% 0.3% 0.0% 0.1%
Gains (losses) on disposal of right-of-use assets 0 2 -100% -100% 0 0 - - 0 2 -100% -100% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on divestment of subsidiaries 0 0 - - 1 1 0% 4% 1 1 0% 4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of products 585 338 73% 76% -27 274 - - 558 612 -9% -6% 1.0% 0.9% 2.0% -0.1% 1.0% 1.0%
Other general items - Other operating income and expense 260 84 210% 215% -512 120 - - -252 204 - - 0.3% 0.4% 0.9% -1.8% 0.3% -0.4%
IFRS operating profit 9,764 11,547 -15% -7% 5,631 5,929 -5% 21% 15,395 17,476 -12% 3% 35.8% 19.1% 32.8% 19.5% 27.6% 26.2%
as % of sales 32.8% 35.8% 19.5% 19.1% 26.2% 27.6%
Depreciation, amortisation and impairments 2,052 2,351 -13% -9% 3,280 4,458 -26% -21% 5,332 6,809 -22% -17% 7.3% 14.4% 6.9% 11.3% 10.8% 9.1%
Depreciation of property, plant and equipment 1,228 1,255 -2% 3% 1,195 1,310 -9% -3% 2,423 2,565 -6% 0% 3.9% 4.2% 4.1% 4.1% 4.1% 4.1%
Depreciation of right-of-use assets 161 174 -7% -1% 164 167 -2% 7% 325 341 -5% 3% 0.5% 0.5% 0.5% 0.6% 0.5% 0.6%
Impairment of goodwill 0 0 - - 591 0 - - 591 0 - - 0.0% 0.0% 0.0% 2.0% 0.0% 1.0%
Impairment of property, plant and equipment 40 28 43% 49% 310 95 226% 247% 350 123 185% 201% 0.1% 0.3% 0.1% 1.1% 0.2% 0.6%
Impairment of right-of-use assets 2 0 - - 317 5 6240% 8059% 319 5 6280% 7396% 0.0% 0.0% 0.0% 1.1% 0.0% 0.5%
Impairment of intangible assets 260 423 -39% -37% 348 2,414 -86% -85% 608 2,837 -79% -77% 1.3% 7.8% 0.9% 1.2% 4.5% 1.0%
Impairment of assets and liabilities held for sale 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Provisions -542 -321 69% 73% 82 -213 - - -460 -534 -14% -11% -1.0% -0.7% -1.8% 0.3% -0.8% -0.8%
Equity compensation plans 383 316 21% 24% 447 422 6% 13% 830 738 12% 18% 1.0% 1.4% 1.3% 1.5% 1.2% 1.4%
Other 326 153 113% 125% 440 406 8% 16% 766 559 37% 45% 0.5% 1.3% 1.1% 1.5% 0.9% 1.3%
Operating profit cash adjustments 2,219 2,499 -11% -7% 4,249 5,073 -16% -11% 6,468 7,572 -15% -10% 7.7% 16.4% 7.5% 14.7% 12.0% 11.0%
Operating profit, net of operating cash adjustments 11,983 14,046 -15% -7% 9,880 11,002 -10% 6% 21,863 25,048 -13% -1% 43.5% 35.5% 40.2% 34.1% 39.6% 37.2%
(Increase) / decrease in net working capital -1,804 -2,052 -12% -11% 697 -366 - - -1,107 -2,418 -54% -51% -6.4% -1.2% -6.1% 2.4% -3.8% -1.9%
Receivables -24 -55 -56% -53% -520 -922 -44% -22% -544 -977 -44% -24% -0.2% -3.0% -0.1% -1.8% -1.5% -0.9%
Inventories -370 -763 -52% -54% 61 -866 - - -309 -1,629 -81% -81% -2.4% -2.8% -1.2% 0.2% -2.6% -0.5%
Payables -1,410 -1,234 14% 16% 1,156 1,422 -19% -9% -254 188 - - -3.8% 4.6% -4.7% 4.0% 0.3% -0.4%
Investments in property, plant and equipment -1,740 -1,685 3% 10% -2,002 -1,764 13% 21% -3,742 -3,449 8% 16% -5.2% -5.7% -5.8% -6.9% -5.5% -6.4%
Principal portion of lease liailities -174 -186 -6% 0% -165 -219 -25% -18% -339 -405 -16% -10% -0.6% -0.7% -0.6% -0.6% -0.6% -0.6%
Investments in intangible assets -234 -341 -31% -29% -673 -762 -12% -10% -907 -1,103 -18% -16% -1.1% -2.5% -0.8% -2.3% -1.7% -1.5%
Operating free cash flow 8,031 9,782 -18% -8% 7,737 7,891 -2% 18% 15,768 17,673 -11% 4% 30.3% 25.5% 27.0% 26.7% 27.9% 26.9%
as % of sales 27.0% 30.3% 26.7% 25.5% 26.9% 27.9%
Treasury activities -333 -203 64% 74% -527 -327 61% 71% -860 -530 62% 72% -0.6% -1.1% -1.1% -1.8% -0.8% -1.5%
Taxes paid -1,570 -2,482 -37% -33% -2,050 -1,620 27% 37% -3,620 -4,102 -12% -5% -7.7% -5.2% -5.3% -7.1% -6.5% -6.2%
Free cash flow 6,128 7,097 -14% -2% 5,160 5,944 -13% 10% 11,288 13,041 -13% 4% 22.0% 19.2% 20.6% 17.8% 20.6% 19.2%
Other financial income (expense) -100 -258 -61% -50% -220 -226 -3% 6% -320 -484 -34% -24% -0.8% -0.7% -0.3% -0.8% -0.8% -0.5%
Financing costs -490 -304 61% 68% -506 -361 40% 51% -996 -665 50% 59% -1.0% -1.2% -1.7% -1.7% -1.0% -1.7%
IFRS profit before taxes 9,174 10,985 -16% -8% 4,905 5,342 -8% 20% 14,079 16,327 -14% 1% 34.0% 17.2% 30.8% 17.0% 25.8% 24.0%
Income taxes -1,611 -1,824 -12% -3% -110 -972 -89% -70% -1,721 -2,796 -38% -27% -5.6% -3.1% -5.4% -0.4% -4.4% -3.0%
Tax rate in % 17.6% 16.6% 2.2% 18.2% 12.2% 17.1%
IFRS net income 7,563 9,161 -17% -9% 4,795 4,370 10% 40% 12,358 13,531 -9% 7% 28.4% 14.1% 25.4% 16.6% 21.4% 21.0%
as % of sales 25.4% 28.4% 16.6% 14.1% 21.0% 21.4%
Attributable to
Roche shareholders 7,137 8,530 -16% -8% 4,361 3,891 12% 45% 11,498 12,421 -7% 9%
Non-controlling interests 426 631 -32% -25% 434 479 -9% -3% 860 1,110 -23% -15%
Diluted earnings per share and non-voting equity security

Group (CHF) 8.87 10.54 -16% -6% 5.44 4.83 13% 45% 14.31 15.37 -7% 11%
Roche Online Financial Information System Group IFRS CHF 04/03/2024 18/43
Pharma Division operating results (CHFm) H1 2023 H1 2022 CHF % CER % H2 2023 H2 2022 CHF % CER % Year 2023 Year 2022 CHF % CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 22,681 22,347 1% 8% 21,931 23,204 -5% 4% 44,612 45,551 -2% 6% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 806 1,580 -49% -45% 861 885 -3% 4% 1,667 2,465 -32% -27% 7.1% 3.8% 3.6% 3.9% 5.4% 3.7%
Royalty income 395 471 -16% -14% 440 453 -3% 2% 835 924 -10% -6% 2.1% 2.0% 1.7% 2.0% 2.0% 1.9%
Profit-sharing income and other 340 347 -2% 1% 368 352 5% 14% 708 699 1% 7% 1.6% 1.5% 1.5% 1.7% 1.5% 1.6%
Cost of sales -4,457 -4,851 -8% -3% -4,626 -6,189 -25% -21% -9,083 -11,040 -18% -13% -21.7% -26.6% -19.7% -21.0% -24.3% -20.4%
Manufacturing cost of goods sold and period costs -2,622 -2,591 1% 8% -2,711 -2,766 -2% 0% -5,333 -5,357 0% 4% -11.6% -11.9% -11.6% -12.4% -11.8% -12.0%
Amortisation of intangible assets -124 -215 -42% -41% -120 -200 -40% -36% -244 -415 -41% -38% -1.0% -0.9% -0.5% -0.5% -0.9% -0.5%
Impairment of property, plant and equipment -22 -29 -24% -19% -22 -77 -71% -68% -44 -106 -58% -55% -0.1% -0.3% -0.1% -0.1% -0.2% -0.1%
Impairment of right-of-use assets 0 0 - - -3 0 - - -3 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -22 -29 -24% -19% -25 -77 -68% -64% -47 -106 -56% -51% -0.1% -0.3% -0.1% -0.1% -0.2% -0.1%
Impairment of intangible assets 0 -336 -100% -100% -183 -1,136 -84% -83% -183 -1,472 -88% -87% -1.5% -4.9% 0.0% -0.8% -3.2% -0.4%
Research and development -6,065 -5,667 7% 12% -6,287 -7,717 -19% -13% -12,352 -13,384 -8% -2% -25.4% -33.3% -26.7% -28.7% -29.4% -27.7%
Impairment of intangible assets 260 87 199% 209% 146 1,278 -89% -88% 406 1,365 -70% -69% 0.4% 5.5% 1.1% 0.7% 3.0% 0.9%
Research & development expenses excluding non-cash items -5,654 -5,419 4% 9% -5,991 -6,264 -4% 2% -11,645 -11,683 0% 5% -24.2% -27.0% -24.9% -27.3% -25.6% -26.1%
Selling, general and administration -3,588 -3,468 3% 9% -4,357 -4,130 5% 14% -7,945 -7,598 5% 12% -15.5% -17.8% -15.8% -19.9% -16.6% -17.7%
Marketing and distribution -2,866 -2,738 5% 10% -3,089 -3,246 -5% 4% -5,955 -5,984 0% 7% -12.3% -14.0% -12.6% -14.1% -13.1% -13.3%
Administration -585 -660 -11% -7% -1,123 -761 48% 58% -1,708 -1,421 20% 28% -3.0% -3.3% -2.6% -5.1% -3.1% -3.8%
Other general items - Selling, general and administration -60 -3 1900% 2444% -49 -30 63% 57% -109 -33 230% 214% 0.0% -0.1% -0.3% -0.2% -0.1% -0.2%
Other operating income and expense 708 390 82% 85% -475 382 - - 233 772 -70% -69% 1.7% 1.6% 3.1% -2.2% 1.7% 0.5%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 7 8 -13% 2% 80 -4 - - 87 4 2075% 2454% 0.0% 0.0% 0.0% 0.4% 0.0% 0.2%
Gains (losses) on disposal of property, plant and equipment 7 7 0% 12% 80 -4 - - 87 3 2800% 2956% 0.0% 0.0% 0.0% 0.4% 0.0% 0.2%
Gains (losses) on divestment of subsidiaries 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 116 44 164% 169% -528 108 - - -412 152 - - 0.2% 0.5% 0.5% -2.4% 0.3% -0.9%
IFRS operating profit 10,085 10,331 -2% 5% 7,047 6,435 10% 29% 17,132 16,766 2% 14% 46.2% 27.7% 44.5% 32.1% 36.8% 38.4%
as % of sales 44.5% 46.2% 32.1% 27.7% 38.4% 36.8%
Depreciation of property, plant and equipment 654 665 -2% 2% 609 716 -15% -10% 1,263 1,381 -9% -4% 3.0% 3.1% 2.9% 2.8% 3.0% 2.8%
Provisions -390 -212 84% 88% -116 -36 222% 221% -506 -248 104% 108% -0.9% -0.2% -1.7% -0.5% -0.5% -1.1%
Other 196 33 494% 532% 202 117 73% 84% 398 150 165% 179% 0.1% 0.5% 0.9% 0.9% 0.3% 0.9%
Operating profit, net of operating cash adjustments 11,507 12,008 -4% 3% 9,941 10,526 -6% 8% 21,448 22,534 -5% 5% 53.7% 45.4% 50.7% 45.3% 49.5% 48.1%
(Increase) / decrease in net working capital -638 -958 -33% -38% -76 -787 -90% -87% -714 -1,745 -59% -59% -4.3% -3.4% -2.8% -0.3% -3.8% -1.6%
Receivables 145 304 -52% -46% -204 -1,275 -84% -77% -59 -971 -94% -86% 1.4% -5.5% 0.6% -0.9% -2.1% -0.1%
Inventories -154 -400 -62% -68% -159 -438 -64% -62% -313 -838 -63% -65% -1.8% -1.9% -0.7% -0.7% -1.8% -0.7%
Payables -629 -862 -27% -26% 287 926 -69% -61% -342 64 - - -3.9% 4.0% -2.8% 1.3% 0.1% -0.8%
Investments in property, plant and equipment -979 -959 2% 8% -957 -785 22% 30% -1,936 -1,744 11% 18% -4.3% -3.4% -4.3% -4.4% -3.8% -4.3%
Principal portion of lease liailities -110 -118 -7% -1% -105 -156 -33% -26% -215 -274 -22% -15% -0.5% -0.7% -0.5% -0.5% -0.6% -0.5%
Operating free cash flow 9,562 9,638 -1% 8% 8,166 8,056 1% 18% 17,728 17,694 0% 12% 43.1% 34.7% 42.2% 37.2% 38.8% 39.7%
as % of sales 42.2% 43.1% 37.2% 34.7% 39.7% 38.8%
Roche Online Financial Information System Pharma IFRS CHF 04/03/2024 19/43
Diagnostics Division operating results (CHFm) H1 2023 H1 2022 CHF % CER % H2 2023 H2 2022 CHF % CER % Year 2023 Year 2022 CHF % CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 7,098 9,948 -29% -23% 7,006 7,782 -10% -1% 14,104 17,730 -20% -13% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 31 25 24% 29% 27 43 -37% -35% 58 68 -15% -12% 0.3% 0.6% 0.4% 0.4% 0.4% 0.4%
Royalty income 21 21 0% 2% 22 40 -45% -43% 43 61 -30% -28% 0.2% 0.5% 0.3% 0.3% 0.3% 0.3%
Other income from collaboration and out-licensing agreements 0 0 - - 2 0 - - 2 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cost of sales -3,474 -4,817 -28% -24% -3,800 -3,880 -2% 3% -7,274 -8,697 -16% -12% -48.5% -49.9% -48.9% -54.3% -49.0% -51.6%
Royalty expenses -70 -70 0% 0% -55 -60 -8% -4% -125 -130 -4% -2% -0.7% -0.8% -1.0% -0.8% -0.7% -0.9%
Collaboration and profit-sharing agreements 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Amortisation of intangible assets -67 -74 -9% -5% -69 -71 -3% 1% -136 -145 -6% -2% -0.7% -0.9% -0.9% -1.0% -0.8% -1.0%
Impairment of property, plant and equipment -9 2 - - -63 -15 320% 323% -72 -13 454% 462% 0.0% -0.2% -0.1% -0.9% -0.1% -0.5%
Impairment of right-of-use assets 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -9 2 - - -63 -15 320% 323% -72 -13 454% 462% 0.0% -0.2% -0.1% -0.9% -0.1% -0.5%
Impairment of intangible assets 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Research and development -853 -849 0% 4% -995 -992 0% 5% -1,848 -1,841 0% 5% -8.5% -12.7% -12.0% -14.2% -10.4% -13.1%
Amortisation of intangible assets 4 4 0% 0% 3 4 -25% -3% 7 8 -13% -1% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0%
Research & development expenses excluding non-cash items -849 -845 0% 4% -973 -988 -2% 3% -1,822 -1,833 -1% 3% -8.5% -12.7% -12.0% -13.9% -10.3% -12.9%
Selling, general and administration -1,381 -1,489 -7% -1% -1,661 -1,681 -1% 7% -3,042 -3,170 -4% 3% -15.0% -21.6% -19.5% -23.7% -17.9% -21.5%
Marketing and distribution -1,187 -1,270 -7% 0% -1,381 -1,423 -3% 6% -2,568 -2,693 -5% 3% -12.8% -18.3% -16.7% -19.7% -15.2% -18.2%
Administration -196 -223 -12% -7% -257 -248 4% 11% -453 -471 -4% 2% -2.2% -3.2% -2.8% -3.7% -2.7% -3.2%
Business taxes and capital taxes -10 -10 0% 13% -12 -13 -8% 2% -22 -23 -4% 6% -0.1% -0.2% -0.1% -0.2% -0.1% -0.2%
Other general items - Selling, general and administration 12 14 -14% -8% -11 3 - - 1 17 -94% -96% 0.1% 0.0% 0.1% -0.1% 0.0% 0.0%
Other operating income and expense 146 41 256% 267% 27 18 50% 86% 173 59 193% 214% 0.4% 0.2% 2.1% 0.4% 0.3% 1.2%
Pensions - past service costs 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets -5 1 - - 3 -1 - - -2 0 - - 0.0% 0.0% -0.1% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment -5 0 - - 3 -1 - - -2 -1 100% 92% 0.0% 0.0% -0.1% 0.0% 0.0% 0.0%
Gains (losses) on disposal of products 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 151 40 278% 289% 23 18 28% 65% 174 58 200% 223% 0.4% 0.2% 2.1% 0.3% 0.3% 1.2%
IFRS operating profit 1,567 2,859 -45% -36% 604 1,290 -53% -25% 2,171 4,149 -48% -32% 28.7% 16.6% 22.1% 8.6% 23.4% 15.4%
as % of sales 22.1% 28.7% 8.6% 16.6% 15.4% 23.4%
Depreciation, amortisation and impairments 690 708 -3% 3% 775 726 7% 14% 1,465 1,434 2% 9% 7.1% 9.3% 9.7% 11.1% 8.1% 10.4%
Depreciation of property, plant and equipment 540 562 -4% 2% 555 566 -2% 5% 1,095 1,128 -3% 4% 5.6% 7.3% 7.6% 7.9% 6.4% 7.8%
Depreciation of right-of-use assets 60 59 2% 7% 56 58 -3% 7% 116 117 -1% 7% 0.6% 0.7% 0.8% 0.8% 0.7% 0.8%
Impairment of property, plant and equipment 9 -1 - - 64 16 300% 305% 73 15 387% 401% 0.0% 0.2% 0.1% 0.9% 0.1% 0.5%
Provisions -135 -101 34% 39% 134 -124 - - -1 -225 -100% -100% -1.0% -1.6% -1.9% 1.9% -1.3% 0.0%
Other 130 119 9% 14% 236 272 -13% -6% 366 391 -6% 0% 1.2% 3.5% 1.8% 3.4% 2.2% 2.6%
Operating profit cash adjustments 736 768 -4% 1% 1,207 934 29% 37% 1,943 1,702 14% 21% 7.7% 12.1% 10.4% 17.2% 9.6% 13.8%
(Increase) / decrease in net working capital -1,114 -971 15% 22% 563 265 112% 106% -551 -706 -22% -8% -9.8% 3.4% -15.7% 8.0% -4.0% -3.9%
Receivables -54 -339 -84% -79% -332 361 - - -386 22 - - -3.4% 4.6% -0.8% -4.7% 0.1% -2.7%
Inventories -216 -363 -40% -38% 220 -428 - - 4 -791 - - -3.6% -5.5% -3.0% 3.1% -4.5% 0.0%
Payables -844 -269 214% 222% 675 332 103% 121% -169 63 - - -2.7% 4.3% -11.9% 9.6% 0.4% -1.2%
Investments in property, plant and equipment -713 -687 4% 10% -1,009 -932 8% 16% -1,722 -1,619 6% 14% -6.9% -12.0% -10.0% -14.4% -9.1% -12.2%
Principal portion of lease liailities -58 -61 -5% 2% -54 -57 -5% 3% -112 -118 -5% 2% -0.6% -0.7% -0.8% -0.8% -0.7% -0.8%
Investments in intangible assets -16 -6 167% 173% -36 -20 80% 83% -52 -26 100% 103% -0.1% -0.3% -0.2% -0.5% -0.1% -0.4%
Operating free cash flow 402 1,902 -79% -70% 1,275 1,480 -14% 7% 1,677 3,382 -50% -35% 19.1% 19.0% 5.7% 18.2% 19.1% 11.9%
as % of sales 5.7% 19.1% 18.2% 19.0% 11.9% 19.1%
Roche Online Financial Information System Diagnostics IFRS CHF 04/03/2024 20/43
Group results (CHFm at avg full year 2022 fx rates) H1 2023 H1 2022 CER % H2 2023 H2 2022 CER % Year 2023 Year 2022 CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 31,426 31,966 -2% 32,219 31,289 3% 63,645 63,255 1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other revenue 869 1,554 -44% 943 922 2% 1,812 2,475 -27% 4.9% 2.9% 2.8% 2.9% 3.9% 2.8%
Royalty income 427 494 -14% 484 490 -1% 911 985 -7% 1.5% 1.6% 1.4% 1.5% 1.6% 1.4%
Other income from collaboration and out-licensing agreements 75 704 -89% 60 80 -26% 135 784 -83% 2.2% 0.3% 0.2% 0.2% 1.2% 0.2%
Profit-sharing income and other 366 355 3% 399 352 14% 766 707 8% 1.1% 1.1% 1.2% 1.2% 1.1% 1.2%
Cost of sales -8,225 -9,515 -14% -9,000 -10,222 -12% -17,225 -19,738 -13% -29.8% -32.7% -26.2% -27.9% -31.2% -27.1%
Manufacturing cost of goods sold and period costs -6,145 -7,107 -14% -6,721 -6,660 1% -12,866 -13,768 -7% -22.2% -21.3% -19.6% -20.9% -21.8% -20.2%
Royalty expenses -929 -806 15% -1,057 -938 13% -1,986 -1,744 14% -2.5% -3.0% -3.0% -3.3% -2.8% -3.1%
Collaboration and profit-sharing agreements -918 -943 -3% -735 -1,133 -35% -1,653 -2,076 -20% -2.9% -3.6% -2.9% -2.3% -3.3% -2.6%
Amortisation of intangible assets -199 -292 -32% -199 -268 -26% -398 -559 -29% -0.9% -0.9% -0.6% -0.6% -0.9% -0.6%
Impairment of property, plant and equipment -34 -27 23% -90 -92 -2% -124 -119 4% -0.1% -0.3% -0.1% -0.3% -0.2% -0.2%
Impairment of right-of-use assets 0 0 - -3 0 - -3 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -34 -27 23% -93 -92 2% -127 -119 7% -0.1% -0.3% -0.1% -0.3% -0.2% -0.2%
Impairment of intangible assets 0 -340 -100% -194 -1,132 -83% -194 -1,472 -87% -1.1% -3.6% 0.0% -0.6% -2.3% -0.3%
Research and development -7,181 -6,479 11% -7,800 -8,747 -11% -14,981 -15,225 -2% -20.3% -28.0% -22.8% -24.2% -24.1% -23.5%
Amortisation of intangible assets 160 166 -4% 162 178 -9% 322 345 -7% 0.5% 0.6% 0.5% 0.5% 0.5% 0.5%
Impairment of intangible assets 271 88 209% 178 1,278 -86% 449 1,366 -67% 0.3% 4.1% 0.9% 0.6% 2.2% 0.7%
Research & development expenses excluding non-cash items -6,750 -6,225 8% -7,460 -7,290 2% -14,210 -13,515 5% -19.5% -23.3% -21.5% -23.2% -21.4% -22.3%
Selling, general and administration -7,125 -6,559 9% -8,651 -7,643 13% -15,776 -14,202 11% -20.5% -24.4% -22.7% -26.9% -22.5% -24.8%
Marketing and distribution -4,254 -3,974 7% -4,905 -4,703 4% -9,159 -8,677 6% -12.4% -15.0% -13.5% -15.2% -13.7% -14.4%
Administration -2,723 -2,517 8% -3,553 -2,799 27% -6,276 -5,316 18% -7.9% -8.9% -8.7% -11.0% -8.4% -9.9%
Business taxes and capital taxes -100 -79 27% -129 -113 14% -229 -192 20% -0.2% -0.4% -0.3% -0.4% -0.3% -0.4%
Other general items - Selling, general and administration -48 11 - -64 -28 127% -112 -17 540% 0.0% -0.1% -0.2% -0.2% 0.0% -0.2%
Other operating income and expense 869 433 101% -461 393 - 407 825 -51% 1.4% 1.3% 2.8% -1.4% 1.3% 0.6%
Pensions - past service costs 0 0 - 1 4 -100% 0 4 -100% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 2 8 -71% 94 -4 - 97 4 2356% 0.0% 0.0% 0.0% 0.3% 0.0% 0.2%
Gains (losses) on disposal of property, plant and equipment 2 6 -63% 94 -4 - 96 2 4797% 0.0% 0.0% 0.0% 0.3% 0.0% 0.2%
Gains (losses) on disposal of right-of-use assets 0 2 -100% 0 0 - 0 2 -100% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on divestment of subsidiaries 0 0 - 1 1 4% 1 1 4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of products 595 338 76% -21 273 - 575 612 -6% 1.1% 0.9% 1.9% -0.1% 1.0% 0.9%
Other general items - Other operating income and expense 271 86 215% -537 119 - -266 205 - 0.3% 0.4% 0.9% -1.7% 0.3% -0.4%
IFRS operating profit 10,633 11,399 -7% 7,249 5,991 21% 17,882 17,390 3% 35.7% 19.1% 33.8% 22.5% 27.5% 28.1%
as % of sales 33.8% 35.7% 22.5% 19.1% 28.1% 27.5%
Depreciation, amortisation and impairments 2,134 2,343 -9% 3,509 4,466 -21% 5,643 6,809 -17% 7.3% 14.3% 6.8% 10.9% 10.8% 8.9%
Depreciation of property, plant and equipment 1,275 1,241 3% 1,287 1,324 -3% 2,562 2,565 0% 3.9% 4.2% 4.1% 4.0% 4.1% 4.0%
Depreciation of right-of-use assets 169 171 -1% 181 170 7% 350 341 3% 0.5% 0.5% 0.5% 0.6% 0.5% 0.6%
Impairment of goodwill 0 0 - 628 0 - 628 0 - 0.0% 0.0% 0.0% 1.9% 0.0% 1.0%
Impairment of property, plant and equipment 42 28 49% 329 95 247% 371 123 201% 0.1% 0.3% 0.1% 1.0% 0.2% 0.6%
Impairment of right-of-use assets 2 0 - 337 4 8059% 339 5 7396% 0.0% 0.0% 0.0% 1.0% 0.0% 0.5%
Impairment of intangible assets 271 428 -37% 372 2,409 -85% 643 2,837 -77% 1.3% 7.7% 0.9% 1.2% 4.5% 1.0%
Impairment of assets and liabilities held for sale 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Provisions -554 -319 73% 80 -215 - -474 -534 -11% -1.0% -0.7% -1.8% 0.2% -0.8% -0.7%
Equity compensation plans 397 319 24% 474 419 13% 871 738 18% 1.0% 1.3% 1.3% 1.5% 1.2% 1.4%
Other 334 148 125% 476 411 16% 810 559 45% 0.5% 1.3% 1.1% 1.5% 0.9% 1.3%
Operating profit cash adjustments 2,312 2,491 -7% 4,539 5,081 -11% 6,851 7,572 -10% 7.8% 16.2% 7.4% 14.1% 12.0% 10.8%
Operating profit, net of operating cash adjustments 12,945 13,890 -7% 11,788 11,072 6% 24,733 24,962 -1% 43.5% 35.4% 41.2% 36.6% 39.5% 38.9%
(Increase) / decrease in net working capital -1,829 -2,064 -11% 633 -354 - -1,196 -2,418 -51% -6.5% -1.1% -5.8% 2.0% -3.8% -1.9%
Receivables -27 -58 -53% -717 -919 -22% -744 -977 -24% -0.2% -2.9% -0.1% -2.2% -1.5% -1.2%
Inventories -353 -762 -54% 49 -866 - -304 -1,629 -81% -2.4% -2.8% -1.1% 0.2% -2.6% -0.5%
Payables -1,449 -1,244 16% 1,302 1,431 -9% -147 187 - -3.9% 4.6% -4.6% 4.0% 0.3% -0.2%
Investments in property, plant and equipment -1,819 -1,657 10% -2,176 -1,791 21% -3,994 -3,449 16% -5.2% -5.7% -5.8% -6.8% -5.5% -6.3%
Principal portion of lease liailities -183 -183 0% -183 -222 -18% -366 -405 -10% -0.6% -0.7% -0.6% -0.6% -0.6% -0.6%
Investments in intangible assets -243 -342 -29% -686 -760 -10% -929 -1,103 -16% -1.1% -2.4% -0.8% -2.1% -1.7% -1.5%
Operating free cash flow 8,871 9,644 -8% 9,377 7,944 18% 18,248 17,588 4% 30.2% 25.4% 28.2% 29.1% 27.8% 28.7%
as % of sales 28.2% 30.2% 29.1% 25.4% 28.7% 27.8%
Treasury activities -351 -202 74% -563 -329 71% -914 -530 72% -0.6% -1.1% -1.1% -1.7% -0.8% -1.4%
Taxes paid -1,638 -2,447 -33% -2,267 -1,655 37% -3,905 -4,102 -5% -7.7% -5.3% -5.2% -7.0% -6.5% -6.1%
Free cash flow 6,881 6,996 -2% 6,547 5,960 10% 13,428 12,956 4% 21.9% 19.0% 21.9% 20.3% 20.5% 21.1%
Other financial income (expense) -127 -255 -50% -244 -229 6% -370 -484 -24% -0.8% -0.7% -0.4% -0.8% -0.8% -0.6%
Financing costs -513 -305 68% -544 -360 51% -1,057 -665 59% -1.0% -1.2% -1.6% -1.7% -1.1% -1.7%
IFRS profit before taxes 9,993 10,839 -8% 6,462 5,402 20% 16,455 16,241 1% 33.9% 17.3% 31.8% 20.1% 25.7% 25.9%
Income taxes -1,722 -1,779 -3% -296 -998 -70% -2,018 -2,777 -27% -5.6% -3.2% -5.5% -0.9% -4.4% -3.2%
Tax rate in % 17.2% 16.4% 4.6% 18.5% 12.3% 17.1%
IFRS net income 8,271 9,059 -9% 6,166 4,404 40% 14,437 13,464 7% 28.3% 14.1% 26.3% 19.1% 21.3% 22.7%
as % of sales 26.3% 28.3% 19.1% 14.1% 22.7% 21.3%
Attributable to
Roche shareholders 7,822 8,461 -8% 5,684 3,908 45% 13,506 12,370 9%
Non-controlling interests 449 598 -25% 482 496 -3% 930 1,094 -15%

Group (CHF) 9.96 10.55 -6% 7.44 5.15 45% 17.41 15.69 11%
Roche Online Financial Information System Group IFRS CER 04/03/2024 21/43
Pharmaceuticals Division op. results (CHFm at avg full year 2022 fx rates) H1 2023 H1 2022 CER % H2 2023 H2 2022 CER % Year 2023 Year 2022 CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 23,907 22,173 8% 24,323 23,352 4% 48,230 45,525 6% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 837 1,529 -45% 915 878 4% 1,751 2,407 -27% 6.9% 3.8% 3.5% 3.8% 5.3% 3.6%
Royalty income 406 473 -14% 461 450 2% 867 923 -6% 2.1% 1.9% 1.7% 1.9% 2.0% 1.8%
Cost of sales -4,628 -4,758 -3% -4,942 -6,282 -21% -9,571 -11,040 -13% -21.5% -26.9% -19.4% -20.3% -24.2% -19.8%
Manufacturing cost of goods sold and period costs -2,699 -2,493 8% -2,857 -2,864 0% -5,556 -5,357 4% -11.2% -12.3% -11.3% -11.7% -11.8% -11.5%
Amortisation of intangible assets -129 -217 -41% -128 -198 -36% -257 -415 -38% -1.0% -0.8% -0.5% -0.5% -0.9% -0.5%
Impairment of property, plant and equipment -24 -30 -19% -24 -76 -68% -48 -106 -55% -0.1% -0.3% -0.1% -0.1% -0.2% -0.1%
Impairment of right-of-use assets 0 0 - -3 0 - -3 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -24 -30 -19% -28 -76 -64% -52 -106 -51% -0.1% -0.3% -0.1% -0.1% -0.2% -0.1%
Impairment of intangible assets 0 -340 -100% -194 -1,132 -83% -194 -1,472 -87% -1.5% -4.8% 0.0% -0.8% -3.2% -0.4%
Research and development -6,304 -5,633 12% -6,753 -7,751 -13% -13,057 -13,384 -2% -25.4% -33.2% -26.4% -27.8% -29.4% -27.1%
Impairment of intangible assets 271 88 209% 158 1,278 -88% 429 1,366 -69% 0.4% 5.5% 1.1% 0.6% 3.0% 0.9%
Research & development expenses excluding non-cash items -5,877 -5,383 9% -6,437 -6,299 2% -12,314 -11,682 5% -24.3% -27.0% -24.6% -26.5% -25.7% -25.5%
Administration -613 -658 -7% -1,206 -763 58% -1,819 -1,420 28% -3.0% -3.3% -2.6% -5.0% -3.1% -3.8%
Other general items - Selling, general and administration -60 -2 2444% -52 -33 57% -112 -36 214% 0.0% -0.1% -0.3% -0.2% -0.1% -0.2%
Other operating income and expense 723 391 85% -486 382 - 237 773 -69% 1.8% 1.6% 3.0% -2.0% 1.7% 0.5%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 7 7 2% 91 -3 - 99 4 2454% 0.0% 0.0% 0.0% 0.4% 0.0% 0.2%
Gains (losses) on disposal of property, plant and equipment 7 7 12% 91 -3 - 98 3 2956% 0.0% 0.0% 0.0% 0.4% 0.0% 0.2%
Gains (losses) on divestment of subsidiaries 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 121 45 169% -557 109 - -436 154 - 0.2% 0.5% 0.5% -2.3% 0.3% -0.9%
IFRS operating profit 10,774 10,255 5% 8,306 6,427 29% 19,080 16,681 14% 46.2% 27.5% 45.1% 34.2% 36.6% 39.6%
as % of sales 45.1% 46.2% 34.2% 27.5% 39.6% 36.6%
Depreciation of property, plant and equipment 676 661 2% 648 720 -10% 1,325 1,381 -4% 3.0% 3.1% 2.8% 2.7% 3.0% 2.7%
Provisions -396 -211 88% -120 -37 221% -516 -248 108% -1.0% -0.2% -1.7% -0.5% -0.5% -1.1%
Other 201 32 532% 218 118 84% 420 150 179% 0.1% 0.5% 0.8% 0.9% 0.3% 0.9%
Operating profit, net of operating cash adjustments 12,257 11,938 3% 11,399 10,512 8% 23,656 22,450 5% 53.8% 45.1% 51.3% 46.9% 49.3% 49.0%
(Increase) / decrease in net working capital -614 -986 -38% -95 -760 -87% -709 -1,746 -59% -4.4% -3.3% -2.6% -0.4% -3.8% -1.5%
Receivables 156 287 -46% -295 -1,258 -77% -138 -971 -86% 1.3% -5.4% 0.7% -1.2% -2.1% -0.3%
Inventories -129 -403 -68% -164 -435 -62% -294 -838 -65% -1.8% -1.9% -0.5% -0.7% -1.8% -0.6%
Payables -641 -870 -26% 364 933 -61% -277 62 - -3.9% 4.0% -2.7% 1.5% 0.1% -0.6%
Investments in property, plant and equipment -1,022 -942 8% -1,042 -801 30% -2,065 -1,744 18% -4.2% -3.4% -4.3% -4.3% -3.8% -4.3%
Principal portion of lease liailities -116 -117 -1% -116 -157 -26% -232 -274 -15% -0.5% -0.7% -0.5% -0.5% -0.6% -0.5%
Operating free cash flow 10,278 9,557 8% 9,496 8,053 18% 19,774 17,610 12% 43.1% 34.5% 43.0% 39.0% 38.7% 41.0%
as % of sales 43.0% 43.1% 39.0% 34.5% 41.0% 38.7%
Roche Online Financial Information System Pharma IFRS CER 04/03/2024 22/43
Diagnostics Division operating results (CHFm at avg full year 2022 fx rates) H1 2023 H1 2022 CER % H2 2023 H2 2022 CER % Year 2023 Year 2022 CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 7,519 9,793 -23% 7,896 7,937 -1% 15,415 17,730 -13% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 32 25 29% 28 44 -35% 60 68 -12% 0.3% 0.5% 0.4% 0.4% 0.4% 0.4%
Royalty income 21 21 2% 23 40 -43% 45 61 -28% 0.2% 0.5% 0.3% 0.3% 0.3% 0.3%
Other income from collaboration and out-licensing agreements 0 0 - 2 0 - 2 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cost of sales -3,596 -4,757 -24% -4,058 -3,941 3% -7,654 -8,698 -12% -48.6% -49.7% -47.8% -51.4% -49.1% -49.7%
Royalty expenses -70 -70 0% -57 -59 -4% -127 -130 -2% -0.7% -0.7% -0.9% -0.7% -0.7% -0.8%
Collaboration and profit-sharing agreements 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Amortisation of intangible assets -71 -75 -5% -71 -70 1% -141 -144 -2% -0.8% -0.9% -0.9% -0.9% -0.8% -0.9%
Impairment of property, plant and equipment -10 2 - -66 -16 323% -75 -13 462% 0.0% -0.2% -0.1% -0.8% -0.1% -0.5%
Impairment of right-of-use assets 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -10 2 - -66 -16 323% -75 -13 462% 0.0% -0.2% -0.1% -0.8% -0.1% -0.5%
Impairment of intangible assets 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Research and development -877 -846 4% -1,047 -995 5% -1,924 -1,841 5% -8.6% -12.5% -11.7% -13.3% -10.4% -12.5%
Amortisation of intangible assets 4 4 0% 4 4 -3% 8 8 -1% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0%
Research & development expenses excluding non-cash items -873 -842 4% -1,023 -992 3% -1,896 -1,833 3% -8.6% -12.5% -11.6% -13.0% -10.3% -12.3%
Selling, general and administration -1,451 -1,469 -1% -1,826 -1,702 7% -3,277 -3,170 3% -15.0% -21.4% -19.3% -23.1% -17.9% -21.3%
Administration -204 -220 -7% -279 -252 11% -483 -472 2% -2.2% -3.2% -2.7% -3.5% -2.7% -3.1%
Other general items - Selling, general and administration 12 13 -8% -11 5 - 1 18 -96% 0.1% 0.1% 0.2% -0.1% 0.1% 0.0%
Other operating income and expense 153 42 267% 32 17 86% 185 59 214% 0.4% 0.2% 2.0% 0.4% 0.3% 1.2%
Pensions - past service costs 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets -5 1 - 3 -1 - -2 0 - 0.0% 0.0% -0.1% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment -5 0 - 3 -1 - -2 -1 92% 0.0% 0.0% -0.1% 0.0% 0.0% 0.0%
Gains (losses) on disposal of products 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 158 41 289% 28 17 65% 186 57 223% 0.4% 0.2% 2.1% 0.4% 0.3% 1.2%
IFRS operating profit 1,780 2,788 -36% 1,026 1,360 -25% 2,806 4,148 -32% 28.5% 17.1% 23.7% 13.0% 23.4% 18.2%
as % of sales 23.7% 28.5% 13.0% 17.1% 18.2% 23.4%
Depreciation, amortisation and impairments 720 698 3% 839 736 14% 1,559 1,434 9% 7.1% 9.3% 9.6% 10.6% 8.1% 10.1%
Depreciation of property, plant and equipment 563 552 2% 605 575 5% 1,169 1,128 4% 5.6% 7.3% 7.5% 7.7% 6.4% 7.6%
Depreciation of right-of-use assets 63 58 7% 63 59 7% 126 117 7% 0.6% 0.7% 0.8% 0.8% 0.7% 0.8%
Impairment of property, plant and equipment 10 -1 - 66 16 305% 76 15 401% 0.0% 0.2% 0.1% 0.8% 0.1% 0.5%
Provisions -140 -101 39% 135 -124 - -5 -225 -100% -1.0% -1.6% -1.9% 1.7% -1.3% 0.0%
Other 133 116 14% 257 275 -6% 390 391 0% 1.2% 3.5% 1.8% 3.3% 2.2% 2.5%
Operating profit cash adjustments 765 755 1% 1,296 947 37% 2,061 1,702 21% 7.7% 12.0% 10.2% 16.4% 9.6% 13.4%
Operating profit, net of operating cash adjustments 2,545 3,543 -28% 2,322 2,307 1% 4,867 5,850 -17% 36.2% 29.1% 33.8% 29.4% 33.0% 31.6%
(Increase) / decrease in net working capital -1,164 -955 22% 515 249 106% -649 -705 -8% -9.8% 3.1% -15.5% 6.5% -4.0% -4.2%
Receivables -67 -325 -79% -437 347 - -504 22 - -3.3% 4.4% -0.9% -5.5% 0.1% -3.3%
Inventories -224 -359 -38% 213 -431 - -11 -791 - -3.7% -5.4% -3.0% 2.7% -4.5% -0.1%
Payables -872 -271 222% 739 334 121% -134 63 - -2.8% 4.2% -11.6% 9.4% 0.4% -0.9%
Investments in property, plant and equipment -746 -676 10% -1,095 -943 16% -1,841 -1,619 14% -6.9% -11.9% -9.9% -13.9% -9.1% -11.9%
Principal portion of lease liailities -61 -60 2% -60 -59 3% -121 -118 2% -0.6% -0.7% -0.8% -0.8% -0.7% -0.8%
Investments in intangible assets -16 -6 173% -37 -20 83% -53 -26 103% -0.1% -0.3% -0.2% -0.5% -0.1% -0.3%
Operating free cash flow 559 1,847 -70% 1,644 1,534 7% 2,203 3,381 -35% 18.9% 19.3% 7.4% 20.8% 19.1% 14.3%
as % of sales 7.4% 18.9% 20.8% 19.3% 14.3% 19.1%
Roche Online Financial Information System Diagnostics IFRS CER 04/03/2024 23/43
Group Core results (CHFm) H1 2023 H1 2022 CHF % CER % H2 2023 H2 2022 CHF % CER % Year 2023 Year 2022 CHF % CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 29,779 32,295 -8% -2% 28,937 30,986 -7% 3% 58,716 63,281 -7% 1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 837 1,605 -48% -44% 888 928 -4% 2% 1,725 2,533 -32% -27% 5.0% 3.0% 2.8% 3.1% 4.0% 2.9%
Royalty income 416 492 -15% -14% 462 493 -6% -1% 878 985 -11% -7% 1.5% 1.6% 1.4% 1.6% 1.6% 1.5%
Cost of sales -7,456 -8,986 -17% -12% -7,795 -8,429 -8% -3% -15,251 -17,415 -12% -8% -27.9% -27.2% -25.1% -26.9% -27.6% -25.9%
Amortisation of intangible assets commercial software -3 -3 0% -8% -2 -2 0% 79% -5 -5 0% 22% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment -25 -27 -7% -4% -4 -5 -20% 32% -29 -32 -9% 1% -0.1% 0.0% -0.1% 0.0% -0.1% 0.0%
Impairment of property, plant and equipment and right-of-use assets -25 -27 -7% -4% -4 -5 -20% 32% -29 -32 -9% 1% -0.1% 0.0% -0.1% 0.0% -0.1% 0.0%
Impairment of intangible assets commercial software 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Research and development -6,449 -6,245 3% 8% -6,788 -7,010 -3% 3% -13,237 -13,255 0% 5% -19.3% -22.6% -21.7% -23.5% -20.9% -22.5%
Selling, general and administration -6,505 -6,416 1% 6% -7,013 -7,351 -5% 3% -13,518 -13,767 -2% 4% -19.9% -23.7% -21.8% -24.2% -21.8% -23.1%
Marketing and distribution -3,939 -3,982 -1% 5% -4,374 -4,602 -5% 4% -8,313 -8,584 -3% 4% -12.3% -14.9% -13.2% -15.1% -13.6% -14.2%
Administration -2,431 -2,354 3% 6% -2,462 -2,587 -5% 0% -4,893 -4,941 -1% 3% -7.3% -8.3% -8.2% -8.5% -7.8% -8.3%
Other general items - Selling, general and administration -40 1 - - -62 -51 22% 27% -102 -50 104% 107% 0.0% -0.2% -0.2% -0.3% -0.1% -0.2%
Other operating income and expense 705 415 70% 73% 100 381 -74% -69% 805 796 1% 6% 1.3% 1.2% 2.4% 0.3% 1.3% 1.4%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 9 9 0% 7% 1 -4 - - 10 5 100% 143% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment 9 7 29% 38% 1 -4 - - 10 3 233% 308% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 111 68 63% 70% 125 106 18% 29% 236 174 36% 45% 0.2% 0.3% 0.4% 0.4% 0.3% 0.4%
Core operating profit 10,911 12,668 -14% -6% 8,329 9,505 -12% 6% 19,240 22,173 -13% -1% 39.2% 30.7% 36.6% 28.8% 35.0% 32.8%
as % of sales 36.6% 39.2% 28.8% 30.7% 32.8% 35.0%
Non-Core items -1,147 -1,121 2% 6% -2,698 -3,576 -25% -20% -3,845 -4,697 -18% -14% -3.5% -11.5% -3.9% -9.3% -7.4% -6.5%
as % of sales 32.8% 35.8% 19.5% 19.1% 26.2% 27.6%
Depreciation of property, plant and equipment 1,228 1,255 -2% 3% 1,195 1,310 -9% -3% 2,423 2,565 -6% 0% 3.9% 4.2% 4.1% 4.1% 4.1% 4.1%
Provisions -542 -321 69% 73% 82 -213 - - -460 -534 -14% -11% -1.0% -0.7% -1.8% 0.3% -0.8% -0.8%
Other 326 153 113% 125% 440 406 8% 16% 766 559 37% 45% 0.5% 1.3% 1.1% 1.5% 0.9% 1.3%
(Increase) / decrease in net working capital -1,804 -2,052 -12% -11% 697 -366 - - -1,107 -2,418 -54% -51% -6.4% -1.2% -6.1% 2.4% -3.8% -1.9%
Receivables -24 -55 -56% -53% -520 -922 -44% -22% -544 -977 -44% -24% -0.2% -3.0% -0.1% -1.8% -1.5% -0.9%
Inventories -370 -763 -52% -54% 61 -866 - - -309 -1,629 -81% -81% -2.4% -2.8% -1.2% 0.2% -2.6% -0.5%
Payables -1,410 -1,234 14% 16% 1,156 1,422 -19% -9% -254 188 - - -3.8% 4.6% -4.7% 4.0% 0.3% -0.4%
Investments in property, plant and equipment -1,740 -1,685 3% 10% -2,002 -1,764 13% 21% -3,742 -3,449 8% 16% -5.2% -5.7% -5.8% -6.9% -5.5% -6.4%
Principal portion of lease liailities -174 -186 -6% 0% -165 -219 -25% -18% -339 -405 -16% -10% -0.6% -0.7% -0.6% -0.6% -0.6% -0.6%
Operating free cash flow 8,031 9,782 -18% -8% 7,737 7,891 -2% 18% 15,768 17,673 -11% 4% 30.3% 25.5% 27.0% 26.7% 27.9% 26.9%
as % of sales 27.0% 30.3% 26.7% 25.5% 26.9% 27.9%
Treasury activities -333 -203 64% 74% -527 -327 61% 71% -860 -530 62% 72% -0.6% -1.1% -1.1% -1.8% -0.8% -1.5%
Taxes paid -1,570 -2,482 -37% -33% -2,050 -1,620 27% 37% -3,620 -4,102 -12% -5% -7.7% -5.2% -5.3% -7.1% -6.5% -6.2%
Free cash flow 6,128 7,097 -14% -2% 5,160 5,944 -13% 10% 11,288 13,041 -13% 4% 22.0% 19.2% 20.6% 17.8% 20.6% 19.2%
Core operating profit 10,911 12,668 -14% -6% 8,329 9,505 -12% 6% 19,240 22,173 -13% -1% 39.2% 30.7% 36.6% 28.8% 35.0% 32.8%
Other financial income (expense) -100 -258 -61% -50% -220 -270 -19% -11% -320 -528 -39% -30% -0.8% -0.9% -0.3% -0.8% -0.7% -0.4%
Financing costs -482 -300 61% 68% -498 -386 29% 39% -980 -686 43% 52% -0.9% -1.2% -1.6% -1.7% -1.1% -1.7%
Core profit before taxes 10,329 12,110 -15% -7% 7,611 8,849 -14% 5% 17,940 20,959 -14% -2% 37.5% 28.6% 34.7% 26.3% 33.1% 30.6%
Income taxes -1,742 -1,950 -11% -2% -394 -1,479 -73% -60% -2,136 -3,429 -38% -28% -6.0% -4.8% -5.9% -1.4% -5.4% -3.7%
Tax rate in % 16.9% 16.1% 5.2% 16.7% 11.9% 16.4%
Core net income 8,587 10,160 -15% -7% 7,217 7,370 -2% 18% 15,804 17,530 -10% 3% 31.5% 23.8% 28.8% 24.9% 27.7% 26.9%
as % of sales 28.8% 31.5% 24.9% 23.8% 26.9% 27.7%
Attributable to
Roche shareholders 8,124 9,518 -15% -6% 6,803 6,883 -1% 20% 14,927 16,401 -9% 5%
Non-controlling interests 463 642 -28% -20% 414 487 -15% -8% 877 1,129 -22% -15%

Core (CHF) 10.10 11.76 -14% -5% 8.47 8.54 -1% 20% 18.57 20.30 -9% 6%
Roche Online Financial Information System Group Core CHF 04/03/2024 24/43
Pharma Division Core operating results (CHFm) H1 2023 H1 2022 CHF % CER % H2 2023 H2 2022 CHF % CER % Year 2023 Year 2022 CHF % CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 22,681 22,347 1% 8% 21,931 23,204 -5% 4% 44,612 45,551 -2% 6% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 806 1,580 -49% -45% 861 885 -3% 4% 1,667 2,465 -32% -27% 7.1% 3.8% 3.6% 3.9% 5.4% 3.7%
Royalty income 395 471 -16% -14% 440 453 -3% 2% 835 924 -10% -6% 2.1% 2.0% 1.7% 2.0% 2.0% 1.9%
Profit-sharing income and other 340 347 -2% 1% 368 352 5% 14% 708 699 1% 7% 1.6% 1.5% 1.5% 1.7% 1.5% 1.6%
Cost of sales -4,107 -4,252 -3% 3% -4,236 -4,653 -9% -5% -8,343 -8,905 -6% -1% -19.0% -20.1% -18.0% -19.3% -19.5% -18.6%
Manufacturing cost of goods sold and period costs -2,393 -2,542 -6% 1% -2,649 -2,639 0% 2% -5,042 -5,181 -3% 1% -11.4% -11.4% -10.6% -12.1% -11.4% -11.3%
Amortisation of intangible assets commercial software -2 -1 100% 20% -1 -2 -50% 0% -3 -3 0% 9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment -23 -29 -21% -19% 1 -2 - - -22 -31 -29% -17% -0.1% 0.0% -0.1% 0.0% -0.1% 0.0%
Impairment of property, plant and equipment and right-of-use assets -23 -29 -21% -19% 1 -2 - - -22 -31 -29% -17% -0.1% 0.0% -0.1% 0.0% -0.1% 0.0%
Research and development -5,617 -5,402 4% 9% -5,873 -6,018 -2% 4% -11,490 -11,420 1% 6% -24.2% -25.9% -24.8% -26.8% -25.1% -25.8%
Selling, general and administration -3,444 -3,382 2% 7% -3,771 -3,942 -4% 4% -7,215 -7,324 -1% 6% -15.2% -17.0% -15.3% -17.2% -16.1% -16.2%
Marketing and distribution -2,779 -2,722 2% 8% -3,057 -3,194 -4% 4% -5,836 -5,916 -1% 6% -12.2% -13.8% -12.3% -13.9% -13.0% -13.1%
Administration -535 -586 -9% -4% -569 -607 -6% 2% -1,104 -1,193 -7% -1% -2.6% -2.6% -2.4% -2.6% -2.6% -2.5%
Other general items - Selling, general and administration -53 -7 657% 544% -49 -48 2% 11% -102 -55 85% 90% 0.0% -0.2% -0.2% -0.2% -0.1% -0.2%
Other operating income and expense 699 398 76% 79% 59 366 -84% -80% 758 764 -1% 3% 1.8% 1.6% 3.1% 0.3% 1.7% 1.7%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 8 8 0% 17% -1 -3 -67% -66% 7 5 40% 74% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment 8 7 14% 28% -1 -3 -67% -54% 7 4 75% 94% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on divestment of subsidiaries 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 106 52 104% 107% 87 91 -4% 6% 193 143 35% 43% 0.2% 0.4% 0.5% 0.4% 0.3% 0.4%
Core operating profit 11,018 11,289 -2% 5% 8,971 9,842 -9% 5% 19,989 21,131 -5% 5% 50.5% 42.4% 48.6% 40.9% 46.4% 44.8%
as % of sales 48.6% 50.5% 40.9% 42.4% 44.8% 46.4%
Non-Core items -933 -958 -3% 1% -1,924 -3,407 -44% -40% -2,857 -4,365 -35% -31% -4.3% -14.7% -4.1% -8.8% -9.6% -6.4%
IFRS operating profit 10,085 10,331 -2% 5% 7,047 6,435 10% 29% 17,132 16,766 2% 14% 46.2% 27.7% 44.5% 32.1% 36.8% 38.4%
as % of sales 44.5% 46.2% 32.1% 27.7% 38.4% 36.8%
Depreciation of property, plant and equipment 654 665 -2% 2% 609 716 -15% -10% 1,263 1,381 -9% -4% 3.0% 3.1% 2.9% 2.8% 3.0% 2.8%
Provisions -390 -212 84% 88% -116 -36 222% 221% -506 -248 104% 108% -0.9% -0.2% -1.7% -0.5% -0.5% -1.1%
Other 196 33 494% 532% 202 117 73% 84% 398 150 165% 179% 0.1% 0.5% 0.9% 0.9% 0.3% 0.9%
Operating profit, net of operating cash adjustment 11,507 12,008 -4% 3% 9,941 10,526 -6% 8% 21,448 22,534 -5% 5% 53.7% 45.4% 50.7% 45.3% 49.5% 48.1%
(Increase) / decrease in net working capital -638 -958 -33% -38% -76 -787 -90% -87% -714 -1,745 -59% -59% -4.3% -3.4% -2.8% -0.3% -3.8% -1.6%
Receivables 145 304 -52% -46% -204 -1,275 -84% -77% -59 -971 -94% -86% 1.4% -5.5% 0.6% -0.9% -2.1% -0.1%
Inventories -154 -400 -62% -68% -159 -438 -64% -62% -313 -838 -63% -65% -1.8% -1.9% -0.7% -0.7% -1.8% -0.7%
Payables -629 -862 -27% -26% 287 926 -69% -61% -342 64 - - -3.9% 4.0% -2.8% 1.3% 0.1% -0.8%
Investments in property, plant and equipment -979 -959 2% 8% -957 -785 22% 30% -1,936 -1,744 11% 18% -4.3% -3.4% -4.3% -4.4% -3.8% -4.3%
Principal portion of lease liailities -110 -118 -7% -1% -105 -156 -33% -26% -215 -274 -22% -15% -0.5% -0.7% -0.5% -0.5% -0.6% -0.5%
Operating free cash flow 9,562 9,638 -1% 8% 8,166 8,056 1% 18% 17,728 17,694 0% 12% 43.1% 34.7% 42.2% 37.2% 38.8% 39.7%
as % of sales 42.2% 43.1% 37.2% 34.7% 39.7% 38.8%
Roche Online Financial Information System Pharma Core CHF 04/03/2024 25/43
Diagnostics Division Core operating results (CHFm) H1 2023 H1 2022 CHF % CER % H2 2023 H2 2022 CHF % CER % Year 2023 Year 2022 CHF % CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 7,098 9,948 -29% -23% 7,006 7,782 -10% -1% 14,104 17,730 -20% -13% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 31 25 24% 29% 27 43 -37% -35% 58 68 -15% -12% 0.3% 0.6% 0.4% 0.4% 0.4% 0.4%
Royalty income 21 21 0% 2% 22 40 -45% -43% 43 61 -30% -28% 0.2% 0.5% 0.3% 0.3% 0.3% 0.3%
Other income from collaboration and out-licensing agreements 0 0 - - 2 0 - - 2 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cost of sales -3,349 -4,734 -29% -26% -3,559 -3,776 -6% -1% -6,908 -8,510 -19% -15% -47.6% -48.6% -47.2% -50.8% -48.1% -48.9%
Manufacturing cost of goods sold and period costs -3,276 -4,664 -30% -26% -3,498 -3,713 -6% -1% -6,774 -8,377 -19% -15% -46.9% -47.7% -46.2% -49.9% -47.2% -48.0%
Royalty expenses -70 -70 0% 0% -55 -60 -8% -4% -125 -130 -4% -2% -0.7% -0.8% -1.0% -0.8% -0.7% -0.9%
Collaboration and profit-sharing agreements 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Amortisation of intangible assets commercial software -1 -2 -50% -29% -1 0 - - -2 -2 0% 44% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment -2 2 - - -5 -3 67% 30% -7 -1 600% 425% 0.0% 0.0% 0.0% -0.1% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -2 2 - - -5 -3 67% 30% -7 -1 600% 425% 0.0% 0.0% 0.0% -0.1% 0.0% 0.0%
Research and development -832 -843 -1% 2% -915 -992 -8% -3% -1,747 -1,835 -5% -1% -8.5% -12.7% -11.7% -13.1% -10.3% -12.4%
Selling, general and administration -1,342 -1,465 -8% -2% -1,557 -1,650 -6% 3% -2,899 -3,115 -7% 0% -14.7% -21.2% -18.9% -22.2% -17.5% -20.6%
Marketing and distribution -1,160 -1,260 -8% -2% -1,317 -1,408 -6% 2% -2,477 -2,668 -7% 0% -12.7% -18.1% -16.3% -18.8% -15.0% -17.6%
Administration -185 -203 -9% -5% -215 -225 -4% 4% -400 -428 -7% 0% -2.0% -2.9% -2.6% -3.1% -2.4% -2.8%
Business taxes and capital taxes -10 -10 0% 13% -12 -13 -8% 2% -22 -23 -4% 6% -0.1% -0.2% -0.1% -0.2% -0.1% -0.2%
Other general items - Selling, general and administration 13 8 63% 50% -13 -4 225% 240% 0 4 -100% -100% 0.0% 0.0% 0.1% -0.1% 0.0% 0.0%
Other operating income and expense 13 22 -41% -35% 47 21 124% 137% 60 43 40% 50% 0.2% 0.3% 0.2% 0.7% 0.2% 0.4%
Pensions - past service costs 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 1 1 0% -56% 2 -1 - - 3 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment 1 0 - - 2 -1 - - 3 -1 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of products 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 12 21 -43% -33% 44 21 110% 122% 56 42 33% 45% 0.2% 0.3% 0.2% 0.6% 0.2% 0.4%
Core operating profit 1,619 2,953 -45% -36% 1,049 1,428 -27% -1% 2,668 4,381 -39% -24% 29.7% 18.4% 22.8% 15.0% 24.7% 18.9%
as % of sales 22.8% 29.7% 15.0% 18.4% 18.9% 24.7%
Non-Core items -52 -94 -45% -45% -445 -138 222% 234% -497 -232 114% 122% -0.9% -1.8% -0.7% -6.4% -1.3% -3.5%
IFRS operating profit 1,567 2,859 -45% -36% 604 1,290 -53% -25% 2,171 4,149 -48% -32% 28.7% 16.6% 22.1% 8.6% 23.4% 15.4%
as % of sales 22.1% 28.7% 8.6% 16.6% 15.4% 23.4%
Depreciation, amortisation and impairments 690 708 -3% 3% 775 726 7% 14% 1,465 1,434 2% 9% 7.1% 9.3% 9.7% 11.1% 8.1% 10.4%
Depreciation of property, plant and equipment 540 562 -4% 2% 555 566 -2% 5% 1,095 1,128 -3% 4% 5.6% 7.3% 7.6% 7.9% 6.4% 7.8%
Depreciation of right-of-use assets 60 59 2% 7% 56 58 -3% 7% 116 117 -1% 7% 0.6% 0.7% 0.8% 0.8% 0.7% 0.8%
Impairment of property, plant and equipment 9 -1 - - 64 16 300% 305% 73 15 387% 401% 0.0% 0.2% 0.1% 0.9% 0.1% 0.5%
Provisions -135 -101 34% 39% 134 -124 - - -1 -225 -100% -100% -1.0% -1.6% -1.9% 1.9% -1.3% 0.0%
Other 130 119 9% 14% 236 272 -13% -6% 366 391 -6% 0% 1.2% 3.5% 1.8% 3.4% 2.2% 2.6%
Operating profit cash adjustments 736 768 -4% 1% 1,207 934 29% 37% 1,943 1,702 14% 21% 7.7% 12.1% 10.4% 17.2% 9.6% 13.8%
Operating profit, net of operating cash adjustment 2,303 3,627 -37% -28% 1,811 2,224 -19% 1% 4,114 5,851 -30% -17% 36.5% 28.6% 32.4% 25.8% 33.0% 29.2%
(Increase) / decrease in net working capital -1,114 -971 15% 22% 563 265 112% 106% -551 -706 -22% -8% -9.8% 3.4% -15.7% 8.0% -4.0% -3.9%
Receivables -54 -339 -84% -79% -332 361 - - -386 22 - - -3.4% 4.6% -0.8% -4.7% 0.1% -2.7%
Inventories -216 -363 -40% -38% 220 -428 - - 4 -791 - - -3.6% -5.5% -3.0% 3.1% -4.5% 0.0%
Payables -844 -269 214% 222% 675 332 103% 121% -169 63 - - -2.7% 4.3% -11.9% 9.6% 0.4% -1.2%
Investments in property, plant and equipment -713 -687 4% 10% -1,009 -932 8% 16% -1,722 -1,619 6% 14% -6.9% -12.0% -10.0% -14.4% -9.1% -12.2%
Principal portion of lease liailities -58 -61 -5% 2% -54 -57 -5% 3% -112 -118 -5% 2% -0.6% -0.7% -0.8% -0.8% -0.7% -0.8%
Investments in intangible assets -16 -6 167% 173% -36 -20 80% 83% -52 -26 100% 103% -0.1% -0.3% -0.2% -0.5% -0.1% -0.4%
Operating free cash flow 402 1,902 -79% -70% 1,275 1,480 -14% 7% 1,677 3,382 -50% -35% 19.1% 19.0% 5.7% 18.2% 19.1% 11.9%
as % of sales 5.7% 19.1% 18.2% 19.0% 11.9% 19.1%
Roche Online Financial Information System Diagnostics Core CHF 04/03/2024 26/43
Group Core results (CHFm at avg full year 2022 fx rates) H1 2023 H1 2022 CER % H2 2023 H2 2022 CER % Year 2023 Year 2022 CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 31,426 31,966 -2% 32,219 31,289 3% 63,645 63,255 1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 869 1,554 -44% 943 922 2% 1,812 2,475 -27% 4.9% 2.9% 2.8% 2.9% 3.9% 2.8%
Royalty income 427 494 -14% 484 490 -1% 911 985 -7% 1.5% 1.6% 1.4% 1.5% 1.6% 1.4%
Cost of sales -7,734 -8,827 -12% -8,331 -8,588 -3% -16,065 -17,415 -8% -27.6% -27.4% -24.6% -25.9% -27.5% -25.2%
Amortisation of intangible assets commercial software -3 -3 -8% -3 -2 79% -6 -5 22% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment -26 -27 -4% -6 -5 32% -32 -32 1% -0.1% 0.0% -0.1% 0.0% -0.1% -0.1%
Impairment of property, plant and equipment and right-of-use assets -26 -27 -4% -6 -5 32% -32 -32 1% -0.1% 0.0% -0.1% 0.0% -0.1% -0.1%
Impairment of intangible assets commercial software 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Research and development -6,692 -6,206 8% -7,273 -7,050 3% -13,965 -13,256 5% -19.4% -22.5% -21.3% -22.6% -21.0% -21.9%
Administration -2,497 -2,351 6% -2,596 -2,590 0% -5,093 -4,942 3% -7.4% -8.3% -7.9% -8.1% -7.8% -8.0%
Other general items - Selling, general and administration -40 0 - -63 -50 27% -104 -50 107% 0.0% -0.2% -0.1% -0.2% -0.1% -0.2%
Other operating income and expense 720 415 73% 119 380 -69% 840 796 6% 1.3% 1.2% 2.3% 0.4% 1.3% 1.3%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 9 9 7% 2 -4 - 11 5 143% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment 9 7 38% 2 -4 - 11 3 308% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Core operating profit 11,820 12,524 -6% 10,089 9,563 6% 21,909 22,087 -1% 39.2% 30.6% 37.6% 31.3% 34.9% 34.4%
as % of sales 37.6% 39.2% 31.3% 30.6% 34.4% 34.9%
Non-Core items -1,187 -1,125 6% -2,840 -3,572 -20% -4,027 -4,697 -14% -3.5% -11.4% -3.8% -8.8% -7.4% -6.3%
as % of sales 33.8% 35.7% 22.5% 19.1% 28.1% 27.5%
Depreciation of property, plant and equipment 1,275 1,241 3% 1,287 1,324 -3% 2,562 2,565 0% 3.9% 4.2% 4.1% 4.0% 4.1% 4.0%
Provisions -554 -319 73% 80 -215 - -474 -534 -11% -1.0% -0.7% -1.8% 0.2% -0.8% -0.7%
Other 334 148 125% 476 411 16% 810 559 45% 0.5% 1.3% 1.1% 1.5% 0.9% 1.3%
Operating profit, net of operating cash adjustment 12,945 13,890 -7% 11,788 11,072 6% 24,733 24,962 -1% 43.5% 35.4% 41.2% 36.6% 39.5% 38.9%
(Increase) / decrease in net working capital -1,829 -2,064 -11% 633 -354 - -1,196 -2,418 -51% -6.5% -1.1% -5.8% 2.0% -3.8% -1.9%
Receivables -27 -58 -53% -717 -919 -22% -744 -977 -24% -0.2% -2.9% -0.1% -2.2% -1.5% -1.2%
Inventories -353 -762 -54% 49 -866 - -304 -1,629 -81% -2.4% -2.8% -1.1% 0.2% -2.6% -0.5%
Payables -1,449 -1,244 16% 1,302 1,431 -9% -147 187 - -3.9% 4.6% -4.6% 4.0% 0.3% -0.2%
Investments in property, plant and equipment -1,819 -1,657 10% -2,176 -1,791 21% -3,994 -3,449 16% -5.2% -5.7% -5.8% -6.8% -5.5% -6.3%
Principal portion of lease liailities -183 -183 0% -183 -222 -18% -366 -405 -10% -0.6% -0.7% -0.6% -0.6% -0.6% -0.6%
Operating free cash flow 8,871 9,644 -8% 9,377 7,944 18% 18,248 17,588 4% 30.2% 25.4% 28.2% 29.1% 27.8% 28.7%
as % of sales 28.2% 30.2% 29.1% 25.4% 28.7% 27.8%
Treasury activities -351 -202 74% -563 -329 71% -914 -530 72% -0.6% -1.1% -1.1% -1.7% -0.8% -1.4%
Taxes paid -1,638 -2,447 -33% -2,267 -1,655 37% -3,905 -4,102 -5% -7.7% -5.3% -5.2% -7.0% -6.5% -6.1%
Free cash flow 6,881 6,996 -2% 6,547 5,960 10% 13,428 12,956 4% 21.9% 19.0% 21.9% 20.3% 20.5% 21.1%
Core operating profit 11,820 12,524 -6% 10,089 9,563 6% 21,909 22,087 -1% 39.2% 30.6% 37.6% 31.3% 34.9% 34.4%
Other financial income (expense) -127 -255 -50% -244 -273 -11% -370 -528 -30% -0.8% -0.9% -0.4% -0.8% -0.8% -0.6%
Financing costs -505 -301 68% -536 -385 39% -1,041 -686 52% -0.9% -1.2% -1.6% -1.7% -1.1% -1.6%
Core profit before taxes 11,188 11,968 -7% 9,310 8,906 5% 20,498 20,873 -2% 37.4% 28.5% 35.6% 28.9% 33.0% 32.2%
Income taxes -1,860 -1,905 -2% -597 -1,506 -60% -2,457 -3,411 -28% -6.0% -4.8% -5.9% -1.9% -5.4% -3.9%
Tax rate in % 16.6% 15.9% 6.4% 16.9% 12.0% 16.3%
Core net income 9,329 10,063 -7% 8,712 7,399 18% 18,041 17,463 3% 31.5% 23.6% 29.7% 27.0% 27.6% 28.3%
as % of sales 29.7% 31.5% 27.0% 23.6% 28.3% 27.6%
Attributable to
Roche shareholders 8,841 9,455 -6% 8,250 6,895 20% 17,091 16,350 5%
Non-controlling interests 488 608 -20% 462 504 -8% 950 1,113 -15%

Core (CHF) 11.23 11.77 -5% 10.64 8.84 20% 21.87 20.62 6%
Roche Online Financial Information System Group Core CER 04/03/2024 27/43
Pharmaceuticals Division Core op. results (CHFm at avg full year 2022 fx rates) H1 2023 H1 2022 CER % H2 2023 H2 2022 CER % Year 2023 Year 2022 CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 23,907 22,173 8% 24,323 23,352 4% 48,230 45,525 6% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 837 1,529 -45% 915 878 4% 1,751 2,407 -27% 6.9% 3.8% 3.5% 3.8% 5.3% 3.6%
Royalty income 406 473 -14% 461 450 2% 867 923 -6% 2.1% 1.9% 1.7% 1.9% 2.0% 1.8%
Cost of sales -4,266 -4,153 3% -4,524 -4,751 -5% -8,790 -8,904 -1% -18.7% -20.3% -17.8% -18.6% -19.6% -18.2%
Manufacturing cost of goods sold and period costs -2,464 -2,443 1% -2,785 -2,737 2% -5,249 -5,181 1% -11.0% -11.7% -10.3% -11.4% -11.4% -10.9%
Amortisation of intangible assets commercial software -2 -1 20% -2 -2 0% -3 -3 9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment -24 -30 -19% -1 -1 - -25 -31 -17% -0.1% 0.0% -0.1% 0.0% -0.1% -0.1%
Impairment of property, plant and equipment and right-of-use assets -24 -30 -19% -1 -1 - -25 -31 -17% -0.1% 0.0% -0.1% 0.0% -0.1% -0.1%
Research and development -5,836 -5,367 9% -6,311 -6,055 4% -12,147 -11,422 6% -24.2% -25.9% -24.4% -25.9% -25.1% -25.2%
Administration -562 -584 -4% -620 -609 2% -1,183 -1,193 -1% -2.6% -2.6% -2.4% -2.5% -2.6% -2.5%
Other general items - Selling, general and administration -52 -8 544% -52 -47 11% -104 -55 90% 0.0% -0.2% -0.2% -0.2% -0.1% -0.2%
Other operating income and expense 713 399 79% 75 365 -80% 788 763 3% 1.8% 1.6% 3.0% 0.3% 1.7% 1.6%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 9 7 17% -1 -3 -66% 8 4 74% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment 9 7 28% -1 -3 -54% 7 4 94% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on divestment of subsidiaries 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Core operating profit 11,747 11,218 5% 10,354 9,828 5% 22,100 21,047 5% 50.6% 42.1% 49.1% 42.6% 46.2% 45.8%
as % of sales 49.1% 50.6% 42.6% 42.1% 45.8% 46.2%
Non-Core items -973 -964 1% -2,047 -3,402 -40% -3,020 -4,365 -31% -4.3% -14.6% -4.1% -8.4% -9.6% -6.3%
IFRS operating profit 10,774 10,255 5% 8,306 6,427 29% 19,080 16,681 14% 46.2% 27.5% 45.1% 34.2% 36.6% 39.6%
as % of sales 45.1% 46.2% 34.2% 27.5% 39.6% 36.6%
Depreciation of property, plant and equipment 676 661 2% 648 720 -10% 1,325 1,381 -4% 3.0% 3.1% 2.8% 2.7% 3.0% 2.7%
Provisions -396 -211 88% -120 -37 221% -516 -248 108% -1.0% -0.2% -1.7% -0.5% -0.5% -1.1%
Other 201 32 532% 218 118 84% 420 150 179% 0.1% 0.5% 0.8% 0.9% 0.3% 0.9%
Operating profit, net of operating cash adjustment 12,257 11,938 3% 11,399 10,512 8% 23,656 22,450 5% 53.8% 45.1% 51.3% 46.9% 49.3% 49.0%
(Increase) / decrease in net working capital -614 -986 -38% -95 -760 -87% -709 -1,746 -59% -4.4% -3.3% -2.6% -0.4% -3.8% -1.5%
Receivables 156 287 -46% -295 -1,258 -77% -138 -971 -86% 1.3% -5.4% 0.7% -1.2% -2.1% -0.3%
Inventories -129 -403 -68% -164 -435 -62% -294 -838 -65% -1.8% -1.9% -0.5% -0.7% -1.8% -0.6%
Payables -641 -870 -26% 364 933 -61% -277 62 - -3.9% 4.0% -2.7% 1.5% 0.1% -0.6%
Investments in property, plant and equipment -1,022 -942 8% -1,042 -801 30% -2,065 -1,744 18% -4.2% -3.4% -4.3% -4.3% -3.8% -4.3%
Principal portion of lease liailities -116 -117 -1% -116 -157 -26% -232 -274 -15% -0.5% -0.7% -0.5% -0.5% -0.6% -0.5%
Operating free cash flow 10,278 9,557 8% 9,496 8,053 18% 19,774 17,610 12% 43.1% 34.5% 43.0% 39.0% 38.7% 41.0%
as % of sales 43.0% 43.1% 39.0% 34.5% 41.0% 38.7%
Roche Online Financial Information System Pharma Core CER 04/03/2024 28/43
Diagnostics Division Core op. results (CHFm at avg full year 2022 fx rates) H1 2023 H1 2022 CER % H2 2023 H2 2022 CER % Year 2023 Year 2022 CER % H1 2022 H2 2022 H1 2023 H2 2023 Year 2022 Year 2023
Sales 3rd 7,519 9,793 -23% 7,896 7,937 -1% 15,415 17,730 -13% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other revenue 32 25 29% 28 44 -35% 60 68 -12% 0.3% 0.5% 0.4% 0.4% 0.4% 0.4%
Royalty income 21 21 2% 23 40 -43% 45 61 -28% 0.2% 0.5% 0.3% 0.3% 0.3% 0.3%
Other income from collaboration and out-licensing agreements 0 0 - 2 0 - 2 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cost of sales -3,468 -4,674 -26% -3,808 -3,837 -1% -7,275 -8,511 -15% -47.7% -48.3% -46.1% -48.2% -48.0% -47.2%
Manufacturing cost of goods sold and period costs -3,393 -4,604 -26% -3,745 -3,774 -1% -7,139 -8,378 -15% -47.0% -47.5% -45.1% -47.4% -47.3% -46.3%
Royalty expenses -70 -70 0% -57 -59 -4% -127 -130 -2% -0.7% -0.7% -0.9% -0.7% -0.7% -0.8%
Collaboration and profit-sharing agreements 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Amortisation of intangible assets commercial software -1 -2 -29% -1 0 - -2 -2 44% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Impairment of property, plant and equipment -3 2 - -5 -4 30% -7 -1 425% 0.0% 0.0% 0.0% -0.1% 0.0% 0.0%
Impairment of property, plant and equipment and right-of-use assets -3 2 - -5 -4 30% -7 -1 425% 0.0% 0.0% 0.0% -0.1% 0.0% 0.0%
Research and development -856 -839 2% -962 -995 -3% -1,818 -1,834 -1% -8.6% -12.5% -11.4% -12.2% -10.3% -11.8%
Selling, general and administration -1,411 -1,445 -2% -1,717 -1,672 3% -3,128 -3,117 0% -14.8% -21.1% -18.8% -21.7% -17.6% -20.3%
Marketing and distribution -1,220 -1,242 -2% -1,455 -1,427 2% -2,675 -2,669 0% -12.7% -18.0% -16.2% -18.4% -15.1% -17.4%
Administration -192 -202 -5% -237 -228 4% -429 -429 0% -2.1% -2.9% -2.6% -3.0% -2.4% -2.8%
Other general items - Selling, general and administration 12 8 50% -11 -3 240% 1 5 -100% 0.1% 0.0% 0.2% -0.1% 0.0% 0.0%
Other operating income and expense 14 22 -35% 50 21 137% 64 43 50% 0.2% 0.3% 0.2% 0.6% 0.2% 0.4%
Pensions - past service costs 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment and right-of-use assets 1 1 -56% 3 -1 - 4 1 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of property, plant and equipment 1 0 - 3 -1 - 4 -1 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gains (losses) on disposal of products 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other general items - Other operating income and expense 14 20 -33% 46 21 122% 59 41 45% 0.2% 0.3% 0.2% 0.6% 0.2% 0.4%
Core operating profit 1,831 2,881 -36% 1,488 1,498 -1% 3,318 4,379 -24% 29.4% 18.9% 24.3% 18.8% 24.7% 21.5%
as % of sales 24.3% 29.4% 18.8% 18.9% 21.5% 24.7%
Non-Core items -51 -93 -45% -461 -138 234% -512 -231 122% -1.0% -1.7% -0.7% -5.8% -1.3% -3.3%
IFRS operating profit 1,780 2,788 -36% 1,026 1,360 -25% 2,806 4,148 -32% 28.5% 17.1% 23.7% 13.0% 23.4% 18.2%
as % of sales 23.7% 28.5% 13.0% 17.1% 18.2% 23.4%
Depreciation, amortisation and impairments 720 698 3% 839 736 14% 1,559 1,434 9% 7.1% 9.3% 9.6% 10.6% 8.1% 10.1%
Depreciation of property, plant and equipment 563 552 2% 605 575 5% 1,169 1,128 4% 5.6% 7.3% 7.5% 7.7% 6.4% 7.6%
Depreciation of right-of-use assets 63 58 7% 63 59 7% 126 117 7% 0.6% 0.7% 0.8% 0.8% 0.7% 0.8%
Impairment of property, plant and equipment 10 -1 - 66 16 305% 76 15 401% 0.0% 0.2% 0.1% 0.8% 0.1% 0.5%
Provisions -140 -101 39% 135 -124 - -5 -225 -100% -1.0% -1.6% -1.9% 1.7% -1.3% 0.0%
Other 133 116 14% 257 275 -6% 390 391 0% 1.2% 3.5% 1.8% 3.3% 2.2% 2.5%
Operating profit cash adjustments 765 755 1% 1,296 947 37% 2,061 1,702 21% 7.7% 12.0% 10.2% 16.4% 9.6% 13.4%
Operating profit, net of operating cash adjustment 2,545 3,543 -28% 2,322 2,307 1% 4,867 5,850 -17% 36.2% 29.1% 33.8% 29.4% 33.0% 31.6%
(Increase) / decrease in net working capital -1,164 -955 22% 515 249 106% -649 -705 -8% -9.8% 3.1% -15.5% 6.5% -4.0% -4.2%
Receivables -67 -325 -79% -437 347 - -504 22 - -3.3% 4.4% -0.9% -5.5% 0.1% -3.3%
Inventories -224 -359 -38% 213 -431 - -11 -791 - -3.7% -5.4% -3.0% 2.7% -4.5% -0.1%
Payables -872 -271 222% 739 334 121% -134 63 - -2.8% 4.2% -11.6% 9.4% 0.4% -0.9%
Investments in property, plant and equipment -746 -676 10% -1,095 -943 16% -1,841 -1,619 14% -6.9% -11.9% -9.9% -13.9% -9.1% -11.9%
Principal portion of lease liailities -61 -60 2% -60 -59 3% -121 -118 2% -0.6% -0.7% -0.8% -0.8% -0.7% -0.8%
Investments in intangible assets -16 -6 173% -37 -20 83% -53 -26 103% -0.1% -0.3% -0.2% -0.5% -0.1% -0.3%
Operating free cash flow 559 1,847 -70% 1,644 1,534 7% 2,203 3,381 -35% 18.9% 19.3% 7.4% 20.8% 19.1% 14.3%
as % of sales 7.4% 18.9% 20.8% 19.3% 14.3% 19.1%
Roche Online Financial Information System Diagnostics Core CER 04/03/2024 29/43
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2022
H1 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Group reconciliation (CHFm)
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 32,295 0 0 0 0 0 0 0 0 0 32,295
Sales to other ODGs / Divisions 0 0 0 0 0 0 0 0 0 0 0
Other revenue 1,605 0 0 0 0 0 0 0 0 0 1,605
Cost of sales -9,668 60 286 336 0 0 0 0 0 0 -8,986
Research and development -6,516 19 165 87 0 0 0 0 0 0 -6,245
Selling, general and administration -6,600 167 17 0 0 0 0 0 0 0 -6,416
Other operating income and expense 431 20 0 0 -17 -19 0 0 0 0 415
Operating profit 11,547 266 468 423 -17 -19 0 0 0 0 12,668
Other financial income (expense) -258 0 0 0 0 0 0 0 0 0 -258

Financing costs -304 0 0 0 2 2 0 0 0 0 -300
Profit before taxes 10,985 266 468 423 -15 -17 0 0 0 0 12,110
Income taxes -1,824 -48 -42 -74 0 6 0 0 32 0 -1,950
Net income 9,161 218 426 349 -15 -11 0 0 32 0 10,160
Attributable to
Roche shareholders 8,530 208 425 349 -15 -11 0 0 32 0 9,518
Non-controlling interests 631 10 1 0 0 0 0 0 0 0 642
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2022
H2 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 30,986 0 0 0 0 0 0 0 0 0 30,986
Other revenue 928 0 0 0 0 0 0 0 0 0 928
Cost of sales -10,069 235 269 1,136 0 0 0 0 0 0 -8,429
Research and development -8,709 242 179 1,278 0 0 0 0 0 0 -7,010
Other operating income and expense 394 -7 0 0 -3 -3 0 0 0 0 381
Operating profit 5,929 703 465 2,414 -3 -3 0 0 0 0 9,505
Other financial income (expense) -226 0 0 0 -44 0 0 0 0 0 -270

Financing costs -361 0 0 0 -3 -22 0 0 0 0 -386
Profit before taxes 5,342 703 465 2,414 -50 -25 0 0 0 0 8,849
Income taxes -972 -145 -38 -361 -1 2 0 0 36 0 -1,479
Net income 4,370 558 427 2,053 -51 -23 0 0 36 0 7,370
Attributable to
Roche shareholders 3,891 553 424 2,053 -51 -23 0 0 36 0 6,883
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Year 2022
Year 2022
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 63,281 0 0 0 0 0 0 0 0 0 63,281
Other revenue 2,533 0 0 0 0 0 0 0 0 0 2,533
Cost of sales -19,737 295 555 1,472 0 0 0 0 0 0 -17,415
Other financial income (expense) -484 0 0 0 -44 0 0 0 0 0 -528

Financing costs -665 0 0 0 -1 -20 0 0 0 0 -686
Profit before taxes 16,327 969 933 2,837 -65 -42 0 0 0 0 20,959
Income taxes -2,796 -193 -80 -435 -1 8 0 0 68 0 -3,429
Net income 13,531 776 853 2,402 -66 -34 0 0 68 0 17,530
Attributable to
Roche shareholders 12,421 761 849 2,402 -66 -34 0 0 68 0 16,401
Non-controlling interests 1,110 15 4 0 0 0 0 0 0 0 1,129
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2023
H1 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Group reconciliation (CHFm)

Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 29,779 0 0 0 0 0 0 0 0 0 29,779

Other revenue 837 0 0 0 0 0 0 0 0 0 837
Cost of sales -7,931 287 188 0 0 0 0 0 0 0 -7,456
Other operating income and expense 847 7 0 0 1 -150 0 0 0 0 705
Operating profit 9,764 678 358 260 1 -150 0 0 0 0 10,911

Financing costs -490 0 0 0 3 5 0 0 0 0 -482
Profit before taxes 9,174 678 358 260 4 -145 0 0 0 0 10,329
Income taxes -1,611 -134 -22 -52 0 46 0 0 31 0 -1,742
Net income 7,563 544 336 208 4 -99 0 0 31 0 8,587
Attributable to
Roche shareholders 7,137 515 334 202 4 -99 0 0 31 0 8,124
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2023
H2 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 28,937 0 0 0 0 0 0 0 0 0 28,937

Other revenue 888 0 0 0 0 0 0 0 0 0 888
Cost of sales -8,426 261 187 183 0 0 0 0 0 0 -7,795
Selling, general and administration -8,031 1,005 13 0 0 0 0 0 0 0 -7,013
Other operating income and expense -455 -82 0 591 18 28 0 0 0 0 100
Operating profit 5,631 1,360 353 939 18 28 0 0 0 0 8,329

Financing costs -506 0 0 0 3 5 0 0 0 0 -498
Profit before taxes 4,905 1,360 353 939 21 33 0 0 0 0 7,611
Income taxes -110 -269 -22 -19 -4 -7 0 0 37 0 -394
Net income 4,795 1,091 331 920 17 26 0 0 37 0 7,217
Attributable to
Roche shareholders 4,361 1,111 330 921 17 26 0 0 37 0 6,803
Non-controlling interests 434 -20 1 -1 0 0 0 0 0 0 414
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Year 2023
Year 2023
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 58,716 0 0 0 0 0 0 0 0 0 58,716

Other revenue 1,725 0 0 0 0 0 0 0 0 0 1,725
Cost of sales -16,357 548 375 183 0 0 0 0 0 0 -15,251
Selling, general and administration -14,881 1,335 28 0 0 0 0 0 0 0 -13,518
Other operating income and expense 392 -75 0 591 19 -122 0 0 0 0 805
Operating profit 15,395 2,038 711 1,199 19 -122 0 0 0 0 19,240

Financing costs -996 0 0 0 6 10 0 0 0 0 -980
Profit before taxes 14,079 2,038 711 1,199 25 -112 0 0 0 0 17,940
Income taxes -1,721 -403 -44 -71 -4 39 0 0 68 0 -2,136
Net income 12,358 1,635 667 1,128 21 -73 0 0 68 0 15,804
Attributable to
Roche shareholders 11,498 1,626 664 1,123 21 -73 0 0 68 0 14,927
Roche Online Financial Information System Group CHF Recon 04/03/2024 30/43
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2022
H1 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Pharmaceuticals Division reconciliation (CHFm)
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 22,347 0 0 0 0 0 0 0 0 0 22,347
Other revenue 1,580 0 0 0 0 0 0 0 0 0 1,580
Cost of sales -4,851 49 214 336 0 0 0 0 0 0 -4,252
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2022
H2 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
Issues
Sales 3rd 23,204 0 0 0 0 0 0 0 0 0 23,204
Other revenue 885 0 0 0 0 0 0 0 0 0 885
Cost of sales -6,189 202 198 1,136 0 0 0 0 0 0 -4,653
Other operating income and expense 382 -4 0 0 -10 -2 0 0 0 0 366
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Year 2022
Year 2022
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 45,551 0 0 0 0 0 0 0 0 0 45,551
Other revenue 2,465 0 0 0 0 0 0 0 0 0 2,465
Cost of sales -11,040 251 412 1,472 0 0 0 0 0 0 -8,905
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2023
H1 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Pharmaceuticals Division reconciliation (CHFm)

Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 22,681 0 0 0 0 0 0 0 0 0 22,681
Other revenue 806 0 0 0 0 0 0 0 0 0 806
Cost of sales -4,457 228 122 0 0 0 0 0 0 0 -4,107
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2023
H2 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 21,931 0 0 0 0 0 0 0 0 0 21,931

Other revenue 861 0 0 0 0 0 0 0 0 0 861
Cost of sales -4,626 88 119 183 0 0 0 0 0 0 -4,236
Other operating income and expense -475 -82 0 591 18 7 0 0 0 0 59
Operating profit 7,047 706 273 920 18 7 0 0 0 0 8,971
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Year 2023
Year 2023
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 44,612 0 0 0 0 0 0 0 0 0 44,612

Other revenue 1,667 0 0 0 0 0 0 0 0 0 1,667
Cost of sales -9,083 316 241 183 0 0 0 0 0 0 -8,343
Other operating income and expense 233 -80 0 591 14 0 0 0 0 0 758
Operating profit 17,132 1,112 551 1,180 14 0 0 0 0 0 19,989
Roche Online Financial Information System Pharma Div CHF Recon 04/03/2024 31/43
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2022
H1 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Diagnostics Division reconciliation (CHFm)
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 9,948 0 0 0 0 0 0 0 0 0 9,948
Other revenue 25 0 0 0 0 0 0 0 0 0 25
Cost of sales -4,817 11 72 0 0 0 0 0 0 0 -4,734
Research and development -849 2 4 0 0 0 0 0 0 0 -843
Other operating income and expense 41 1 0 0 -21 1 0 0 0 0 22
Operating profit 2,859 28 86 0 -21 1 0 0 0 0 2,953
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2022
H2 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
Issues
Sales 3rd 7,782 0 0 0 0 0 0 0 0 0 7,782
Other revenue 43 0 0 0 0 0 0 0 0 0 43
Cost of sales -3,880 33 71 0 0 0 0 0 0 0 -3,776
Research and development -992 -4 4 0 0 0 0 0 0 0 -992
Other operating income and expense 18 -1 0 0 7 -3 0 0 0 0 21
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Year 2022
Year 2022
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 17,730 0 0 0 0 0 0 0 0 0 17,730
Other revenue 68 0 0 0 0 0 0 0 0 0 68
Cost of sales -8,697 44 143 0 0 0 0 0 0 0 -8,510
Research and development -1,841 -2 8 0 0 0 0 0 0 0 -1,835
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2023
H1 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Diagnostics Division reconciliation (CHFm)

Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 7,098 0 0 0 0 0 0 0 0 0 7,098
Other revenue 31 0 0 0 0 0 0 0 0 0 31
Cost of sales -3,474 59 66 0 0 0 0 0 0 0 -3,349
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2023
H2 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 7,006 0 0 0 0 0 0 0 0 0 7,006

Other revenue 27 0 0 0 0 0 0 0 0 0 27
Cost of sales -3,800 173 68 0 0 0 0 0 0 0 -3,559
Other operating income and expense 27 1 0 0 0 19 0 0 0 0 47
Operating profit 604 327 80 19 0 19 0 0 0 0 1,049
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Year 2023
Year 2023
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 14,104 0 0 0 0 0 0 0 0 0 14,104

Other revenue 58 0 0 0 0 0 0 0 0 0 58
Cost of sales -7,274 232 134 0 0 0 0 0 0 0 -6,908
Roche Online Financial Information System Dia Div CHF Recon 04/03/2024 32/43
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2022
H1 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Corporate reconciliation (CHFm)
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 0 0 0 0 0 0 0 0 0 0 0
Other revenue 0 0 0 0 0 0 0 0 0 0 0
Cost of sales 0 0 0 0 0 0 0 0 0 0 0
Research and development 0 0 0 0 0 0 0 0 0 0 0
Other operating income and expense 0 1 0 0 0 -6 0 0 0 0 -5
Operating profit -1,643 75 0 0 0 -6 0 0 0 0 -1,574
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2022
H2 2022
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
Issues
Sales 3rd 0 0 0 0 0 0 0 0 0 0 0
Other revenue 0 0 0 0 0 0 0 0 0 0 0
Cost of sales 0 0 0 0 0 0 0 0 0 0 0
Other operating income and expense -6 -2 0 0 0 2 0 0 0 0 -6
Operating profit -1,796 29 0 0 0 2 0 0 0 0 -1,765
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Year 2022
Year 2022
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 0 0 0 0 0 0 0 0 0 0 0
Other revenue 0 0 0 0 0 0 0 0 0 0 0
Cost of sales 0 0 0 0 0 0 0 0 0 0 0
Other operating income and expense -6 -1 0 0 0 -4 0 0 0 0 -11
Operating profit -3,439 104 0 0 0 -4 0 0 0 0 -3,339
of ECP tax benefit

Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H1 2023
H1 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Corporate reconciliation (CHFm)

Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 0 0 0 0 0 0 0 0 0 0 0
Other revenue 0 0 0 0 0 0 0 0 0 0 0
Cost of sales 0 0 0 0 0 0 0 0 0 0 0
Other operating income and expense -7 0 0 0 0 0 0 0 0 0 -7
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Environmental
Normalisation
H2 2023
H2 2023
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 0 0 0 0 0 0 0 0 0 0 0
Other revenue 0 0 0 0 0 0 0 0 0 0 0
Cost of sales 0 0 0 0 0 0 0 0 0 0 0
of ECP tax benefit
Intangible assets -
Intangible assets -
acquisitions and
Year 2023
Year 2023
Environmental
Normalisation
pension plans
CORE
Settlement of
restructuring
restructuring
IFRS
Mergers and
amortisation
transactions
impairment
Major debt
Legal &
alliance
Global
Global
issues
Sales 3rd 0 0 0 0 0 0 0 0 0 0 0
Other revenue 0 0 0 0 0 0 0 0 0 0 0
Cost of sales 0 0 0 0 0 0 0 0 0 0 0
Roche Online Financial Information System Corporate CHF Recon 04/03/2024 33/43
AVERAGE EXCHANGE RATES (INCOME STATEMENT)
Average Average Average Average Average Average Average Average

Jan - Mar 22 Jan - Jun 22 Jan - Sep 22 Jan - Dec 22 Jan - Mar 23 Jan - Jun 23 Jan - Sep 23 Jan - Dec 23
Country Code Units (in CHF for constant currency)

United States USD 100 92.35600 94.40500 95.14800 95.48100 92.52500 91.20800 90.25900 89.87900
EU EUR 100 103.69700 103.22500 101.16500 100.42900 99.26500 98.58100 97.77100 97.18900
Albania ALL 100 0.85064 0.85219 0.84500 0.84486 0.85978 0.87314 0.88546 0.89291
Algeria DZD 100 0.65544 0.66040 0.66492 0.67181 0.67847 0.67008 0.66299 0.66096
Argentina ARS 100 0.86764 0.84220 0.79387 0.73243 0.48197 0.43099 0.36834 0.30609
Armenia AMD 100 0.18975 0.20122 0.21194 0.21890 0.23557 0.23393 0.23214 0.22895
Australia AUD 100 66.81402 67.89467 67.25573 66.21007 63.28235 61.65607 60.35834 59.69079
Azerbaijan AZN 100 54.35322 55.55344 55.99483 56.18316 54.41168 53.64204 53.08037 52.85997
Barbados BBD 100 45.76841 46.77826 47.14291 47.30850 45.82497 45.17276 44.68946 44.51240
Bahrain BHD 100 244.98065 250.41030 252.38258 253.26089 245.42609 241.93339 239.42964 238.44005
Bangladesh BDT 100 1.07392 1.08123 1.05384 1.02161 0.87486 0.85667 0.84051 0.83149
Belarus BYN 1,000,000 32.97400 30.67572 32.72345 33.94752 36.66962 36.15277 35.77755 33.09560
Bolivia BOB 100 13.41617 13.71927 13.81226 13.84085 13.35306 13.16316 13.02304 12.96909
Bosnia BAM 100 52.88793 52.64521 51.59481 51.21700 50.62589 50.28349 49.86632 49.56983
Brazil BRL 100 17.61576 18.59615 18.53439 18.48330 17.81081 17.97741 18.01777 17.98982
Bulgaria BGN 100 53.01956 52.77786 51.72292 51.34441 50.75050 50.40786 49.99179 49.69129
Canada CAD 100 72.90143 74.25298 74.18614 73.36807 68.44261 67.68242 67.08699 66.60550
Central African CFA franc XAF 100 0.15610 0.15538 0.15233 0.15112 0.14880 0.14802 0.14681 0.14594
Chile CLP 100 0.11411 0.11431 0.11070 0.10930 0.11406 0.11313 0.10986 0.10698
China CNY 100 14.53543 14.55689 14.40060 14.17500 13.51354 13.15767 12.82212 12.68013
Colombia COP 1,000,000 235.82844 241.13653 233.70652 224.29427 194.42479 198.56287 204.62315 207.80778
Congo, Democratic Republic CDF 100 0.04616 0.04720 0.04739 0.04729 0.04464 0.04234 0.03990 0.03841
Costa Rica CRC 100 0.14376 0.14380 0.14475 0.14804 0.16468 0.16586 0.16527 0.16585
Croatia HRK 100 13.74865 13.68802 13.43012 13.32989 - - - -
Czech Republic CZK 100 4.20900 4.18970 4.11004 4.08975 4.17393 4.16413 4.10407 4.05044
Denmark DKK 100 13.93641 13.87440 13.59783 13.49955 13.33736 13.23916 13.12630 13.04397
Dominican Republic DOP 100 1.63705 1.69475 1.72680 1.73788 1.65413 1.64763 1.61985 1.60396
Egypt EGP 100 5.76334 5.46604 5.31783 4.97957 3.09075 2.99901 2.95194 2.93174
El Salvador SVC 100 10.54990 10.78386 10.86868 10.90667 10.56899 10.41846 10.30985 10.26661
Georgia GEL 100 29.83810 31.07545 32.11896 32.90317 35.30098 35.25051 34.74851 34.29324
Ghana GHS 100 13.91789 13.16989 12.12991 10.61123 7.65322 7.77120 7.76634 7.68486
Guatemala GTQ 100 11.99027 12.26704 12.32916 12.32017 11.82096 11.66332 11.52298 11.47459
Honduras HNL 100 3.75536 3.84248 3.87011 3.87912 3.75232 3.70348 3.66448 3.64692
Hong Kong HKD 100 11.83427 12.06441 12.14746 12.19374 11.80499 11.63547 11.52147 11.48030
Hungary HUF 100 0.28480 0.27529 0.26290 0.25652 0.25573 0.25909 0.25629 0.25464
Iceland ISK 100 0.72081 0.73042 0.71846 0.70619 0.65155 0.65252 0.65589 0.65160
India INR 100 1.22849 1.23942 1.22993 1.21553 1.12530 1.10978 1.09608 1.08852
Indonesia IDR 1,000,000 64.38011 65.35121 65.13104 64.30867 60.71442 60.57728 59.73784 58.98475
Iran IRR 1,000,000 3.83162 3.87681 3.79969 3.71788 3.05845 2.68678 2.57791 2.52053
Iraq IQD 100 0.06328 0.06468 0.06519 0.06542 0.06396 0.06610 0.06653 0.06683
Israel ILS 100 28.91345 28.89278 28.72358 28.44436 26.19418 25.40615 24.79113 24.38957
Jamaica JMD 100 0.59585 0.61119 0.61981 0.62231 0.60440 0.59448 0.58636 0.58264
Japan JPY 100 0.79503 0.76832 0.74329 0.72665 0.69908 0.67669 0.65391 0.63976
Jordan JOD 100 130.25913 133.14586 134.19659 134.66121 130.43544 128.57449 127.24972 126.71176
Kazakhstan KZT 100 0.20193 0.20965 0.20742 0.20710 0.20319 0.20169 0.19913 0.19688
Kenya KES 100 0.81162 0.82054 0.81673 0.81008 0.73237 0.69251 0.66450 0.64270
Kuwait KWD 100 304.88683 310.02421 311.31335 311.70528 302.22006 297.54793 294.02717 292.40792
Lebanon LBP 1,000,000 610.77374 624.24413 629.15831 631.38437 89.95387 72.08989 33.35292 21.56857
Libya LYD 100 20.03035 20.13669 19.98401 19.87450 19.29295 19.03444 18.80747 18.67835
Macedonia MKD 100 1.68221 1.67502 1.64164 1.62940 1.61006 1.59960 1.58701 1.57759
Malaysia MYR 100 22.03267 22.11164 21.92489 21.70689 21.09191 20.47889 20.00515 19.71576
Mauritius MUR 100 2.10375 2.15629 2.15206 2.15974 2.03650 2.00788 1.98753 1.99183
Mexico MXN 100 4.50302 4.65757 4.69651 4.74661 4.95487 5.01539 5.06707 5.06400
Moldova MDL 100 5.12283 5.12910 5.08884 5.06602 4.92228 4.96978 4.96350 4.96512
Morocco MAD 100 9.75710 9.73185 9.55824 9.40158 8.98820 8.94161 8.91604 8.86882
Myanmar MMK 100 0.05195 0.05211 0.05080 0.04948 0.04406 0.04344 0.04298 0.04280
New Zealand NZD 100 62.42715 62.60197 61.43261 60.53231 58.28215 56.93220 55.73980 55.17888
Nicaragua NIO 100 2.59683 2.64407 2.65979 2.66171 2.53117 2.49444 2.46693 2.45630
Nigeria NGN 100 0.22173 0.22636 0.22604 0.22373 0.20059 0.18779 0.15528 0.13910
Norway NOK 100 10.43688 10.34142 10.10703 9.93435 9.04764 8.71730 8.61897 8.51090
Oman OMR 100 239.88840 245.20890 247.13919 248.00306 240.33240 236.91792 234.44451 233.45962
Pakistan PKR 100 0.52026 0.50766 0.47953 0.46665 0.35623 0.33439 0.32358 0.32091
Paraguay PYG 1,000,000 132.44666 136.52785 137.68444 136.76155 126.98811 125.84200 124.38205 123.30260
Peru PEN 100 24.23134 24.98451 24.93463 24.89058 24.24210 24.26240 24.18632 24.00356
Philippines PHP 100 1.79296 1.81253 1.77761 1.75282 1.68669 1.65129 1.62688 1.61570
Poland PLN 100 22.46038 22.27859 21.65838 21.43245 21.07775 21.29732 21.31855 21.38916
Qatar QAR 100 25.24548 25.82666 25.99878 26.09948 25.33028 24.98399 24.73636 24.63722
Romania RON 100 20.96689 20.87515 20.50766 20.37268 20.18357 19.98502 19.79871 19.64993
Russian Federation RUB 100 1.04704 1.20930 1.32081 1.36879 1.26499 1.18264 1.08990 1.05306
Saudi Arabia SAR 100 24.61426 25.16371 25.34953 25.42879 24.64507 24.30633 24.05631 23.95689
Serbia RSD 100 0.88175 0.87792 0.86099 0.85509 0.84609 0.84049 0.83379 0.82891
Singapore SGD 100 68.31117 69.18322 69.17466 69.25194 69.43188 68.28077 67.33900 66.93199
South Africa ZAR 100 6.05898 6.13013 5.96892 5.83473 5.21525 5.01290 4.91997 4.87294
South Korea KRW 1,000,000 766.79156 766.25845 750.52357 739.51599 725.68964 704.18225 693.60892 688.07367
Sri Lanka LKR 100 0.42093 0.33293 0.30765 0.29514 0.26129 0.27412 0.27449 0.27382
Sweden SEK 100 9.89220 9.84968 9.60669 9.44170 8.86020 8.69919 8.51960 8.47048
Switzerland CHF 100 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000
Taiwan TWD 100 3.30108 3.28984 3.25212 3.20583 3.04306 2.98491 2.91798 2.88453
Tajikistan TJS 100 7.91815 8.00298 8.43919 8.68296 8.77186 8.49699 8.34742 8.28618
Thailand THB 100 2.79457 2.80176 2.75064 2.72421 2.72573 2.66759 2.61567 2.58324
Trinidad and Tobago TTD 100 13.60308 13.90448 14.01444 14.06588 13.63173 13.44080 13.29960 13.24328
Tunisia TND 100 31.83313 31.78957 31.28576 30.95404 29.81339 29.51756 29.18095 28.96049
Turkey TRY 100 6.64245 6.37037 6.00403 5.77358 4.90387 4.59118 4.07093 3.78346
United Arab Emirates AED 100 25.14426 25.70205 25.90438 25.99495 25.19093 24.83383 24.57469 24.47133
United Kingdom GBP 100 123.96600 122.58600 119.43800 117.75100 112.40300 112.44700 112.26100 111.72700
Ukraine UAH 100 3.21570 3.23583 3.05698 2.93213 2.51074 2.47333 2.44723 2.44129
Uruguay UYP 100 2.12972 2.24880 2.28763 2.31777 2.35957 2.34345 2.33849 2.31440
Venezuela VES 100 20.71399 20.31709 17.89024 14.26820 4.10009 3.77952 3.40933 3.13526
Vietnam VND 1,000,000 40.56484 41.19224 41.18822 40.79856 39.25140 38.76657 38.15004 37.70691
West African CFA franc XOF 100 0.15796 0.15739 0.15428 0.15290 0.15134 0.14988 0.14848 0.14769
Roche Online Financial Information System Average Exchange Rates 04/03/2024 34/43
Average Average Average Average Average Average Average Average Average Average Average
Jan - Jun 22 Jan - Sep 22 Jan - Dec 22 Jan - Mar 23 Jan - Jun 23 Jan - Sep 23 Jan - Dec 23 Jan - Mar 23 Jan - Jun 23 Jan - Sep 23 Jan - Dec 23
vs. vs. vs. vs. vs. vs. vs. vs. vs. vs. vs.
Jan - Mar 22 Jan - Jun 22 Jan - Sep 22 Jan - Dec 22 Jan - Mar 23 Jan - Jun 23 Jan - Sep 23 Jan - Mar 22 Jan - Jun 22 Jan - Sep 22 Jan - Dec 22
Country Code Units
United States USD 100 2.2% 0.8% 0.3% -3.1% -1.4% -1.0% -0.4% 0.2% -3.4% -5.1% -5.9%
EU EUR 100 -0.5% -2.0% -0.7% -1.2% -0.7% -0.8% -0.6% -4.3% -4.5% -3.4% -3.2%
Albania ALL 100 0.2% -0.8% 0.0% 1.8% 1.6% 1.4% 0.8% 1.1% 2.5% 4.8% 5.7%
Algeria DZD 100 0.8% 0.7% 1.0% 1.0% -1.2% -1.1% -0.3% 3.5% 1.5% -0.3% -1.6%
Argentina ARS 100 -2.9% -5.7% -7.7% -34.2% -10.6% -14.5% -16.9% -44.5% -48.8% -53.6% -58.2%
Armenia AMD 100 6.0% 5.3% 3.3% 7.6% -0.7% -0.8% -1.4% 24.1% 16.3% 9.5% 4.6%
Australia AUD 100 1.6% -0.9% -1.6% -4.4% -2.6% -2.1% -1.1% -5.3% -9.2% -10.3% -9.8%
Azerbaijan AZN 100 2.2% 0.8% 0.3% -3.2% -1.4% -1.0% -0.4% 0.1% -3.4% -5.2% -5.9%
Barbados BBD 100 2.2% 0.8% 0.4% -3.1% -1.4% -1.1% -0.4% 0.1% -3.4% -5.2% -5.9%
Bahrain BHD 100 2.2% 0.8% 0.3% -3.1% -1.4% -1.0% -0.4% 0.2% -3.4% -5.1% -5.9%
Bangladesh BDT 100 0.7% -2.5% -3.1% -14.4% -2.1% -1.9% -1.1% -18.5% -20.8% -20.2% -18.6%
Belarus BYN 1,000,000 -7.0% 6.7% 3.7% 8.0% -1.4% -1.0% -7.5% 11.2% 17.9% 9.3% -2.5%
Bolivia BOB 100 2.3% 0.7% 0.2% -3.5% -1.4% -1.1% -0.4% -0.5% -4.1% -5.7% -6.3%
Bosnia BAM 100 -0.5% -2.0% -0.7% -1.2% -0.7% -0.8% -0.6% -4.3% -4.5% -3.4% -3.2%
Brazil BRL 100 5.6% -0.3% -0.3% -3.6% 0.9% 0.2% -0.2% 1.1% -3.3% -2.8% -2.7%
Bulgaria BGN 100 -0.5% -2.0% -0.7% -1.2% -0.7% -0.8% -0.6% -4.3% -4.5% -3.3% -3.2%
Canada CAD 100 1.9% -0.1% -1.1% -6.7% -1.1% -0.9% -0.7% -6.1% -8.8% -9.6% -9.2%
Central African CFA franc XAF 100 -0.5% -2.0% -0.8% -1.5% -0.5% -0.8% -0.6% -4.7% -4.7% -3.6% -3.4%
Chile CLP 100 0.2% -3.2% -1.3% 4.4% -0.8% -2.9% -2.6% 0.0% -1.0% -0.8% -2.1%
China CNY 100 0.1% -1.1% -1.6% -4.7% -2.6% -2.6% -1.1% -7.0% -9.6% -11.0% -10.5%
Colombia COP 1,000,000 2.3% -3.1% -4.0% -13.3% 2.1% 3.1% 1.6% -17.6% -17.7% -12.4% -7.4%
Congo, Democratic Republic CDF 100 2.3% 0.4% -0.2% -5.6% -5.2% -5.8% -3.7% -3.3% -10.3% -15.8% -18.8%
Costa Rica CRC 100 0.0% 0.7% 2.3% 11.2% 0.7% -0.4% 0.4% 14.6% 15.3% 14.2% 12.0%
Croatia HRK 100 -0.4% -1.9% -0.7% - - - - - - - -
Czech Republic CZK 100 -0.5% -1.9% -0.5% 2.1% -0.2% -1.4% -1.3% -0.8% -0.6% -0.1% -1.0%
Denmark DKK 100 -0.4% -2.0% -0.7% -1.2% -0.7% -0.9% -0.6% -4.3% -4.6% -3.5% -3.4%
Dominican Republic DOP 100 3.5% 1.9% 0.6% -4.8% -0.4% -1.7% -1.0% 1.0% -2.8% -6.2% -7.7%
Egypt EGP 100 -5.2% -2.7% -6.4% -37.9% -3.0% -1.6% -0.7% -46.4% -45.1% -44.5% -41.1%
El Salvador SVC 100 2.2% 0.8% 0.3% -3.1% -1.4% -1.0% -0.4% 0.2% -3.4% -5.1% -5.9%
Georgia GEL 100 4.1% 3.4% 2.4% 7.3% -0.1% -1.4% -1.3% 18.3% 13.4% 8.2% 4.2%
Ghana GHS 100 -5.4% -7.9% -12.5% -27.9% 1.5% -0.1% -1.0% -45.0% -41.0% -36.0% -27.6%
Guatemala GTQ 100 2.3% 0.5% -0.1% -4.1% -1.3% -1.2% -0.4% -1.4% -4.9% -6.5% -6.9%
Honduras HNL 100 2.3% 0.7% 0.2% -3.3% -1.3% -1.1% -0.5% -0.1% -3.6% -5.3% -6.0%
Hong Kong HKD 100 1.9% 0.7% 0.4% -3.2% -1.4% -1.0% -0.4% -0.2% -3.6% -5.2% -5.9%
Hungary HUF 100 -3.3% -4.5% -2.4% -0.3% 1.3% -1.1% -0.6% -10.2% -5.9% -2.5% -0.7%
Iceland ISK 100 1.3% -1.6% -1.7% -7.7% 0.1% 0.5% -0.7% -9.6% -10.7% -8.7% -7.7%
India INR 100 0.9% -0.8% -1.2% -7.4% -1.4% -1.2% -0.7% -8.4% -10.5% -10.9% -10.4%
Indonesia IDR 1,000,000 1.5% -0.3% -1.3% -5.6% -0.2% -1.4% -1.3% -5.7% -7.3% -8.3% -8.3%
Iran IRR 1,000,000 1.2% -2.0% -2.2% -17.7% -12.2% -4.1% -2.2% -20.2% -30.7% -32.2% -32.2%
Iraq IQD 100 2.2% 0.8% 0.4% -2.2% 3.3% 0.7% 0.5% 1.1% 2.2% 2.1% 2.2%
Israel ILS 100 -0.1% -0.6% -1.0% -7.9% -3.0% -2.4% -1.6% -9.4% -12.1% -13.7% -14.3%
Jamaica JMD 100 2.6% 1.4% 0.4% -2.9% -1.6% -1.4% -0.6% 1.4% -2.7% -5.4% -6.4%
Japan JPY 100 -3.4% -3.3% -2.2% -3.8% -3.2% -3.4% -2.2% -12.1% -11.9% -12.0% -12.0%
Jordan JOD 100 2.2% 0.8% 0.3% -3.1% -1.4% -1.0% -0.4% 0.1% -3.4% -5.2% -5.9%
Kazakhstan KZT 100 3.8% -1.1% -0.2% -1.9% -0.7% -1.3% -1.1% 0.6% -3.8% -4.0% -4.9%
Kenya KES 100 1.1% -0.5% -0.8% -9.6% -5.4% -4.0% -3.3% -9.8% -15.6% -18.6% -20.7%
Kuwait KWD 100 1.7% 0.4% 0.1% -3.0% -1.5% -1.2% -0.6% -0.9% -4.0% -5.6% -6.2%
Lebanon LBP 1,000,000 2.2% 0.8% 0.4% -85.8% -19.9% -53.7% -35.3% -85.3% -88.5% -94.7% -96.6%
Libya LYD 100 0.5% -0.8% -0.5% -2.9% -1.3% -1.2% -0.7% -3.7% -5.5% -5.9% -6.0%
Macedonia MKD 100 -0.4% -2.0% -0.7% -1.2% -0.6% -0.8% -0.6% -4.3% -4.5% -3.3% -3.2%
Malaysia MYR 100 0.4% -0.8% -1.0% -2.8% -2.9% -2.3% -1.4% -4.3% -7.4% -8.8% -9.2%
Mauritius MUR 100 2.5% -0.2% 0.4% -5.7% -1.4% -1.0% 0.2% -3.2% -6.9% -7.6% -7.8%
Mexico MXN 100 3.4% 0.8% 1.1% 4.4% 1.2% 1.0% -0.1% 10.0% 7.7% 7.9% 6.7%
Moldova MDL 100 0.1% -0.8% -0.4% -2.8% 1.0% -0.1% 0.0% -3.9% -3.1% -2.5% -2.0%
Morocco MAD 100 -0.3% -1.8% -1.6% -4.4% -0.5% -0.3% -0.5% -7.9% -8.1% -6.7% -5.7%
Myanmar MMK 100 0.3% -2.5% -2.6% -11.0% -1.4% -1.1% -0.4% -15.2% -16.6% -15.4% -13.5%
New Zealand NZD 100 0.3% -1.9% -1.5% -3.7% -2.3% -2.1% -1.0% -6.6% -9.1% -9.3% -8.8%
Nicaragua NIO 100 1.8% 0.6% 0.1% -4.9% -1.5% -1.1% -0.4% -2.5% -5.7% -7.3% -7.7%
Nigeria NGN 100 2.1% -0.1% -1.0% -10.3% -6.4% -17.3% -10.4% -9.5% -17.0% -31.3% -37.8%
Norway NOK 100 -0.9% -2.3% -1.7% -8.9% -3.7% -1.1% -1.3% -13.3% -15.7% -14.7% -14.3%
Oman OMR 100 2.2% 0.8% 0.3% -3.1% -1.4% -1.0% -0.4% 0.2% -3.4% -5.1% -5.9%
Pakistan PKR 100 -2.4% -5.5% -2.7% -23.7% -6.1% -3.2% -0.8% -31.5% -34.1% -32.5% -31.2%
Paraguay PYG 1,000,000 3.1% 0.8% -0.7% -7.1% -0.9% -1.2% -0.9% -4.1% -7.8% -9.7% -9.8%
Peru PEN 100 3.1% -0.2% -0.2% -2.6% 0.1% -0.3% -0.8% 0.0% -2.9% -3.0% -3.6%
Philippines PHP 100 1.1% -1.9% -1.4% -3.8% -2.1% -1.5% -0.7% -5.9% -8.9% -8.5% -7.8%
Poland PLN 100 -0.8% -2.8% -1.0% -1.7% 1.0% 0.1% 0.3% -6.2% -4.4% -1.6% -0.2%
Qatar QAR 100 2.3% 0.7% 0.4% -2.9% -1.4% -1.0% -0.4% 0.3% -3.3% -4.9% -5.6%
Romania RON 100 -0.4% -1.8% -0.7% -0.9% -1.0% -0.9% -0.8% -3.7% -4.3% -3.5% -3.5%
Russian Federation RUB 100 15.5% 9.2% 3.6% -7.6% -6.5% -7.8% -3.4% 20.8% -2.2% -17.5% -23.1%
Saudi Arabia SAR 100 2.2% 0.7% 0.3% -3.1% -1.4% -1.0% -0.4% 0.1% -3.4% -5.1% -5.8%
Serbia RSD 100 -0.4% -1.9% -0.7% -1.1% -0.7% -0.8% -0.6% -4.0% -4.3% -3.2% -3.1%
Singapore SGD 100 1.3% 0.0% 0.1% 0.3% -1.7% -1.4% -0.6% 1.6% -1.3% -2.7% -3.4%
South Africa ZAR 100 1.2% -2.6% -2.2% -10.6% -3.9% -1.9% -1.0% -13.9% -18.2% -17.6% -16.5%
South Korea KRW 1,000,000 -0.1% -2.1% -1.5% -1.9% -3.0% -1.5% -0.8% -5.4% -8.1% -7.6% -7.0%
Sri Lanka LKR 100 -20.9% -7.6% -4.1% -11.5% 4.9% 0.1% -0.2% -37.9% -17.7% -10.8% -7.2%
Sweden SEK 100 -0.4% -2.5% -1.7% -6.2% -1.8% -2.1% -0.6% -10.4% -11.7% -11.3% -10.3%
Switzerland CHF 100 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Taiwan TWD 100 -0.3% -1.1% -1.4% -5.1% -1.9% -2.2% -1.1% -7.8% -9.3% -10.3% -10.0%
Tajikistan TJS 100 1.1% 5.5% 2.9% 1.0% -3.1% -1.8% -0.7% 10.8% 6.2% -1.1% -4.6%
Thailand THB 100 0.3% -1.8% -1.0% 0.1% -2.1% -1.9% -1.2% -2.5% -4.8% -4.9% -5.2%
Trinidad and Tobago TTD 100 2.2% 0.8% 0.4% -3.1% -1.4% -1.1% -0.4% 0.2% -3.3% -5.1% -5.8%
Tunisia TND 100 -0.1% -1.6% -1.1% -3.7% -1.0% -1.1% -0.8% -6.3% -7.1% -6.7% -6.4%
Turkey TRY 100 -4.1% -5.8% -3.8% -15.1% -6.4% -11.3% -7.1% -26.2% -27.9% -32.2% -34.5%
United Arab Emirates AED 100 2.2% 0.8% 0.3% -3.1% -1.4% -1.0% -0.4% 0.2% -3.4% -5.1% -5.9%
United Kingdom GBP 100 -1.1% -2.6% -1.4% -4.5% 0.0% -0.2% -0.5% -9.3% -8.3% -6.0% -5.1%
Ukraine UAH 100 0.6% -5.5% -4.1% -14.4% -1.5% -1.1% -0.2% -21.9% -23.6% -19.9% -16.7%
Uruguay UYP 100 5.6% 1.7% 1.3% 1.8% -0.7% -0.2% -1.0% 10.8% 4.2% 2.2% -0.1%
Venezuela VES 100 -1.9% -11.9% -20.2% -71.3% -7.8% -9.8% -8.0% -80.2% -81.4% -80.9% -78.0%
Vietnam VND 1,000,000 1.5% 0.0% -0.9% -3.8% -1.2% -1.6% -1.2% -3.2% -5.9% -7.4% -7.6%
West African CFA franc XOF 100 -0.4% -2.0% -0.9% -1.0% -1.0% -0.9% -0.5% -4.2% -4.8% -3.8% -3.4%
AVERAGE QUARTERLY EXCHANGE RATES
Average Average Average Average Average Average Average Average

Jan - Mar 22 Apr - Jun 22 Jul - Sep 22 Oct - Dec 22 Jan - Mar 23 Apr - Jun 23 Jul - Sep 23 Oct - Dec 23

United States USD 100 92.35600 96.45400 96.63400 96.48000 92.52500 89.89100 88.36100 88.73900
EU EUR 100 103.69700 102.75300 97.04500 98.22100 99.26500 97.89700 96.15100 95.44300
Albania ALL 100 0.85064 0.85374 0.83062 0.84444 0.85978 0.88650 0.91010 0.91526
Algeria DZD 100 0.65544 0.66536 0.67396 0.69248 0.67847 0.66169 0.64881 0.65487
Argentina ARS 100 0.86764 0.81676 0.69721 0.54811 0.48197 0.38001 0.24304 0.11934
Armenia AMD 100 0.18975 0.21269 0.23338 0.23978 0.23557 0.23229 0.22856 0.21938
Australia AUD 100 66.81402 68.97532 65.97785 63.07309 63.28235 60.02979 57.76288 57.68814
Azerbaijan AZN 100 54.35322 56.75366 56.87761 56.74815 54.41168 52.87240 51.95703 52.19877
Barbados BBD 100 45.76841 47.78811 47.87221 47.80527 45.82497 44.52055 43.72286 43.98122
Bahrain BHD 100 244.98065 255.83995 256.32714 255.89582 245.42609 238.44069 234.42214 235.47128
Bangladesh BDT 100 1.07392 1.08854 0.99906 0.92492 0.87486 0.83848 0.80819 0.80443
Belarus BYN 1,000,000 32.97400 28.37744 36.81891 37.61973 36.66962 35.63592 35.02711 25.04975
Bolivia BOB 100 13.41617 14.02237 13.99824 13.92662 13.35306 12.97326 12.74280 12.80724
Bosnia BAM 100 52.88793 52.40249 49.49401 50.08357 50.62589 49.94109 49.03198 48.68036
Brazil BRL 100 17.61576 19.57654 18.41087 18.33003 17.81081 18.14401 18.09849 17.90597
Bulgaria BGN 100 53.01956 52.53616 49.61304 50.20888 50.75050 50.06522 49.15965 48.78979
Canada CAD 100 72.90143 75.60453 74.05246 70.91386 68.44261 66.92223 65.89613 65.16103
Central African CFA franc XAF 100 0.15610 0.15466 0.14623 0.14749 0.14880 0.14724 0.14439 0.14333
Chile CLP 100 0.11411 0.11451 0.10348 0.10510 0.11406 0.11220 0.10332 0.09834
China CNY 100 14.53543 14.57835 14.08802 13.49820 13.51354 12.80180 12.15102 12.25416
Colombia COP 1,000,000 235.82844 246.44462 218.84650 196.05752 194.42479 202.70095 216.74371 217.36167
Congo, Democratic Republic CDF 100 0.04616 0.04824 0.04777 0.04699 0.04464 0.04004 0.03502 0.03394
Costa Rica CRC 100 0.14376 0.14384 0.14665 0.15791 0.16468 0.16704 0.16409 0.16759
Croatia HRK 100 13.74865 13.62739 12.91432 13.02920 - - - -
Czech Republic CZK 100 4.20900 4.17040 3.95072 4.02888 4.17393 4.15433 3.98395 3.88955
Denmark DKK 100 13.93641 13.81239 13.04469 13.20471 13.33736 13.14096 12.90058 12.79698
Dominican Republic DOP 100 1.63705 1.75245 1.79090 1.77112 1.65413 1.64113 1.56429 1.55629
Egypt EGP 100 5.76334 5.16874 5.02141 3.96479 3.09075 2.90727 2.85780 2.87114
El Salvador SVC 100 10.54990 11.01782 11.03832 11.02064 10.56899 10.26793 10.09263 10.13689
Georgia GEL 100 29.83810 32.31280 34.20598 35.25580 35.30098 35.20004 33.74451 32.92743
Ghana GHS 100 13.91789 12.42189 10.04995 6.05519 7.65322 7.88918 7.75662 7.44042
Guatemala GTQ 100 11.99027 12.54381 12.45340 12.29320 11.82096 11.50568 11.24230 11.32942
Honduras HNL 100 3.75536 3.92960 3.92537 3.90615 3.75232 3.65464 3.58648 3.59424
Hong Kong HKD 100 11.83427 12.29455 12.31356 12.33258 11.80499 11.46595 11.29347 11.35679
Hungary HUF 100 0.28480 0.26578 0.23812 0.23738 0.25573 0.26245 0.25069 0.24969
Iceland ISK 100 0.72081 0.74003 0.69454 0.66938 0.65155 0.65349 0.66263 0.63873
India INR 100 1.22849 1.25035 1.21095 1.17233 1.12530 1.09426 1.06868 1.06584
Indonesia IDR 1,000,000 64.38011 66.32231 64.69070 61.84156 60.71442 60.44014 58.05896 56.72548
Iran IRR 1,000,000 3.83162 3.92200 3.64545 3.47245 3.05845 2.31511 2.36017 2.34839
Iraq IQD 100 0.06328 0.06608 0.06621 0.06611 0.06396 0.06824 0.06739 0.06773
Israel ILS 100 28.91345 28.87211 28.38518 27.60670 26.19418 24.61812 23.56109 23.18489
Jamaica JMD 100 0.59585 0.62653 0.63705 0.62981 0.60440 0.58456 0.57012 0.57148
Japan JPY 100 0.79503 0.74161 0.69323 0.67673 0.69908 0.65430 0.60835 0.59731
Jordan JOD 100 130.25913 136.03259 136.29805 136.05507 130.43544 126.71354 124.60018 125.09788
Kazakhstan KZT 100 0.20193 0.21737 0.20296 0.20614 0.20319 0.20019 0.19401 0.19013
Kenya KES 100 0.81162 0.82946 0.80911 0.79013 0.73237 0.65265 0.60848 0.57730
Kuwait KWD 100 304.88683 315.16159 313.89163 312.88107 302.22006 292.87580 286.98565 287.55017
Lebanon LBP 1,000,000 610.77374 637.71452 638.98667 638.06255 89.95387 54.22591 - -
Libya LYD 100 20.03035 20.24303 19.67865 19.54597 19.29295 18.77593 18.35353 18.29099
Macedonia MKD 100 1.68221 1.66783 1.57488 1.59268 1.61006 1.58914 1.56183 1.54933
Malaysia MYR 100 22.03267 22.19061 21.55139 21.05289 21.09191 19.86587 19.05767 18.84759
Mauritius MUR 100 2.10375 2.20883 2.14360 2.18278 2.03650 1.97926 1.94683 2.00473
Mexico MXN 100 4.50302 4.81212 4.77439 4.89691 4.95487 5.07591 5.17043 5.05479
Moldova MDL 100 5.12283 5.13537 5.00832 4.99756 4.92228 5.01728 4.95094 4.96998
Morocco MAD 100 9.75710 9.70660 9.21102 8.93160 8.98820 8.89502 8.86490 8.72716
Myanmar MMK 100 0.05195 0.05227 0.04818 0.04552 0.04406 0.04282 0.04206 0.04226
New Zealand NZD 100 62.42715 62.77679 59.09389 57.83141 58.28215 55.58225 53.35500 53.49612
Nicaragua NIO 100 2.59683 2.69131 2.69123 2.66747 2.53117 2.45771 2.41191 2.42441
Nigeria NGN 100 0.22173 0.23099 0.22540 0.21680 0.20059 0.17499 0.09026 0.09056
Norway NOK 100 10.43688 10.24596 9.63825 9.41631 9.04764 8.38696 8.42231 8.18669
Oman OMR 100 239.88840 250.52940 250.99977 250.59467 240.33240 233.50344 229.49769 230.50495
Pakistan PKR 100 0.52026 0.49506 0.42327 0.42801 0.35623 0.31255 0.30196 0.31290
Paraguay PYG 1,000,000 132.44666 140.60904 139.99762 133.99288 126.98811 124.69589 121.46215 120.06425
Peru PEN 100 24.23134 25.73768 24.83487 24.75843 24.24210 24.28270 24.03416 23.45528
Philippines PHP 100 1.79296 1.83210 1.70777 1.67845 1.68669 1.61589 1.57806 1.58216
Poland PLN 100 22.46038 22.09680 20.41796 20.75466 21.07775 21.51689 21.36101 21.60099
Qatar QAR 100 25.24548 26.40784 26.34302 26.40158 25.33028 24.63770 24.24110 24.33980
Romania RON 100 20.96689 20.78341 19.77268 19.96774 20.18357 19.78647 19.42609 19.20359
Russian Federation RUB 100 1.04704 1.37156 1.54383 1.51273 1.26499 1.10029 0.90442 0.94254
Saudi Arabia SAR 100 24.61426 25.71316 25.72117 25.66657 24.64507 23.96759 23.55627 23.65863
Serbia RSD 100 0.88175 0.87409 0.82713 0.83739 0.84609 0.83489 0.82039 0.81427
Singapore SGD 100 68.31117 70.05527 69.15754 69.48378 69.43188 67.12966 65.45546 65.71096
South Africa ZAR 100 6.05898 6.20128 5.64650 5.43216 5.21525 4.81055 4.73411 4.73185
South Korea KRW 1,000,000 766.79156 765.72534 719.05381 706.49325 725.68964 682.67486 672.46226 671.46792
Sri Lanka LKR 100 0.42093 0.24493 0.25709 0.25761 0.26129 0.28695 0.27523 0.27181
Sweden SEK 100 9.89220 9.80716 9.12071 8.94673 8.86020 8.53818 8.16042 8.32312
Switzerland CHF 100 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000
Taiwan TWD 100 3.30108 3.27860 3.17668 3.06696 3.04306 2.92676 2.78412 2.78418
Tajikistan TJS 100 7.91815 8.08781 9.31161 9.41427 8.77186 8.22212 8.04828 8.10246
Thailand THB 100 2.79457 2.80895 2.64840 2.64492 2.72573 2.60945 2.51183 2.48595
Trinidad and Tobago TTD 100 13.60308 14.20588 14.23436 14.22020 13.63173 13.24987 13.01720 13.07432
Tunisia TND 100 31.83313 31.74601 30.27814 29.95888 29.81339 29.22173 28.50773 28.29911
Turkey TRY 100 6.64245 6.09829 5.27135 5.08223 4.90387 4.27849 3.03043 2.92105
United Arab Emirates AED 100 25.14426 26.25984 26.30904 26.26666 25.19093 24.47673 24.05641 24.16125
United Kingdom GBP 100 123.96600 121.20600 113.14200 112.69000 112.40300 112.49100 111.88900 110.12500
Ukraine UAH 100 3.21570 3.25596 2.69928 2.55758 2.51074 2.43592 2.39503 2.42347
Uruguay UYP 100 2.12972 2.36788 2.36529 2.40819 2.35957 2.32733 2.32857 2.24213
Venezuela VES 100 20.71399 19.92019 13.03654 3.40208 4.10009 3.45895 2.66895 2.31305
Vietnam VND 1,000,000 40.56484 41.81964 41.18018 39.62958 39.25140 38.28174 36.91698 36.37752
West African CFA franc XOF 100 0.15796 0.15682 0.14806 0.14876 0.15134 0.14842 0.14568 0.14532
Average Average Average Average Average Average Average Average Average Average Average
Apr - Jun 22 Jul - Sep 22 Oct - Dec 22 Jan - Mar 23 Apr - Jun 23 Jul - Sep 23 Oct - Dec 23 Jan - Mar 23 Apr - Jun 23 Jul - Sep 23 Oct - Dec 23
vs. vs. vs. vs. vs. vs. vs. vs. vs. vs. vs.
Jan - Mar 22 Apr - Jun 22 Jul - Sep 22 Oct - Dec 22 Jan - Mar 23 Apr - Jun 23 Jul - Sep 23 Jan - Mar 22 Apr - Jun 22 Jul - Sep 22 Oct - Dec 22
Country Code Units
United States USD 100 4.4% 0.2% -0.2% -4.1% -2.8% -1.7% 0.4% 0.2% -6.8% -8.6% -8.0%
EU EUR 100 -0.9% -5.6% 1.2% 1.1% -1.4% -1.8% -0.7% -4.3% -4.7% -0.9% -2.8%
Albania ALL 100 0.4% -2.7% 1.7% 1.8% 3.1% 2.7% 0.6% 1.1% 3.8% 9.6% 8.4%
Algeria DZD 100 1.5% 1.3% 2.7% -2.0% -2.5% -1.9% 0.9% 3.5% -0.6% -3.7% -5.4%
Argentina ARS 100 -5.9% -14.6% -21.4% -12.1% -21.2% -36.0% -50.9% -44.5% -53.5% -65.1% -78.2%
Armenia AMD 100 12.1% 9.7% 2.7% -1.8% -1.4% -1.6% -4.0% 24.1% 9.2% -2.1% -8.5%
Australia AUD 100 3.2% -4.3% -4.4% 0.3% -5.1% -3.8% -0.1% -5.3% -13.0% -12.5% -8.5%
Azerbaijan AZN 100 4.4% 0.2% -0.2% -4.1% -2.8% -1.7% 0.5% 0.1% -6.8% -8.7% -8.0%
Barbados BBD 100 4.4% 0.2% -0.1% -4.1% -2.8% -1.8% 0.6% 0.1% -6.8% -8.7% -8.0%
Bahrain BHD 100 4.4% 0.2% -0.2% -4.1% -2.8% -1.7% 0.4% 0.2% -6.8% -8.5% -8.0%
Bangladesh BDT 100 1.4% -8.2% -7.4% -5.4% -4.2% -3.6% -0.5% -18.5% -23.0% -19.1% -13.0%
Belarus BYN 1,000,000 -13.9% 29.7% 2.2% -2.5% -2.8% -1.7% -28.5% 11.2% 25.6% -4.9% -33.4%
Bolivia BOB 100 4.5% -0.2% -0.5% -4.1% -2.8% -1.8% 0.5% -0.5% -7.5% -9.0% -8.0%
Bosnia BAM 100 -0.9% -5.6% 1.2% 1.1% -1.4% -1.8% -0.7% -4.3% -4.7% -0.9% -2.8%
Brazil BRL 100 11.1% -6.0% -0.4% -2.8% 1.9% -0.3% -1.1% 1.1% -7.3% -1.7% -2.3%
Bulgaria BGN 100 -0.9% -5.6% 1.2% 1.1% -1.4% -1.8% -0.8% -4.3% -4.7% -0.9% -2.8%
Canada CAD 100 3.7% -2.1% -4.2% -3.5% -2.2% -1.5% -1.1% -6.1% -11.5% -11.0% -8.1%
Central African CFA franc XAF 100 -0.9% -5.5% 0.9% 0.9% -1.0% -1.9% -0.7% -4.7% -4.8% -1.3% -2.8%
Chile CLP 100 0.4% -9.6% 1.6% 8.5% -1.6% -7.9% -4.8% 0.0% -2.0% -0.2% -6.4%
China CNY 100 0.3% -3.4% -4.2% 0.1% -5.3% -5.1% 0.8% -7.0% -12.2% -13.7% -9.2%
Colombia COP 1,000,000 4.5% -11.2% -10.4% -0.8% 4.3% 6.9% 0.3% -17.6% -17.7% -1.0% 10.9%
Congo, Democratic Republic CDF 100 4.5% -1.0% -1.6% -5.0% -10.3% -12.5% -3.1% -3.3% -17.0% -26.7% -27.8%
Costa Rica CRC 100 0.1% 2.0% 7.7% 4.3% 1.4% -1.8% 2.1% 14.6% 16.1% 11.9% 6.1%
Croatia HRK 100 -0.9% -5.2% 0.9% - - - - - - - -
Czech Republic CZK 100 -0.9% -5.3% 2.0% 3.6% -0.5% -4.1% -2.4% -0.8% -0.4% 0.8% -3.5%
Denmark DKK 100 -0.9% -5.6% 1.2% 1.0% -1.5% -1.8% -0.8% -4.3% -4.9% -1.1% -3.1%
Dominican Republic DOP 100 7.0% 2.2% -1.1% -6.6% -0.8% -4.7% -0.5% 1.0% -6.4% -12.7% -12.1%
Egypt EGP 100 -10.3% -2.9% -21.0% -22.0% -5.9% -1.7% 0.5% -46.4% -43.8% -43.1% -27.6%
El Salvador SVC 100 4.4% 0.2% -0.2% -4.1% -2.8% -1.7% 0.4% 0.2% -6.8% -8.6% -8.0%
Georgia GEL 100 8.3% 5.9% 3.1% 0.1% -0.3% -4.1% -2.4% 18.3% 8.9% -1.3% -6.6%
Ghana GHS 100 -10.7% -19.1% -39.7% 26.4% 3.1% -1.7% -4.1% -45.0% -36.5% -22.8% 22.9%
Guatemala GTQ 100 4.6% -0.7% -1.3% -3.8% -2.7% -2.3% 0.8% -1.4% -8.3% -9.7% -7.8%
Honduras HNL 100 4.6% -0.1% -0.5% -3.9% -2.6% -1.9% 0.2% -0.1% -7.0% -8.6% -8.0%
Hong Kong HKD 100 3.9% 0.2% 0.2% -4.3% -2.9% -1.5% 0.6% -0.2% -6.7% -8.3% -7.9%
Hungary HUF 100 -6.7% -10.4% -0.3% 7.7% 2.6% -4.5% -0.4% -10.2% -1.3% 5.3% 5.2%
Iceland ISK 100 2.7% -6.1% -3.6% -2.7% 0.3% 1.4% -3.6% -9.6% -11.7% -4.6% -4.6%
India INR 100 1.8% -3.2% -3.2% -4.0% -2.8% -2.3% -0.3% -8.4% -12.5% -11.7% -9.1%
Indonesia IDR 1,000,000 3.0% -2.5% -4.4% -1.8% -0.5% -3.9% -2.3% -5.7% -8.9% -10.3% -8.3%
Iran IRR 1,000,000 2.4% -7.1% -4.7% -11.9% -24.3% 1.9% -0.5% -20.2% -41.0% -35.3% -32.4%
Iraq IQD 100 4.4% 0.2% -0.2% -3.3% 6.7% -1.2% 0.5% 1.1% 3.3% 1.8% 2.5%
Israel ILS 100 -0.1% -1.7% -2.7% -5.1% -6.0% -4.3% -1.6% -9.4% -14.7% -17.0% -16.0%
Jamaica JMD 100 5.1% 1.7% -1.1% -4.0% -3.3% -2.5% 0.2% 1.4% -6.7% -10.5% -9.3%
Japan JPY 100 -6.7% -6.5% -2.4% 3.3% -6.4% -7.0% -1.8% -12.1% -11.8% -12.2% -11.7%
Jordan JOD 100 4.4% 0.2% -0.2% -4.1% -2.9% -1.7% 0.4% 0.1% -6.9% -8.6% -8.1%
Kazakhstan KZT 100 7.6% -6.6% 1.6% -1.4% -1.5% -3.1% -2.0% 0.6% -7.9% -4.4% -7.8%
Kenya KES 100 2.2% -2.5% -2.3% -7.3% -10.9% -6.8% -5.1% -9.8% -21.3% -24.8% -26.9%
Kuwait KWD 100 3.4% -0.4% -0.3% -3.4% -3.1% -2.0% 0.2% -0.9% -7.1% -8.6% -8.1%
Lebanon LBP 1,000,000 4.4% 0.2% -0.1% -85.9% -39.7% - - -85.3% -91.5% - -
Libya LYD 100 1.1% -2.8% -0.7% -1.3% -2.7% -2.2% -0.3% -3.7% -7.2% -6.7% -6.4%
Macedonia MKD 100 -0.9% -5.6% 1.1% 1.1% -1.3% -1.7% -0.8% -4.3% -4.7% -0.8% -2.7%
Malaysia MYR 100 0.7% -2.9% -2.3% 0.2% -5.8% -4.1% -1.1% -4.3% -10.5% -11.6% -10.5%
Mauritius MUR 100 5.0% -3.0% 1.8% -6.7% -2.8% -1.6% 3.0% -3.2% -10.4% -9.2% -8.2%
Mexico MXN 100 6.9% -0.8% 2.6% 1.2% 2.4% 1.9% -2.2% 10.0% 5.5% 8.3% 3.2%
Moldova MDL 100 0.2% -2.5% -0.2% -1.5% 1.9% -1.3% 0.4% -3.9% -2.3% -1.1% -0.6%
Morocco MAD 100 -0.5% -5.1% -3.0% 0.6% -1.0% -0.3% -1.6% -7.9% -8.4% -3.8% -2.3%
Myanmar MMK 100 0.6% -7.8% -5.5% -3.2% -2.8% -1.8% 0.5% -15.2% -18.1% -12.7% -7.2%
New Zealand NZD 100 0.6% -5.9% -2.1% 0.8% -4.6% -4.0% 0.3% -6.6% -11.5% -9.7% -7.5%
Nicaragua NIO 100 3.6% 0.0% -0.9% -5.1% -2.9% -1.9% 0.5% -2.5% -8.7% -10.4% -9.1%
Nigeria NGN 100 4.2% -2.4% -3.8% -7.5% -12.8% -48.4% 0.3% -9.5% -24.2% -60.0% -58.2%
Norway NOK 100 -1.8% -5.9% -2.3% -3.9% -7.3% 0.4% -2.8% -13.3% -18.1% -12.6% -13.1%
Oman OMR 100 4.4% 0.2% -0.2% -4.1% -2.8% -1.7% 0.4% 0.2% -6.8% -8.6% -8.0%
Pakistan PKR 100 -4.8% -14.5% 1.1% -16.8% -12.3% -3.4% 3.6% -31.5% -36.9% -28.7% -26.9%
Paraguay PYG 1,000,000 6.2% -0.4% -4.3% -5.2% -1.8% -2.6% -1.2% -4.1% -11.3% -13.2% -10.4%
Peru PEN 100 6.2% -3.5% -0.3% -2.1% 0.2% -1.0% -2.4% 0.0% -5.7% -3.2% -5.3%
Philippines PHP 100 2.2% -6.8% -1.7% 0.5% -4.2% -2.3% 0.3% -5.9% -11.8% -7.6% -5.7%
Poland PLN 100 -1.6% -7.6% 1.6% 1.6% 2.1% -0.7% 1.1% -6.2% -2.6% 4.6% 4.1%
Qatar QAR 100 4.6% -0.2% 0.2% -4.1% -2.7% -1.6% 0.4% 0.3% -6.7% -8.0% -7.8%
Romania RON 100 -0.9% -4.9% 1.0% 1.1% -2.0% -1.8% -1.1% -3.7% -4.8% -1.8% -3.8%
Russian Federation RUB 100 31.0% 12.6% -2.0% -16.4% -13.0% -17.8% 4.2% 20.8% -19.8% -41.4% -37.7%
Saudi Arabia SAR 100 4.5% 0.0% -0.2% -4.0% -2.7% -1.7% 0.4% 0.1% -6.8% -8.4% -7.8%
Serbia RSD 100 -0.9% -5.4% 1.2% 1.0% -1.3% -1.7% -0.7% -4.0% -4.5% -0.8% -2.8%
Singapore SGD 100 2.6% -1.3% 0.5% -0.1% -3.3% -2.5% 0.4% 1.6% -4.2% -5.4% -5.4%
South Africa ZAR 100 2.3% -8.9% -3.8% -4.0% -7.8% -1.6% 0.0% -13.9% -22.4% -16.2% -12.9%
South Korea KRW 1,000,000 -0.1% -6.1% -1.7% 2.7% -5.9% -1.5% -0.1% -5.4% -10.8% -6.5% -5.0%
Sri Lanka LKR 100 -41.8% 5.0% 0.2% 1.4% 9.8% -4.1% -1.2% -37.9% 17.2% 7.1% 5.5%
Sweden SEK 100 -0.9% -7.0% -1.9% -1.0% -3.6% -4.4% 2.0% -10.4% -12.9% -10.5% -7.0%
Switzerland CHF 100 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Taiwan TWD 100 -0.7% -3.1% -3.5% -0.8% -3.8% -4.9% 0.0% -7.8% -10.7% -12.4% -9.2%
Tajikistan TJS 100 2.1% 15.1% 1.1% -6.8% -6.3% -2.1% 0.7% 10.8% 1.7% -13.6% -13.9%
Thailand THB 100 0.5% -5.7% -0.1% 3.1% -4.3% -3.7% -1.0% -2.5% -7.1% -5.2% -6.0%
Trinidad and Tobago TTD 100 4.4% 0.2% -0.1% -4.1% -2.8% -1.8% 0.4% 0.2% -6.7% -8.6% -8.1%
Tunisia TND 100 -0.3% -4.6% -1.1% -0.5% -2.0% -2.4% -0.7% -6.3% -8.0% -5.8% -5.5%
Turkey TRY 100 -8.2% -13.6% -3.6% -3.5% -12.8% -29.2% -3.6% -26.2% -29.8% -42.5% -42.5%
United Arab Emirates AED 100 4.4% 0.2% -0.2% -4.1% -2.8% -1.7% 0.4% 0.2% -6.8% -8.6% -8.0%
United Kingdom GBP 100 -2.2% -6.7% -0.4% -0.3% 0.1% -0.5% -1.6% -9.3% -7.2% -1.1% -2.3%
Ukraine UAH 100 1.3% -17.1% -5.2% -1.8% -3.0% -1.7% 1.2% -21.9% -25.2% -11.3% -5.2%
Uruguay UYP 100 11.2% -0.1% 1.8% -2.0% -1.4% 0.1% -3.7% 10.8% -1.7% -1.6% -6.9%
Venezuela VES 100 -3.8% -34.6% -73.9% 20.5% -15.6% -22.8% -13.3% -80.2% -82.6% -79.5% -32.0%
Vietnam VND 1,000,000 3.1% -1.5% -3.8% -1.0% -2.5% -3.6% -1.5% -3.2% -8.5% -10.4% -8.2%
West African CFA franc XOF 100 -0.7% -5.6% 0.5% 1.7% -1.9% -1.8% -0.2% -4.2% -5.4% -1.6% -2.3%
AVERAGE HALF-YEARLY EXCHANGE RATES
Average Average Average Average

Jan - Jun 22 Jul - Dec 22 Jan - Jun 23 Jul - Dec 23

United States USD 100 94.40500 96.55700 91.20800 88.55000
EU EUR 100 103.22500 97.63300 98.58100 95.79700
Albania ALL 100 0.85219 0.83753 0.87314 0.91268
Algeria DZD 100 0.66040 0.68322 0.67008 0.65184
Argentina ARS 100 0.84220 0.62266 0.43099 0.18119
Armenia AMD 100 0.20122 0.23658 0.23393 0.22397
Australia AUD 100 67.89467 64.52547 61.65607 57.72551
Azerbaijan AZN 100 55.55344 56.81288 53.64204 52.07790
Barbados BBD 100 46.77826 47.83874 45.17276 43.85204
Bahrain BHD 100 250.41030 256.11148 241.93339 234.94671
Bangladesh BDT 100 1.08123 0.96199 0.85667 0.80631
Belarus BYN 1,000,000 30.67572 37.21932 36.15277 30.03843
Bolivia BOB 100 13.71927 13.96243 13.16316 12.77502
Bosnia BAM 100 52.64521 49.78879 50.28349 48.85617
Brazil BRL 100 18.59615 18.37045 17.97741 18.00223
Bulgaria BGN 100 52.77786 49.91096 50.40786 48.97472
Canada CAD 100 74.25298 72.48316 67.68242 65.52858
Central African CFA franc XAF 100 0.15538 0.14686 0.14802 0.14386
Chile CLP 100 0.11431 0.10429 0.11313 0.10083
China CNY 100 14.55689 13.79311 13.15767 12.20259
Colombia COP 1,000,000 241.13653 207.45201 198.56287 217.05269
Congo, Democratic Republic CDF 100 0.04720 0.04738 0.04234 0.03448
Costa Rica CRC 100 0.14380 0.15228 0.16586 0.16584
Croatia HRK 100 13.68802 12.97176 - -
Czech Republic CZK 100 4.18970 3.98980 4.16413 3.93675
Denmark DKK 100 13.87440 13.12470 13.23916 12.84878
Dominican Republic DOP 100 1.69475 1.78101 1.64763 1.56029
Egypt EGP 100 5.46604 4.49310 2.99901 2.86447
El Salvador SVC 100 10.78386 11.02948 10.41846 10.11476
Georgia GEL 100 31.07545 34.73089 35.25051 33.33597
Ghana GHS 100 13.16989 8.05257 7.77120 7.59852
Guatemala GTQ 100 12.26704 12.37330 11.66332 11.28586
Honduras HNL 100 3.84248 3.91576 3.70348 3.59036
Hong Kong HKD 100 12.06441 12.32307 11.63547 11.32513
Hungary HUF 100 0.27529 0.23775 0.25909 0.25019
Iceland ISK 100 0.73042 0.68196 0.65252 0.65068
India INR 100 1.23942 1.19164 1.10978 1.06726
Indonesia IDR 1,000,000 65.35121 63.26613 60.57728 57.39222
Iran IRR 1,000,000 3.87681 3.55895 2.68678 2.35428
Iraq IQD 100 0.06468 0.06616 0.06610 0.06756
Israel ILS 100 28.89278 27.99594 25.40615 23.37299
Jamaica JMD 100 0.61119 0.63343 0.59448 0.57080
Japan JPY 100 0.76832 0.68498 0.67669 0.60283
Jordan JOD 100 133.14586 136.17656 128.57449 124.84903
Kazakhstan KZT 100 0.20965 0.20455 0.20169 0.19207
Kenya KES 100 0.82054 0.79962 0.69251 0.59289
Kuwait KWD 100 310.02421 313.38635 297.54793 287.26791
Lebanon LBP 1,000,000 624.24413 638.52461 72.08989 -
Libya LYD 100 20.13669 19.61231 19.03444 18.32226
Macedonia MKD 100 1.67502 1.58378 1.59960 1.55558
Malaysia MYR 100 22.11164 21.30214 20.47889 18.95263
Mauritius MUR 100 2.15629 2.16319 2.00788 1.97578
Mexico MXN 100 4.65757 4.83565 5.01539 5.11261
Moldova MDL 100 5.12910 5.00294 4.96978 4.96046
Morocco MAD 100 9.73185 9.07131 8.94161 8.79603
Myanmar MMK 100 0.05211 0.04685 0.04344 0.04216
New Zealand NZD 100 62.60197 58.46265 56.93220 53.42556
Nicaragua NIO 100 2.64407 2.67935 2.49444 2.41816
Nigeria NGN 100 0.22636 0.22110 0.18779 0.09041
Norway NOK 100 10.34142 9.52728 8.71730 8.30450
Oman OMR 100 245.20890 250.79722 236.91792 230.00132
Pakistan PKR 100 0.50766 0.42564 0.33439 0.30743
Paraguay PYG 1,000,000 136.52785 136.99525 125.84200 120.76320
Peru PEN 100 24.98451 24.79665 24.26240 23.74472
Philippines PHP 100 1.81253 1.69311 1.65129 1.58011
Poland PLN 100 22.27859 20.58631 21.29732 21.48100
Qatar QAR 100 25.82666 26.37230 24.98399 24.29045
Romania RON 100 20.87515 19.87021 19.98502 19.31484
Russian Federation RUB 100 1.20930 1.52828 1.18264 0.92348
Saudi Arabia SAR 100 25.16371 25.69387 24.30633 23.60745
Serbia RSD 100 0.87792 0.83226 0.84049 0.81733
Singapore SGD 100 69.18322 69.32066 68.28077 65.58321
South Africa ZAR 100 6.13013 5.53933 5.01290 4.73298
South Korea KRW 1,000,000 766.25845 712.77353 704.18225 671.96509
Sri Lanka LKR 100 0.33293 0.25735 0.27412 0.27352
Sweden SEK 100 9.84968 9.03372 8.69919 8.24177
Switzerland CHF 100 100.00000 100.00000 100.00000 100.00000
Taiwan TWD 100 3.28984 3.12182 2.98491 2.78415
Tajikistan TJS 100 8.00298 9.36294 8.49699 8.07537
Thailand THB 100 2.80176 2.64666 2.66759 2.49889
Trinidad and Tobago TTD 100 13.90448 14.22728 13.44080 13.04576
Tunisia TND 100 31.78957 30.11851 29.51756 28.40342
Turkey TRY 100 6.37037 5.17679 4.59118 2.97574
United Arab Emirates AED 100 25.70205 26.28785 24.83383 24.10883
United Kingdom GBP 100 122.58600 112.91600 112.44700 111.00700
Ukraine UAH 100 3.23583 2.62843 2.47333 2.40925
Uruguay UYP 100 2.24880 2.38674 2.34345 2.28535
Venezuela VES 100 20.31709 8.21931 3.77952 2.49100
Vietnam VND 1,000,000 41.19224 40.40488 38.76657 36.64725
West African CFA franc XOF 100 0.15739 0.14841 0.14988 0.14550
Average Average Average Average Average
Jul - Dec 22 Jan - Jun 23 Jan - Jun 23 Jul - Dec 23 Jul - Dec 23
vs. vs. vs. vs. vs.
Jan - Jun 22 Jan - Jun 22 Jul - Dec 22 Jan - Jun 23 Jul - Dec 22
Country Code Units
United States USD 100 2.3% -3.4% -5.5% -2.9% -8.3%
EU EUR 100 -5.4% -4.5% 1.0% -2.8% -1.9%
Albania ALL 100 -1.7% 2.5% 4.3% 4.5% 9.0%
Algeria DZD 100 3.5% 1.5% -1.9% -2.7% -4.6%
Argentina ARS 100 -26.1% -48.8% -30.8% -58.0% -70.9%
Armenia AMD 100 17.6% 16.3% -1.1% -4.3% -5.3%
Australia AUD 100 -5.0% -9.2% -4.4% -6.4% -10.5%
Azerbaijan AZN 100 2.3% -3.4% -5.6% -2.9% -8.3%
Barbados BBD 100 2.3% -3.4% -5.6% -2.9% -8.3%
Bahrain BHD 100 2.3% -3.4% -5.5% -2.9% -8.3%
Bangladesh BDT 100 -11.0% -20.8% -10.9% -5.9% -16.2%
Belarus BYN 1,000,000 21.3% 17.9% -2.9% -16.9% -19.3%
Bolivia BOB 100 1.8% -4.1% -5.7% -2.9% -8.5%
Bosnia BAM 100 -5.4% -4.5% 1.0% -2.8% -1.9%
Brazil BRL 100 -1.2% -3.3% -2.1% 0.1% -2.0%
Bulgaria BGN 100 -5.4% -4.5% 1.0% -2.8% -1.9%
Canada CAD 100 -2.4% -8.8% -6.6% -3.2% -9.6%
Central African CFA franc XAF 100 -5.5% -4.7% 0.8% -2.8% -2.0%
Chile CLP 100 -8.8% -1.0% 8.5% -10.9% -3.3%
China CNY 100 -5.2% -9.6% -4.6% -7.3% -11.5%
Colombia COP 1,000,000 -14.0% -17.7% -4.3% 9.3% 4.6%
Congo, Democratic Republic CDF 100 0.4% -10.3% -10.6% -18.6% -27.2%
Costa Rica CRC 100 5.9% 15.3% 8.9% 0.0% 8.9%
Croatia HRK 100 -5.2% - - - -
Czech Republic CZK 100 -4.8% -0.6% 4.4% -5.5% -1.3%
Denmark DKK 100 -5.4% -4.6% 0.9% -2.9% -2.1%
Dominican Republic DOP 100 5.1% -2.8% -7.5% -5.3% -12.4%
Egypt EGP 100 -17.8% -45.1% -33.3% -4.5% -36.2%
El Salvador SVC 100 2.3% -3.4% -5.5% -2.9% -8.3%
Georgia GEL 100 11.8% 13.4% 1.5% -5.4% -4.0%
Ghana GHS 100 -38.9% -41.0% -3.5% -2.2% -5.6%
Guatemala GTQ 100 0.9% -4.9% -5.7% -3.2% -8.8%
Honduras HNL 100 1.9% -3.6% -5.4% -3.1% -8.3%
Hong Kong HKD 100 2.1% -3.6% -5.6% -2.7% -8.1%
Hungary HUF 100 -13.6% -5.9% 9.0% -3.4% 5.2%
Iceland ISK 100 -6.6% -10.7% -4.3% -0.3% -4.6%
India INR 100 -3.9% -10.5% -6.9% -3.8% -10.4%
Indonesia IDR 1,000,000 -3.2% -7.3% -4.3% -5.3% -9.3%
Iran IRR 1,000,000 -8.2% -30.7% -24.5% -12.4% -33.8%
Iraq IQD 100 2.3% 2.2% -0.1% 2.2% 2.1%
Israel ILS 100 -3.1% -12.1% -9.3% -8.0% -16.5%
Jamaica JMD 100 3.6% -2.7% -6.1% -4.0% -9.9%
Japan JPY 100 -10.8% -11.9% -1.2% -10.9% -12.0%
Jordan JOD 100 2.3% -3.4% -5.6% -2.9% -8.3%
Kazakhstan KZT 100 -2.4% -3.8% -1.4% -4.8% -6.1%
Kenya KES 100 -2.5% -15.6% -13.4% -14.4% -25.9%
Kuwait KWD 100 1.1% -4.0% -5.1% -3.5% -8.3%
Lebanon LBP 1,000,000 2.3% -88.5% -88.7% - -
Libya LYD 100 -2.6% -5.5% -2.9% -3.7% -6.6%
Macedonia MKD 100 -5.4% -4.5% 1.0% -2.8% -1.8%
Malaysia MYR 100 -3.7% -7.4% -3.9% -7.5% -11.0%
Mauritius MUR 100 0.3% -6.9% -7.2% -1.6% -8.7%
Mexico MXN 100 3.8% 7.7% 3.7% 1.9% 5.7%
Moldova MDL 100 -2.5% -3.1% -0.7% -0.2% -0.8%
Morocco MAD 100 -6.8% -8.1% -1.4% -1.6% -3.0%
Myanmar MMK 100 -10.1% -16.6% -7.3% -2.9% -10.0%
New Zealand NZD 100 -6.6% -9.1% -2.6% -6.2% -8.6%
Nicaragua NIO 100 1.3% -5.7% -6.9% -3.1% -9.7%
Nigeria NGN 100 -2.3% -17.0% -15.1% -51.9% -59.1%
Norway NOK 100 -7.9% -15.7% -8.5% -4.7% -12.8%
Oman OMR 100 2.3% -3.4% -5.5% -2.9% -8.3%
Pakistan PKR 100 -16.2% -34.1% -21.4% -8.1% -27.8%
Paraguay PYG 1,000,000 0.3% -7.8% -8.1% -4.0% -11.8%
Peru PEN 100 -0.8% -2.9% -2.2% -2.1% -4.2%
Philippines PHP 100 -6.6% -8.9% -2.5% -4.3% -6.7%
Poland PLN 100 -7.6% -4.4% 3.5% 0.9% 4.3%
Qatar QAR 100 2.1% -3.3% -5.3% -2.8% -7.9%
Romania RON 100 -4.8% -4.3% 0.6% -3.4% -2.8%
Russian Federation RUB 100 26.4% -2.2% -22.6% -21.9% -39.6%
Saudi Arabia SAR 100 2.1% -3.4% -5.4% -2.9% -8.1%
Serbia RSD 100 -5.2% -4.3% 1.0% -2.8% -1.8%
Singapore SGD 100 0.2% -1.3% -1.5% -4.0% -5.4%
South Africa ZAR 100 -9.6% -18.2% -9.5% -5.6% -14.6%
South Korea KRW 1,000,000 -7.0% -8.1% -1.2% -4.6% -5.7%
Sri Lanka LKR 100 -22.7% -17.7% 6.5% -0.2% 6.3%
Sweden SEK 100 -8.3% -11.7% -3.7% -5.3% -8.8%
Switzerland CHF 100 0.0% 0.0% 0.0% 0.0% 0.0%
Taiwan TWD 100 -5.1% -9.3% -4.4% -6.7% -10.8%
Tajikistan TJS 100 17.0% 6.2% -9.2% -5.0% -13.8%
Thailand THB 100 -5.5% -4.8% 0.8% -6.3% -5.6%
Trinidad and Tobago TTD 100 2.3% -3.3% -5.5% -2.9% -8.3%
Tunisia TND 100 -5.3% -7.1% -2.0% -3.8% -5.7%
Turkey TRY 100 -18.7% -27.9% -11.3% -35.2% -42.5%
United Arab Emirates AED 100 2.3% -3.4% -5.5% -2.9% -8.3%
United Kingdom GBP 100 -7.9% -8.3% -0.4% -1.3% -1.7%
Ukraine UAH 100 -18.8% -23.6% -5.9% -2.6% -8.3%
Uruguay UYP 100 6.1% 4.2% -1.8% -2.5% -4.2%
Venezuela VES 100 -59.5% -81.4% -54.0% -34.1% -69.7%
Vietnam VND 1,000,000 -1.9% -5.9% -4.1% -5.5% -9.3%
West African CFA franc XOF 100 -5.7% -4.8% 1.0% -2.9% -2.0%
WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5
PERIOD END EXCHANGE RATES (BALANCE SHEET)
Actual Actual Actual Actual Actual Actual Actual Actual Actual

12/31/2021 3/31/2022 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023

United States USD 100 91.36000 92.33000 95.52500 97.56500 92.32000 91.31500 89.94500 91.52000 84.41000
EU EUR 100 103.46500 103.02200 99.73800 95.77000 98.42700 99.56100 97.73400 96.68200 93.40800
Albania ALL 100 0.85800 0.84695 0.83728 0.82153 0.86321 0.87786 0.91608 0.90654 0.89807
Algeria DZD 100 0.65705 0.64817 0.65166 0.69464 0.67174 0.67379 0.66347 0.66462 0.62923
Argentina ARS 100 0.88967 0.83266 0.76392 0.66341 0.52220 0.43780 0.35104 0.26147 0.10447
Armenia AMD 100 0.19053 0.18929 0.23391 0.24035 0.23467 0.23517 0.23283 0.23414 0.20816
Australia AUD 100 66.23600 69.33983 65.74031 63.41725 62.58373 61.27236 59.51211 58.80160 57.66047
Azerbaijan AZN 100 53.77281 54.34373 56.22425 57.42496 54.30588 53.71471 52.90882 53.83529 49.65294
Barbados BBD 100 45.24788 45.72829 47.31068 48.32103 45.72334 45.22560 44.54708 45.32713 42.12917
Bahrain BHD 100 242.32779 244.88443 253.36516 258.51881 244.86440 242.21164 238.58407 243.01646 223.89920
Bangladesh BDT 100 1.06580 1.07080 1.02220 0.96313 0.89501 0.85142 0.83144 0.83011 0.76911
Belarus BYN 1,000,000 35.77204 28.34817 28.29029 38.65338 36.57541 36.17725 35.63448 36.25847 25.61760
Bolivia BOB 100 13.25018 13.42982 13.87436 14.06849 13.31218 13.18628 12.96972 13.19683 12.19798
Bosnia BAM 100 52.77264 52.54083 50.86664 48.83378 50.20120 50.78699 49.83655 49.30769 47.63141
Brazil BRL 100 16.39774 19.35639 18.43169 18.07429 17.46335 17.92582 18.52416 18.16342 17.37564
Bulgaria BGN 100 52.89639 52.67422 50.99562 48.96612 50.32434 50.91299 49.96389 49.43286 47.75807
Canada CAD 100 71.69989 73.96755 74.09059 71.32466 68.14290 67.52570 67.87021 67.83530 63.81161
Central African CFA franc XAF 100 0.15523 0.15349 0.15063 0.14225 0.14756 0.15183 0.14986 0.14542 0.13856
Chile CLP 100 0.10723 0.11700 0.10307 0.10123 0.10779 0.11552 0.11195 0.10108 0.09535
China CNY 100 14.32986 14.51627 14.24163 13.74523 13.23869 13.28305 12.37480 12.54661 11.85700
Colombia COP 1,000,000 224.47174 245.97031 232.02575 215.43734 190.42904 196.79957 214.92234 224.86486 216.99229
Congo, Democratic Republic CDF 100 0.04568 0.04616 0.04778 0.04749 0.04490 0.04380 0.03761 0.03687 0.03092
Costa Rica CRC 100 0.14231 0.14088 0.13915 0.15551 0.15603 0.16888 0.16569 0.17119 0.16245
Croatia HRK 100 13.75655 13.60465 13.24290 12.72432 13.06067 - - - -
Czech Republic CZK 100 4.16039 4.21540 4.03178 3.90901 4.06893 4.23352 4.12119 3.97136 3.78079
Denmark DKK 100 13.91177 13.85234 13.40579 12.87953 13.23670 13.36695 13.12414 12.96501 12.53164
Dominican Republic DOP 100 1.59692 1.67812 1.74762 1.82723 1.64110 1.66269 1.62473 1.61198 1.45660
Egypt EGP 100 5.81540 5.05364 5.08112 4.99309 3.72935 2.95518 2.91556 2.96181 2.72951
El Salvador SVC 100 10.43542 10.54658 10.91116 11.14455 10.54507 10.43028 10.27379 10.45369 9.64620
Georgia GEL 100 29.54435 29.78387 32.57460 34.56687 34.35163 35.87311 34.42212 34.30928 31.37918
Ghana GHS 100 14.85528 12.26977 12.16879 9.42657 9.05098 7.94043 7.82130 7.89987 7.05474
Guatemala GTQ 100 11.83803 12.01431 12.32183 12.38685 11.76426 11.70705 11.46526 11.64377 10.79067
Honduras HNL 100 3.72491 3.76136 3.88656 3.95111 3.74131 3.71184 3.64130 3.68290 3.41464
Hong Kong HKD 100 11.71365 11.79597 12.17391 12.42874 11.84159 11.63263 11.47477 11.68898 10.80358
Hungary HUF 100 0.28065 0.28038 0.25313 0.22755 0.24615 0.26211 0.26317 0.24660 0.24421
Iceland ISK 100 0.70104 0.72558 0.71503 0.68254 0.64806 0.67240 0.65627 0.66723 0.62231
India INR 100 1.22771 1.21770 1.21002 1.19729 1.11515 1.11224 1.09549 1.10046 1.01483
Indonesia IDR 1,000,000 64.02691 64.34595 64.33526 63.98964 58.68667 60.62608 59.96333 58.94628 54.75480
Iran IRR 1,000,000 3.71252 3.90492 3.73295 3.69545 3.18113 2.53544 2.40937 2.47864 2.17326
Iraq IQD 100 0.06260 0.06324 0.06545 0.06685 0.06325 0.06960 0.06866 0.06988 0.06448
Israel ILS 100 29.41593 29.04875 27.62075 27.40205 26.24890 25.38996 24.31274 23.85228 23.28616
Jamaica JMD 100 0.59338 0.60150 0.63396 0.64399 0.60857 0.60274 0.58029 0.59045 0.54458
Japan JPY 100 0.79399 0.75795 0.69933 0.67535 0.69406 0.68836 0.62127 0.61326 0.59706
Jordan JOD 100 128.85755 130.22567 134.73202 137.60931 130.16567 128.73053 126.78131 129.08322 118.98788
Kazakhstan KZT 100 0.20894 0.19807 0.20396 0.20445 0.20002 0.20263 0.19807 0.19287 0.18601
Kenya KES 100 0.80742 0.80322 0.81091 0.80833 0.74814 0.69073 0.64018 0.61796 0.53764
Kuwait KWD 100 301.99656 303.96708 311.47087 314.86800 301.52198 297.81162 292.43749 296.05668 274.62016
Lebanon LBP 1,000,000 604.23280 610.56739 631.69554 645.27116 610.50126 60.83611 59.92338 10.70409 9.87251
Libya LYD 100 19.86692 19.76368 19.79649 19.30967 19.12238 19.10256 18.78021 18.72321 17.71551
Macedonia MKD 100 1.67833 1.67159 1.62471 1.54253 1.59613 1.61734 1.59562 1.57644 1.52172
Malaysia MYR 100 21.87478 21.95980 21.71146 21.04735 20.87035 20.64782 19.25399 19.43925 18.32013
Mauritius MUR 100 2.08109 2.08185 2.12751 2.16091 2.09580 1.98727 1.97464 2.05432 1.92278
Mexico MXN 100 4.46446 4.64565 4.74599 4.83749 4.74421 5.04698 5.25170 5.21331 4.97148
Moldova MDL 100 5.14572 5.05350 5.00131 5.01220 4.83591 4.97088 4.93052 5.04242 4.86275
Morocco MAD 100 9.87793 9.56451 9.40049 8.87552 8.82196 8.94719 9.09270 8.86968 8.53601
Myanmar MMK 100 0.05138 0.05192 0.05159 0.04646 0.04396 0.04348 0.04283 0.04358 0.04020
New Zealand NZD 100 62.40802 64.42326 59.39267 55.85596 58.61397 57.19058 54.59662 54.55507 53.44419
Nicaragua NIO 100 2.58043 2.57977 2.66420 2.71240 2.52862 2.49665 2.45919 2.50123 2.30628
Nigeria NGN 100 0.22044 0.22240 0.22826 0.22337 0.20026 0.19791 0.11958 0.11794 0.08157
Norway NOK 100 10.36063 10.77992 9.65816 9.12010 9.33978 8.78236 8.33229 8.53349 8.27784
Oman OMR 100 237.30178 239.76836 248.11366 253.41229 239.79532 237.17874 233.62338 237.71120 219.23821
Pakistan PKR 100 0.51254 0.50536 0.46612 0.42512 0.40723 0.32193 0.31389 0.31695 0.29880
Paraguay PYG 1,000,000 132.79070 132.87024 139.41551 138.00835 125.92651 127.71007 123.79339 125.39563 116.00357
Peru PEN 100 22.89581 24.78990 25.22745 24.53848 24.37492 24.26461 24.74892 24.15349 22.85861
Philippines PHP 100 1.79049 1.77626 1.73808 1.66635 1.65374 1.67812 1.62224 1.61397 1.51748
Poland PLN 100 22.53632 22.20512 21.36188 19.72704 21.05095 21.30268 21.97022 20.83884 21.56645
Qatar QAR 100 24.88356 25.28550 26.00983 26.62946 25.26408 24.98119 24.67085 25.10010 23.17110
Romania RON 100 20.90594 20.82483 20.17764 19.34739 19.88926 20.12031 19.68270 19.43533 18.80647
Russian Federation RUB 100 1.22435 1.10575 1.83702 1.65364 1.26466 1.18169 1.03552 0.94692 0.95379
Saudi Arabia SAR 100 24.33411 24.61018 25.45908 25.96022 24.55482 24.32634 23.98214 24.40273 22.50993
Serbia RSD 100 0.88003 0.87508 0.84896 0.81610 0.83920 0.84920 0.83402 0.82410 0.79737
Singapore SGD 100 67.56147 68.26617 68.53812 68.09632 68.70837 68.78201 66.31156 66.99608 63.93728
South Africa ZAR 100 5.73617 6.38264 5.88281 5.41764 5.44025 5.12295 4.79337 4.81905 4.54984
South Korea KRW 1,000,000 767.75690 762.73952 733.39168 682.07240 731.97805 704.06409 679.91549 677.89580 654.29797
Sri Lanka LKR 100 0.45033 0.31193 0.26683 0.26804 0.25259 0.27968 0.29227 0.28247 0.26065
Sweden SEK 100 10.10150 9.97812 9.33030 8.74564 8.82465 8.81181 8.27887 8.37735 8.45533
Switzerland CHF 100 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000 100.00000
Roche Online Financial Information System Period End Exchange Rates 04/03/2024 40/43
Taiwan TWD 100 3.29380 3.23035 3.21103 3.07795 3.00864 2.99649 2.89073 2.84648 2.74727
Tajikistan TJS 100 8.09212 7.11874 9.84794 9.95561 9.09557 8.35453 8.17682 8.33515 7.72632
Thailand THB 100 2.73492 2.77226 2.71513 2.56429 2.66436 2.66652 2.52672 2.50465 2.46993
Trinidad and Tobago TTD 100 13.45033 13.58883 14.06631 14.36110 13.58506 13.45311 13.26280 13.48540 12.43646
Tunisia TND 100 31.73545 31.57445 31.03678 30.09037 29.40502 29.74672 29.10135 28.83337 27.47990
Turkey TRY 100 6.95073 6.30011 5.74108 5.27415 4.93435 4.76285 3.45420 3.34027 2.86686
United Arab Emirates AED 100 24.87306 25.13715 26.00664 26.56203 25.13750 24.86352 24.48749 24.91696 22.98247
United Kingdom GBP 100 123.29900 121.25200 115.84300 108.99000 111.29200 113.10700 113.44300 111.65000 107.47900
Ukraine UAH 100 3.34529 3.12453 3.23554 2.64158 2.49976 2.47251 2.43541 2.49068 2.22424
Uruguay UYP 100 2.04408 2.25366 2.42032 2.34588 2.32984 2.35136 2.39719 2.36205 2.16192
Venezuela VES 100 19.89784 21.12028 17.37034 11.93679 5.34968 3.73230 3.23313 2.67149 2.35220
Vietnam VND 1,000,000 40.12297 40.39551 41.05071 40.93350 39.08552 38.89055 38.15837 37.50820 34.80825
West African CFA franc XOF 100 0.15765 0.15649 0.15290 0.14374 0.14945 0.15106 0.14288 0.14749 0.14222
Actual Actual Actual Actual Actual Actual Actual Actual
3/31/2022 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023
vs. vs. vs. vs. vs. vs. vs. vs.
12/31/2021 12/31/2021 12/31/2021 12/31/2021 12/31/2022 12/31/2022 12/31/2022 12/31/2022
Country Code Units
United States USD 100 1.1% 4.6% 6.8% 1.1% -1.1% -2.6% -0.9% -8.6%
EU EUR 100 -0.4% -3.6% -7.4% -4.9% 1.2% -0.7% -1.8% -5.1%
Albania ALL 100 -1.3% -2.4% -4.3% 0.6% 1.7% 6.1% 5.0% 4.0%
Algeria DZD 100 -1.4% -0.8% 5.7% 2.2% 0.3% -1.2% -1.1% -6.3%
Argentina ARS 100 -6.4% -14.1% -25.4% -41.3% -16.2% -32.8% -49.9% -80.0%
Armenia AMD 100 -0.7% 22.8% 26.1% 23.2% 0.2% -0.8% -0.2% -11.3%
Australia AUD 100 4.7% -0.7% -4.3% -5.5% -2.1% -4.9% -6.0% -7.9%
Azerbaijan AZN 100 1.1% 4.6% 6.8% 1.0% -1.1% -2.6% -0.9% -8.6%
Barbados BBD 100 1.1% 4.6% 6.8% 1.1% -1.1% -2.6% -0.9% -7.9%
Bahrain BHD 100 1.1% 4.6% 6.7% 1.0% -1.1% -2.6% -0.8% -8.6%
Bangladesh BDT 100 0.5% -4.1% -9.6% -16.0% -4.9% -7.1% -7.3% -14.1%
Belarus BYN 1,000,000 -20.8% -20.9% 8.1% 2.2% -1.1% -2.6% -0.9% -30.0%
Bolivia BOB 100 1.4% 4.7% 6.2% 0.5% -0.9% -2.6% -0.9% -8.4%
Bosnia BAM 100 -0.4% -3.6% -7.5% -4.9% 1.2% -0.7% -1.8% -5.1%
Brazil BRL 100 18.0% 12.4% 10.2% 6.5% 2.6% 6.1% 4.0% -0.5%
Bulgaria BGN 100 -0.4% -3.6% -7.4% -4.9% 1.2% -0.7% -1.8% -5.1%
Canada CAD 100 3.2% 3.3% -0.5% -5.0% -0.9% -0.4% -0.5% -6.4%
Central African CFA franc XAF 100 -1.1% -3.0% -8.4% -4.9% 2.9% 1.6% -1.5% -6.1%
Chile CLP 100 9.1% -3.9% -5.6% 0.5% 7.2% 3.9% -6.2% -11.5%
China CNY 100 1.3% -0.6% -4.1% -7.6% 0.3% -6.5% -5.2% -10.4%
Colombia COP 1,000,000 9.6% 3.4% -4.0% -15.2% 3.3% 12.9% 18.1% 13.9%
Congo, Democratic Republic CDF 100 1.1% 4.6% 4.0% -1.7% -2.4% -16.2% -17.9% -31.1%
Costa Rica CRC 100 -1.0% -2.2% 9.3% 9.6% 8.2% 6.2% 9.7% 4.1%
Croatia HRK 100 -1.1% -3.7% -7.5% -5.1% - - - -
Czech Republic CZK 100 1.3% -3.1% -6.0% -2.2% 4.0% 1.3% -2.4% -7.1%
Denmark DKK 100 -0.4% -3.6% -7.4% -4.9% 1.0% -0.9% -2.1% -5.3%
Dominican Republic DOP 100 5.1% 9.4% 14.4% 2.8% 1.3% -1.0% -1.8% -11.2%
Egypt EGP 100 -13.1% -12.6% -14.1% -35.9% -20.8% -21.8% -20.6% -26.8%
El Salvador SVC 100 1.1% 4.6% 6.8% 1.1% -1.1% -2.6% -0.9% -8.5%
Georgia GEL 100 0.8% 10.3% 17.0% 16.3% 4.4% 0.2% -0.1% -8.7%
Ghana GHS 100 -17.4% -18.1% -36.5% -39.1% -12.3% -13.6% -12.7% -22.1%
Guatemala GTQ 100 1.5% 4.1% 4.6% -0.6% -0.5% -2.5% -1.0% -8.3%
Honduras HNL 100 1.0% 4.3% 6.1% 0.4% -0.8% -2.7% -1.6% -8.7%
Hong Kong HKD 100 0.7% 3.9% 6.1% 1.1% -1.8% -3.1% -1.3% -8.8%
Hungary HUF 100 -0.1% -9.8% -18.9% -12.3% 6.5% 6.9% 0.2% -0.8%
Iceland ISK 100 3.5% 2.0% -2.6% -7.6% 3.8% 1.3% 3.0% -4.0%
India INR 100 -0.8% -1.4% -2.5% -9.2% -0.3% -1.8% -1.3% -9.0%
Indonesia IDR 1,000,000 0.5% 0.5% -0.1% -8.3% 3.3% 2.2% 0.4% -6.7%
Iran IRR 1,000,000 5.2% 0.6% -0.5% -14.3% -20.3% -24.3% -22.1% -31.7%
Iraq IQD 100 1.0% 4.6% 6.8% 1.0% 10.0% 8.6% 10.5% 1.9%
Israel ILS 100 -1.2% -6.1% -6.8% -10.8% -3.3% -7.4% -9.1% -11.3%
Jamaica JMD 100 1.4% 6.8% 8.5% 2.6% -1.0% -4.6% -3.0% -10.5%
Japan JPY 100 -4.5% -11.9% -14.9% -12.6% -0.8% -10.5% -11.6% -14.0%
Jordan JOD 100 1.1% 4.6% 6.8% 1.0% -1.1% -2.6% -0.8% -8.6%
Kazakhstan KZT 100 -5.2% -2.4% -2.1% -4.3% 1.3% -1.0% -3.6% -7.0%
Kenya KES 100 -0.5% 0.4% 0.1% -7.3% -7.7% -14.4% -17.4% -28.1%
Kuwait KWD 100 0.7% 3.1% 4.3% -0.2% -1.2% -3.0% -1.8% -8.9%
Lebanon LBP 1,000,000 1.0% 4.5% 6.8% 1.0% -90.0% -90.2% -98.2% -98.4%
Libya LYD 100 -0.5% -0.4% -2.8% -3.7% -0.1% -1.8% -2.1% -7.4%
Macedonia MKD 100 -0.4% -3.2% -8.1% -4.9% 1.3% 0.0% -1.2% -4.7%
Malaysia MYR 100 0.4% -0.7% -3.8% -4.6% -1.1% -7.7% -6.9% -12.2%
Mauritius MUR 100 0.0% 2.2% 3.8% 0.7% -5.2% -5.8% -2.0% -8.3%
Mexico MXN 100 4.1% 6.3% 8.4% 6.3% 6.4% 10.7% 9.9% 4.8%
Moldova MDL 100 -1.8% -2.8% -2.6% -6.0% 2.8% 2.0% 4.3% 0.6%
Morocco MAD 100 -3.2% -4.8% -10.1% -10.7% 1.4% 3.1% 0.5% -3.2%
Myanmar MMK 100 1.1% 0.4% -9.6% -14.4% -1.1% -2.6% -0.9% -8.6%
New Zealand NZD 100 3.2% -4.8% -10.5% -6.1% -2.4% -6.9% -6.9% -8.8%
Nicaragua NIO 100 0.0% 3.2% 5.1% -2.0% -1.3% -2.7% -1.1% -8.8%
Nigeria NGN 100 0.9% 3.5% 1.3% -9.2% -1.2% -40.3% -41.1% -59.3%
Norway NOK 100 4.0% -6.8% -12.0% -9.9% -6.0% -10.8% -8.6% -11.4%
Oman OMR 100 1.0% 4.6% 6.8% 1.1% -1.1% -2.6% -0.9% -8.6%
Pakistan PKR 100 -1.4% -9.1% -17.1% -20.5% -20.9% -22.9% -22.2% -26.6%
Paraguay PYG 1,000,000 0.1% 5.0% 3.9% -5.2% 1.4% -1.7% -0.4% -7.9%
Peru PEN 100 8.3% 10.2% 7.2% 6.5% -0.5% 1.5% -0.9% -6.2%
Philippines PHP 100 -0.8% -2.9% -6.9% -7.6% 1.5% -1.9% -2.4% -8.2%
Poland PLN 100 -1.5% -5.2% -12.5% -6.6% 1.2% 4.4% -1.0% 2.4%
Qatar QAR 100 1.6% 4.5% 7.0% 1.5% -1.1% -2.3% -0.6% -8.3%
Romania RON 100 -0.4% -3.5% -7.5% -4.9% 1.2% -1.0% -2.3% -5.4%
Russian Federation RUB 100 -9.7% 50.0% 35.1% 3.3% -6.6% -18.1% -25.1% -24.6%
Saudi Arabia SAR 100 1.1% 4.6% 6.7% 0.9% -0.9% -2.3% -0.6% -8.3%
Serbia RSD 100 -0.6% -3.5% -7.3% -4.6% 1.2% -0.6% -1.8% -5.0%
Singapore SGD 100 1.0% 1.4% 0.8% 1.7% 0.1% -3.5% -2.5% -6.9%
South Africa ZAR 100 11.3% 2.6% -5.6% -5.2% -5.8% -11.9% -11.4% -16.4%
South Korea KRW 1,000,000 -0.7% -4.5% -11.2% -4.7% -3.8% -7.1% -7.4% -10.6%
Sri Lanka LKR 100 -30.7% -40.7% -40.5% -43.9% 10.7% 15.7% 11.8% 3.2%
Sweden SEK 100 -1.2% -7.6% -13.4% -12.6% -0.1% -6.2% -5.1% -4.2%
Switzerland CHF 100 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Taiwan TWD 100 -1.9% -2.5% -6.6% -8.7% -0.4% -3.9% -5.4% -8.7%
Tajikistan TJS 100 -12.0% 21.7% 23.0% 12.4% -8.1% -10.1% -8.4% -15.1%
Thailand THB 100 1.4% -0.7% -6.2% -2.6% 0.1% -5.2% -6.0% -7.3%
Trinidad and Tobago TTD 100 1.0% 4.6% 6.8% 1.0% -1.0% -2.4% -0.7% -8.5%
Tunisia TND 100 -0.5% -2.2% -5.2% -7.3% 1.2% -1.0% -1.9% -6.5%
Turkey TRY 100 -9.4% -17.4% -24.1% -29.0% -3.5% -30.0% -32.3% -41.9%
United Arab Emirates AED 100 1.1% 4.6% 6.8% 1.1% -1.1% -2.6% -0.9% -8.6%
United Kingdom GBP 100 -1.7% -6.0% -11.6% -9.7% 1.6% 1.9% 0.3% -3.4%
Ukraine UAH 100 -6.6% -3.3% -21.0% -25.3% -1.1% -2.6% -0.4% -11.0%
Uruguay UYP 100 10.3% 18.4% 14.8% 14.0% 0.9% 2.9% 1.4% -7.2%
Venezuela VES 100 6.1% -12.7% -40.0% -73.1% -30.2% -39.6% -50.1% -56.0%
Vietnam VND 1,000,000 0.7% 2.3% 2.0% -2.6% -0.5% -2.4% -4.0% -10.9%
West African CFA franc XOF 100 -0.7% -3.0% -8.8% -5.2% 1.1% -4.4% -1.3% -4.8%

Roche Group Financial Data

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Roche Group Financial Data

Uploaded by

Copyright:

Available Formats

WAcAAB+LCAAAAAAABADtVcuSmzAQ/KAcFsGSKg57EOZhXEY2GCSkmwVebCw2rgWbx9dnwBUnldPm5Et0AJVK3TPT9AwYuxhj52VaOMK/ljvvN4GdGmosfNquz+Qm/V5xI75I3R

Year-To-Date in CHFm at reported exchange rates Year-To-Date CHF growth rates

Quarterly in CHFm at reported exchange rates Quarterly CHF growth rates

31 December 31 December 31 December

Total assets 90,468 88,151 92,317

Total liabilities -57,205 -56,136 -63,972

Total net assets 33,263 32,015 28,345

Net Cash (debt)

Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Diluted earnings per share and non-voting equity security

Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Diluted earnings per share and non-voting equity security

Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Diluted earnings per share and non-voting equity security

Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - - 0 0 - - 0 0 - - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Diluted earnings per share and non-voting equity security

Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Sales to other ODGs/Divisions 0 0 - 0 0 - 0 0 - 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

of ECP tax benefit

Other financial income (expense) -258 0 0 0 0 0 0 0 0 0 -258

Income taxes -1,824 -48 -42 -74 0 6 0 0 32 0 -1,950

Net income 9,161 218 426 349 -15 -11 0 0 32 0 10,160

of ECP tax benefit

Other financial income (expense) -226 0 0 0 -44 0 0 0 0 0 -270

Income taxes -972 -145 -38 -361 -1 2 0 0 36 0 -1,479

Net income 4,370 558 427 2,053 -51 -23 0 0 36 0 7,370

of ECP tax benefit

Other financial income (expense) -484 0 0 0 -44 0 0 0 0 0 -528

Income taxes -2,796 -193 -80 -435 -1 8 0 0 68 0 -3,429

Net income 13,531 776 853 2,402 -66 -34 0 0 68 0 17,530

Group reconciliation (CHFm)

Sales 3rd 29,779 0 0 0 0 0 0 0 0 0 29,779

Other financial income (expense) -100 0 0 0 0 0 0 0 0 0 -100

Profit before taxes 9,174 678 358 260 4 -145 0 0 0 0 10,329

Income taxes -1,611 -134 -22 -52 0 46 0 0 31 0 -1,742

Net income 7,563 544 336 208 4 -99 0 0 31 0 8,587

Sales 3rd 28,937 0 0 0 0 0 0 0 0 0 28,937

Other financial income (expense) -220 0 0 0 0 0 0 0 0 0 -220

Profit before taxes 4,905 1,360 353 939 21 33 0 0 0 0 7,611

Income taxes -110 -269 -22 -19 -4 -7 0 0 37 0 -394

Net income 4,795 1,091 331 920 17 26 0 0 37 0 7,217

Sales 3rd 58,716 0 0 0 0 0 0 0 0 0 58,716

Other financial income (expense) -320 0 0 0 0 0 0 0 0 0 -320

Profit before taxes 14,079 2,038 711 1,199 25 -112 0 0 0 0 17,940

Income taxes -1,721 -403 -44 -71 -4 39 0 0 68 0 -2,136

Net income 12,358 1,635 667 1,128 21 -73 0 0 68 0 15,804

of ECP tax benefit

of ECP tax benefit

of ECP tax benefit

of ECP tax benefit

Pharmaceuticals Division reconciliation (CHFm)

Sales 3rd 21,931 0 0 0 0 0 0 0 0 0 21,931

Sales 3rd 44,612 0 0 0 0 0 0 0 0 0 44,612

of ECP tax benefit

of ECP tax benefit

of ECP tax benefit

of ECP tax benefit

Diagnostics Division reconciliation (CHFm)